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Abstract 
Recent years have seen several notable advances in therapy for multiple myeloma (MM), 
which have translated into impressive improvements in progression-free and overall 
survival rates.  Nevertheless, patients afflicted with this relatively common, incurable 
cancer can typically expect ever shortening treatment-free intervals between sequential 
therapies; relapsed, treatment-refractory disease remains common.  Myriad experimental 
and observational studies comprehensively document a state of profound immune 
dysfunction in MM.  Intriguingly, an accruing body of evidence indicates that immune 
dysregulation is not only progressive and correlated with disease stage, but that it may 
actually contribute to the pathogenesis of the disease.  This thesis will examine the 
contribution of the recently described Th17 subset of T cells to immune dysfunction in MM 
and the mechanisms of their generation before assessing the use of a novel oncolytic 
virotherapy as an immunomodulatory therapy for MM. 
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Chapter 1 – Introduction and Hypothesis  
The work presented in this thesis comprises two broad strands of work and crosses a 
number of different areas of research.  In order to review the relevant literature, the 
introductory chapter will therefore cover a number of slightly distinct areas in turn: plasma 
cell dyscrasias and the immune dysfunction seen in these disease states will first be 
discussed, followed by an overview of Th17 cells and then a section on Th17 cells in cancer 
and in myeloma specifically.  The second section of the introduction will then discuss 
oncolytic viruses in general, reovirus specifically and finally murine models of myeloma 
which might be used to investigate these agents.  
 
Plasma	cell	dyscrasias	and	multiple	myeloma	
Plasma cell dyscrasias are a common group of haematological disorders characterised by 
the clonal expansion of terminally differentiated B cells (plasma cells, PC) in the bone 
marrow, that typically produce an intact monoclonal immunoglobulin molecule or 
immunoglobulin light chain.  Early in the natural history of the disease, a malignant PC 
clone may be present without any evidence of other organ damage; such cases are 
divided according to the levels of bone marrow infiltration into monoclonal gammopathy 
of uncertain significance (MGUS; malignant PCs <10% of leukocytes) and asymptomatic 
myeloma (AMM; ≥10%) (see Appendix 1 for definitions).  MGUS is a very common 
condition, present in approximately 3% of the population above the age of 501.  However, 
in approximately 1% of cases of MGUS, and a higher proportion of those with AMM, the 
disease progresses to symptomatic myeloma1, resulting in bone destruction causing pain, 
fractures and hypercalcaemia, multifactorial renal insufficiency and bone marrow failure2.  
MM has an annual incidence of 3-4 per 100 000, although there is ethnic variation with 
the disease being commoner in Afro-Caribbean populations.  The median age at 
diagnosis is 65-70 years.  It is the second most common form of bone marrow cancer, 
and represents about 1% of all malignancies.  With the exception of petrochemical 
exposure in a small minority of cases3, environmental aetiological factors are not known to 
play a major role in the pathogenesis of this malignancy. 
The natural history of MM is extremely heterogeneous, with some patients surviving 
decades without requiring therapy and others dying within weeks from aggressive 
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progressive disease.  As a consequence a great deal of effort has been expended on 
developing reliable prognostic systems and clinical scores: ISS4, cytogenetic 
assessment5,6 , flow cytometric phenotyping7 and gene expression profiling8 are among 
the modalities employed clinically at present.   
For patients with symptomatic MM requiring therapy, recent years have seen enormous 
advances.  Younger, biologically fit patients are currently treated with intensive 
chemotherapy, typically with autologous stem cell transplantation as a consolidation 
therapy – a strategy supported by a wealth of evidence from randomised controlled 
trials9,10  (reviewed in11).  However, since MM is predominantly a disease of the elderly, 
many patients are insufficiently fit for such an approach and for this large cohort of 
patients attenuated chemotherapy regimens are typically employed.  Patients in both 
groups have benefitted enormously from the development of a wide range of new agents 
over the last decade, for example: ‘immunomodulatory drugs’ (IMiDs e.g. thalidomide, 
lenalidomide, pomalidomide), proteasome inhibitors (bortezomib, carfilzomib) and 
monoclonal antibodies (elotuzumab, daratumumab).  Unfortunately, MM nonetheless 
remains incurable for the vast majority and is characterised clinically by ever-shortening 
cycles of remission and relapse after sequential therapies.  There therefore remains a 
need for effective and, crucially, minimally toxic new treatment modalities for MM. 
 
Immune	dysfunction	in	myeloma	
Virtually all aspects of cellular and humoral immunity are impaired in MM as a result of 
interations between the malignant PC and the host immune system (Figure 1.1), and this 
immune impairment worsens in association with disease progression12. 
 
Infections in MM 
The increased risk of opportunistic infections in patients with MM is very well described13 - 
indeed it is a diagnostic criterion for symptomatic MM2 (see Appendix 1).  Specific 
immunity against a variety of pathogens is impaired14; infections are a common cause of 
death in MM15, and are also increased with MGUS, correlating with the paraprotein 
concentration16,17.  Interestingly, there may be some reciprocity – i.e. infection may 
encourage tumour growth: malignant plasma cells express a wider range of toll-like 
receptors (TLRs, which recognise the pathogen-associated molecular patterns of 
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microorganisms) than those from healthy donors, and ligation of these induces 
proliferation and survival of both human MM cell lines (HMCL) and primary samples, 
partially due to autocrine interleukin-6 (IL-6) production18,19.  Population-based studies 
also point to an increased incidence of infections in the years preceding diagnosis of 
MM17, although caution is warranted in inferring causality - the association might equally 
represent an immune manifestation of pre-existing but undiagnosed PC dyscrasia.  
Medical interventions also contribute to immune compromise (e.g. corticosteroids, 
chemotherapy, indwelling intravenous lines etc.).  
 
F igure 1.1.  Immune dysfunct ion in mult ip le myeloma.  Adapted from Parrish et 
al. 2013 12.   
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Innate immunity in MM 
Natural killer (NK) cells have been shown to have cytolytic activity against myeloma PCs 20-
22, and may also be increased in number in patients with MM23.  However, the NK cells 
present in patients with MM are abnormal, expressing reduced levels of activatory 
receptors such as NKp46 and NKp3024, the Ig-Fc receptor CD16 and the coreceptor 
2B4/CD24425, and increased levels of inhibitory receptors such as PD-L126.  Functional 
defects are also apparent in NK cells, and seem to deteriorate as the disease 
progresses26-30.  Furthermore, malignant PCs manifest a number of ways to escape NK-
mediated killing, for example, upregulation of ligands for inhibitory receptors, such as 
NCAM14031 and early haematopoietic zinc finger protein-induced MHC class I 
expression32.  Even the myeloma paraprotein itself has been shown to adversely affect NK 
cell function23.  
NK T cells (NKT) can also mediate anti-cancer effects in several malignancies, and NKT 
with anti-myeloma activity are detectable in blood from patients with MM33.  Disease 
progression from MGUS to MM is associated with a loss of ligand-dependent IFNγ 
secretion from such cells28.  Gamma-delta (γδ) T cells, suitably stimulated with 
aminobisphosphates, have anti-MM activity34-36, and this can be enhanced by 
costimulation with MICA produced by PCs in MGUS37. 
 
T cells in MM 
Many aspects of T cell biology are deranged in MM: the CD4:CD8 ratio has been known 
to be reduced since the 1980s38, the Th1:Th2 ratio was later found to be increased39 and 
other subsets of T cells are also affected.  The repertoire of T cell receptor (TCR) 
rearrangements in MM is impaired and correlated with disease stage40, and oligoclonal 
expansions are reported40,41.  Effector T cell responses against tumour cells are inhibited 
via TGFβ-mediated suppression of IL-2 autocrine pathways42, and inhibition of expression 
of perforin, granzyme A, granzyme B, Fas ligand and IFNγ43.  Co-stimulatory signals such 
as CD28 and CD40L, signal transduction molecules (e.g. CD3ζ, p56lck, p59fyn, ZAP-70 
and PI3K) and stimulation-induced cytokine production are impaired in a disease stage-
related manner44. 
Nevertheless, T cells targeting a variety of tumour-associated antigens have been 
identified in patients with MM45, and indeed in MGUS, where they may play a role in 
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combating disease progression46,47 – such cells are often functionally impaired in MM47-49.  
The myeloma paraprotein represents an obvious target and indeed idiotype-reactive T 
cells have been demonstrated45,48,50, which have been shown in vitro to kill autologous 
tumour cells51 and confer a favourable prognosis52.  Unfortunately, attempts to harness 
anti-idiotype immunity for immunotherapy have met with little success, predominantly 
owing to T cell tolerance, the development of which remains to be fully understood 
(reviewed in53).  In the context of allogeneic stem cell transplant (AlloSCT) immunisation of 
the donor against the idiotype protein can confer specific T cell immunity in the recipient54-
56, highlighting the requirement for a competent host immune system before such 
strategies can work.  T cells specific for other cancer antigens present on MM cells also 
occur, can attenuate MM growth, and may represent useful avenues for immunotherapy - 
e.g. cancer testis antigens57,58 , the mucin MUC159 and the embryonal stem cell-
associated antigen SOX249. 
Unsurprisingly, MM cells manifest an assortment of mechanisms to evade T cell-mediated 
immunity and have proven more resistant to donor lymphocyte therapy than many other 
haematological malignancies60.  PD-L1, expressed by MM cell lines, renders cells 
expressing it less susceptible to cytotoxic T cell lysis61,62, and exposed T cells may 
develop an exhausted phenotype and produce IL-1063.  PD-L1 is not present on MGUS 
plasma cells (PC)62 and so this seems to represent another example of the evolution of 
the immune deficit in MM.  Notably, lenalidomide exposure decreases PD-1 expression 
on T cells in vitro64.  Interestingly, the antigen presentation and costimulatory function of 
the malignant PCs themselves also seems to deteriorate with disease progression65. 
Our group and others have found regulatory T cells (Treg, CD4+CD25+FoxP3+) and 
CD8+CD25+FoxP3+ to be expanded in MM, in a stage-related manner66-69, although 
expanded total CD4+CD25+ with decreased CD4+CD25+FoxP3+ populations have also 
been reported70.  Regulatory T cells effect immune suppression by myriad mechanisms71; 
circulating Treg have been correlated inversely with survival72 and reduced BM Treg after 
treatment are associated with long-term disease control68.  Non-classical regulatory T 
cells subsets may also play a role73.  The recently described Th17 subset of T cells, the 
main focus of the following work, may also be expanded in the blood and bone marrow of 
patients with MM74, and are reviewed in detail in a later section.   
Immunotherapy in the clinic 
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Cellular immunotherapy, in the form of allogeneic stem cell transplant, is already in use in 
the clinic and a range of other cellular therapies are under investigation, including dendritic 
cell (DC) vaccination, NK, NKT and T cell strategies and humoral immunotherapy75.  In 
reality, many of the pharmacological agents already in routine clinical use have 
immunomodulatory effects that are likely to be at least partially responsible for their action.  
The prototypic immunomodulatory drug (IMiD), thalidomide, for example, has a 
stimulatory effect on T cells in vitro, augmenting their proliferation54 and improving their 
capacity to secrete IFNγ54,76 (and similar effects on NK cells77).  Second generation IMiDs, 
lenalidomide and pomalidomide, have even more potent co-stimulatory actions on T78,79, 
NK77,80,81 and NKT82 cells, and may be sufficiently potent to empower anti-tumour vaccine 
strategies33,83.  Clearly this is a rapidly expanding field at present, which promises to 
transform therapy for MM over the next few years. 
	
Th17	cells	–	origins	and	differentiation	
For over 20 years, immunologists relied on the Th1 vs. Th2 paradigm, first proposed by 
Mosmann and Coffman in 198984, to explain skewing of the adaptive immune response in 
one of two directions via the action of two distinct subsets of effector T lymphocytes: Th1 
& Th2, the balance of which would configure immune responses85.  The paradigm was 
widely accepted for a number of years, being an elegant explanation for many immune 
phenomena86.  However, a number of pathological states could not be explained by the 
model and a large and expanding number of effector T cell subsets has now been 
described and characterized.  Of these, the Th17 subset, the principal focus of this thesis, 
is defined by its production of IL-17. 
Cytokine drivers of Th17 differentiation 
TGFβ ,  IL-6, IL-1β ,  IL-21. On binding to its heteromeric transmembrane receptor 
TGFβ acts through SMAD-dependent and independent pathways87,88  to inhibit STAT4, T-
bet and GATA389,90  (so inhibiting Th1 and Th2 development), and reduce STAT5-
mediated IL-2 production in TCR-stimulated cells, which otherwise constrains early Th17 
differentiation.  TGFβ also increases FoxP3 expression and induces development of Treg 
cells - the addition of pro-inflammatory cytokines such as IL-6, IL-1β, IL-21 and IL-23 
(and TNFα in mice) then favours Th17 development91-95   .   
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In 2007, the role of TGFβ in Th17 lineage determination in humans was called into doubt 
by a small number of studies which reported contradictory information96-99 - these 
discrepancies can probably be accounted for by methodological differences.  However, 
subsequent work has demonstrated there are indeed	 significant differences in Th17 
lineage determination between mice and humans.  Although IL-6 and TGFβ will induce 
RORC2 (the human homologue of murine RORγt, with equivalent functions93), the 
combination seems insufficient to induce a full effector phenotype or IL-17 production 
from naive T cells100, although TGFβ and IL-6 induced during the early stages of an 
inflammatory response may act on memory T cells to promote IL-17 and IL-21 secretion.  
In fact, whilst TGFβ does induce RORγt expression, it also paradoxically inhibits RORγt’s 
transcriptional activity via induction of FoxP3101. A combination of IL-1β, TGFβ and any of 
IL-6, IL-21 or IL-23 overcomes this inhibition and is required for IL-17 expression, with IL-
1β, TGFβ and IL-23 reportedly being the most potent combination in humans102.  Some 
human studies have also reported IL-17 expression in response to IL-1β with or without 
IL-21100.  Some recent evidence suggests that in humans (and possibly mice103) TGFβ is 
dispensable but has an indirect role in Th17 development through inhibition of Th1 cells104.  
The level of TGFβ is also probably important, with low levels synergising with IL-6 and IL-
21 to promote IL-23R expression and high levels favouring FoxP3 expression and 
repression of IL-23R expression101.  To further complicate matters, IL-1β has been 
reported to induce Th17 development in humans independently of RORC2105.  
It is difficult to compose a definitive synthesis of the published data on the drivers of Th17 
differentiation in humans, and even harder to know which of the proposed cytokine 
combinations is likely to be of relevance in any given situation.  It is likely Th17 
differentiation usually occurs within secondary lymphoid tissue when antigen-specific 
naive T cells recognise migrating antigen-presenting cells, and that a number of 
combinations have activity on naive precursors e.g. TGFβ + IL-21, IL-1β + IL-6 and IL-1β 
+ IL-23102.  Through T cell plasticity, Th17 cells may also be derived from other subsets, 
notably FoxP3+ Treg cells106-108.  
IL-23.  A considerable body of work has now demonstrated the role of IL-23 in 
stabilization of the Th17 phenotype109-112.  In brief, TGFβ upregulates IL-23R expression 
(which is absent in naive T cells), so conferring IL-23 responsiveness during Th17 
development112; IL-6 may be able to substitute in this role103.  Through its receptor IL-23 
then induces further expression of its own receptor and RORC2 - a positive-feedback 
loop that stabilises and maintains the Th17 phenotype. IL-23 signalling may also be 
University of Leeds – School of Medicine Christopher Parrish 
- 30 - 
required for the up-regulation of T-bet within Th17 cells that is necessary for skewing 
towards a Th17-1 profile (i.e. ability to produce both Th17 and Th1 cytokines)113.  Such data 
are strongly suggestive that Th17 cells induced in the presence of IL-23 are phenotypically 
altered, having, for example, altered trafficking properties, and may explain both the 
limited pathogenicity in murine models of Th17 cells generated with TGFβ alone and the 
altered susceptibility to human autoimmune diseases associated with IL-23 gene 
polymorphisms114,115 . 
IL-2 & other cytokines.  Murine work has shown an inhibitory effect of IL-2 on IL-17 
expression102,116,117, but it may have a positive effect in human CD4+ T cell culture.  These 
discrepancies may reflect differences between mouse ‘naïve’ T cells and 
CD45RA+CD45RO- T cells from human peripheral blood.  As might be anticipated, a wide 
variety of other cytokines also have pro- (GM-CSF118,119 ) and anti-Th17 (IL-27120, IL-25121, 
IL-4122,123 , IL-13124,125  and IFNγ123) properties. 
‘Signal 2’ co-stimulation 
A basic tenet of T cell biology is that co-stimulation via CD28 is required for survival and 
expansion of T cells, the subsequent lineage of which is determined by ‘signal 3’ 
factors126.  However, recent studies have unexpectedly reported that CD28 co-stimulation 
actually impairs development of Th17 cells from naïve T cells127; instead Th17 cells may be 
best induced via ligation of the inducible co-stimulator, ICOS128 or lymphocyte receptors 
CD5 or CD6129 (both members of the Scavenger Receptor Cysteine-Rich domains 
superfamily, SRCR-SF) - the latter effects are antagonised by CD28 co-stimulation.  ICOS 
ligation was shown to up-regulate RORC expression, and to augment human Th17 
function through induction of c-Maf and IL-21128.  In the case of CD5 and CD6, this effect 
was mediated via up-regulation of IL-23R with consequent prolonged STAT3 activation 
and enhanced RORγt expression.  Interestingly the inhibitory effect of simultaneous CD28 
co-stimulation suggests optimal Th17 induction via CD5 could not be elicited by activated 
APCs, such as mature mouse bone marrow-derived or human monocyte-derived 
dendritic cells (DCs), which have high expression of CD80 and CD86, ligands of CD28.  
This may suggest a role for other DCs, such as mouse CD103+ lamina propria DCs, 
which have high MHC II expression but do not up-regulate CD80 or CD86 expression 
after lipopolysaccharide stimulation in vitro130.  Ligands for CD5 and CD6, however, are 
poorly identified.  CD72131 and CD5 itself132 are both suggested to be ligands of CD5 and 
are present on B cells; ALCAM and protein 3A11, ligands of CD6, are present on DCs 
and B cells133.  Alternatively CD5 and CD6 might constitute innate immune receptors, 
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since polysaccharide β-glycan (present on Candida albicans) can activate CD5134, 
whereas bacterial LPS may activate CD6135. 
Transcriptional regulation 
Genome-wide gene expression profiling has yielded large numbers of candidate genes for 
controlling Th17 differentiation and function136 – some of the more important candidates 
are discussed below. 
RORγ t .  RORγt, a retinoid orphan nuclear receptor closely related to the retinoic acid 
receptor and originally defined as a thymic-specific isoform of RORγ137 is expressed 
specifically in both human and mouse Th17 cells138, and is driven by stimulation of naive T 
cells with the cytokines discussed above97.  Expression of RORγt is necessary and 
sufficient for induction of IL-17, IL-17F and IL-23R expression138.  STAT3-deficient mice 
fail to express RORγt and produce reduced levels of IL-17, and reinstitution of the gene 
via a retroviral vector rescues the defect139. 
STAT3 & RORα .   In addition to RORγt, STAT3 is required for full generation of the Th17 
phenotype140,141 ; over-expression of either STAT3 in RORγt-deficient mice or RORγt in 
STAT3-deficient mice fails to restore normal IL-17 generation142.  IL-6, IL-21 and IL-23 all 
induce activation of STAT399,143, which binds to the Il17 promoter, leading to Th17 
differentiation.  RORα, also induced by TGFβ plus IL-6, synergises with RORγt to promote 
differentiation and function of Th17 cells144.  Simultaneous deficiency of RORγt and RORα 
results in complete failure of IL-17 production144.  
Other transcr ipt ion factors.  The transcriptional regulation of the Th17 lineage is 
complex and many transcription factors are implicated, all of which cannot be discussed 
in detail here.  Many are concerned with the reciprocal regulation of Th17 and Treg 
development e.g. IRF4145, RARα 146, BTBD11136, AHR147-150 & HIF-1151.  Peroxisome 
proliferator-activated receptor γ (PPARγ)152, B cell activating transcription factor (BATF)153, 
ETS1154, IκBζ155, growth factor independent 1 (GFI1)156, Krüppl-like factor 4 (KLF4)157 and 
others also play important roles. 
Hypoxia-inducible factor 1 (HIF-1) is a key metabolic sensor for the detection of hypoxia 
and is one of the mediators which has been shown to regulate the balance between Treg 
and Th17 differentiation151.  This effect is via both direct transcriptional activation of RORγt 
and through formation of a tertiary complex with RORγt and p300 enhancing recruitment 
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to the IL17 promoter, as well as by binding of FoxP3 and targeting it for proteasomal 
degradation. 
Plasticity & Th17-1 cells 
Although it is convenient to classify T cells into subsets, it is increasingly clear that 
considerable plasticity exists; T cells may move between lineages, or exist in intermediate 
chimeric states.  Genetic and epigenetic mechanisms have been described in the 
regulation of this plasticity158,159. 
In the case of Treg cells a picture has emerged whereby not only is there antagonism 
between the effector functions of Th17 and Treg populations, but also reciprocal 
interconnection in the mechanisms giving rise to their differentiation92.  In fact, it seems 
likely that RORγt and FoxP3 exist in the same cell; as discussed above, the levels of 
TGFβ, proinflammatory cytokines160 and other environmental factors such as hypoxia 
control the balance151. 
Th17-1 cells, that is those able to produce both IL-17 and IFNγ, have been described in a 
number of settings, often derive from Th17 cells on exposure to IL-12161 and may be 
important due to their hybrid expression of Th1 and Th17 proteins.  For example, attraction 
by CXCL9, 10 or 11 (ligands of CXCR3, a Th1 protein) may allow delivery of IL-17 where 
‘pure’ Th17 cells cannot access162.  Th17-1 cells are reported in patients with cancer163 and 
may mediate significant anti-tumour responses164. 
Cell surface phenotypes of Th17 cells 
In healthy individuals, roughly 1% of CD4+ T cells are Th17, however, very high levels of 
Th17 cells may be present in pathological micro-environments, possibly because they are 
recruited to sites of active inflammation via CCR6 and the integrin CD49 (and possibly 
CD161, although the function of this integrin is poorly characterised)163.  Th17 cells 
produce multiple other immune mediators (e.g. IL-17F, IL-21, IL-22, CXCL-8 and CXCL-
13), and cell surface proteins (e.g. CCR6, CCR4, IL-23R and CD161) but attempts to 
identify specific cell surface phenotypic markers for the lineage have met with difficulty. 
CD161 
A C-type lectin receptor, CD161 is induced by RORC2 and is found on human IL-17-
producing T cells165, including Th17 cells and others (e.g. CD8+TCRαβ+, CD4-CD8-TCRαβ+ 
and CD4-CD8-TCRγδ+)166.  It has been proposed as a co-activating receptor promoting 
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antigen-dependent T cell proliferation upon engagement by the ligand, PILAR 
(proliferation-induced lymphocyte-associated receptor)167.  CD161+ umbilical cord blood 
CD8+ and CD4-CD8- T cells, but not their CD161- counterparts, express RORC2 and IL-
23R mRNA and can acquire the ability to express IL-17 under the action of IL-1β and IL-
23166.  It is important to note, however, that the CD4+CD161+ lymphocytes found in 
peripheral blood also include Th1, Th2 and Th0 cells and some investigators have even 
reported CD161- IL-17 producing lymphocytes in the context of Treg plasticity168 and 
cancer 169. 
CCR6, CCR4 & IL-23R 
CCR6 (CD196), a G-protein coupled receptor whose ligand is CCL20 (MIP-3α), mediates 
homing to skin and mucosal tissues170.  It is reportedly expressed on all Th17 cells, but 
also on some IL-17- lymphocytes171.  The same authors report that expression of CCR4, a 
receptor typically expressed on Th2 cells and contributing to skin-homing172, identifies that 
portion of the CCR6+ population able to produce IL-17.  IL-23R, as discussed above, is 
upregulated on differentiated Th17 cells173, but is expressed also on Th17-1 and to a lesser 
extent Th1 cells173. 
	
Roles	of	Th17	cells	in	health,	cancer	and	disease	
Th17 cells are best characterised in the setting of autoimmune diseases (or their animal 
models), e.g. multiple sclerosis, inflammatory bowel disease, psoriasis and rheumatoid 
arthritis, where these cells clearly play a central pathogenic role, but which I will not 
discuss further.  The role of immunity in cancer is a complex area; immune responses in 
this context are often represented as a double-edged sword, with the capacity for 
inflammatory responses both to provide proliferative and oncogenic stimuli and to 
mediate anti-tumour responses.  Recent years have seen great advances in 
understanding of this area and an era of clinical immunotherapy has dawned, whereby 
immune responses are beginning to be manipulated to deliver anti-cancer therapy.  In this 
section I will overview the roles of Th17 cells in health and in cancer. 
Th17 cells in infection   
Accumulating evidence shows Th17 cells are crucial for specific and effective immune 
responses against certain pathogens, where Th1 and Th2 responses are insufficient.  
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Roles have been shown in the response to extracellular (e.g. Klebsiella pneumoniae174, 
Mycoplasma pneumoniae175) and intracellular (e.g. Mycobacterium tuberculosis176) 
bacteria – IL-17 induces neutrophil chemotaxis (within 4-8 hours) and upregulates pro-
inflammatory cytokine production by monocytes and macrophages177, epithelial, 
endothelial and fibroblastic cells178.  A crucial role of Th17 cells in health is in the response 
to fungal infections – humans with STAT3 mutations have markedly reduced Th17 cells 
and increased susceptibility to mucosal candidiasis179,180 and memory T cells specific for 
C. albicans reside in the CCR6+CCR4+ subset171. 
Th17 cells in cancer and in myeloma 
Whilst there is an expanding literature concerning Th17 cells in cancer, few hard facts 
about their roles in cancer have been established.  Firstly, it is often difficult to tease apart 
the effects of IL-17, which derives from many tissues, and the role of Th17 cells per se.  It 
is important to consider that ‘IL-17’ in fact represents a family of cytokines; the term is 
most widely used in the published literature to mean any of IL-17A homodimers, IL-17F 
homodimers and IL-17AF heterodimers, although the family also includes IL-17B, IL-17C, 
IL-17D and IL-27E (a.k.a. IL-25), which are far less well characterised and almost certainly 
have disparate functions from IL-17A/F181-183  .  For clarity, in this thesis unless otherwise 
specified, ‘IL-17’ is defined by antibody reactivity to the IL-17A subunit and therefore 
comprises IL-17A homodimers and IL-17AF heterodimers only.   
When reviewing the literature, it is tempting to attempt to draw generalisations about the 
role of Th17 cells and their mediators in tumour initiation, metastasis, angiogenesis, 
lymphangiogenesis and other aspects of neoplasia, however, the evidence from both 
murine and human work is contradictory and points to both pro- and anti-tumour 
effects184-188.  As yet further complication, helper T cells exhibit properties of more than 
one subset, for example IL-17-secreting Treg cells, or CD4+ cells secreting both IL-17 and 
IFNγ (Th17-1 cells), are well documented and may have different roles and effects from the 
‘pure’ populations.  Crucially it is unwise to extrapolate from one malignancy to another 
and I will therefore review only MM here. 
In 2006, Alexandrakis et al. reported increased levels of IL-17 in the sera of patients with 
MM, correlating with disease stage, vascular endothelial growth factor (VEGF), TNFα and 
microvessel density189.  Interestingly, although VEGF receptors are not expressed by 
myeloma cells, they are present on stromal cells190; VEGF signalling has an established 
role in modulating dendritic cell APC function191, and autocrine VEGF signalling may 
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mediate capillarogenesis in MM192. Taken together, these findings suggest an angiogenic 
role for IL-17 in MM, although direct induction of VEGF by IL-17 was not shown.  It is 
notable, however, that whilst some investigators have corroborated such data193, others 
report contradictory findings194.  Observational data suggest bisphosphonates, used 
extensively in the treatment of MM bone disease and recently shown to affect overall 
survival in the disease195, may lower IL-17 levels and might therefore have a suppressive 
effect on angiogenesis194.  This in turn raises the question of whether Th17 cells in the BM 
might show anatomical localisation, for example in, or juxtaposed with the periosteal 
niche. 
Added to primary MM cells or human myeloma cell lines (HMCLs), IL-17 has been 
reported to increase colony size and number, and the fraction of cells in S phase, and to 
increase adhesion of PCs to bone marrow stromal cells (BMSCs)74.  After subcutaneous 
injection of HMCLs into SCID mice, administration of IL-17 was associated with 
significantly larger tumour size at 3 weeks74.  Furthermore the majority of patient MM 
plasma cells and HMCLs express IL-17R, and their growth is blocked by anti-IL-17 
antibody74.  IL-21, also produced by Th17 cells, increases proliferation of both cytokine-
dependent HMCLs and primary myeloma cells and functions as an anti-apoptotic factor, 
via JAK1, STAT3 and Erk1/2196.  In fact, IL-21 was reported to be a more potent growth 
and anti-apoptotic factor than any other known myeloma cell growth factor, including IL-
10, IL-15, TNF and IGF-1196 
Prabhala et al. found Th17 cells were increased in the PB and BM of patients with MM 
compared to healthy donors, by FACS and qPCR, although in BM the difference did not 
reach statistical significance74.  Cultures of PB- and BM-derived mononuclear cells in 
Th17-polarising conditions revealed a greater population of inducible Th17 cells in MM 
patients than in healthy donors.  IL-17, IL-1α, IL-21, IL-22 and IL-23, all Th17 cytokines, 
were increased in plasma from myeloma patients.  Uptake of apoptotic but not necrotic 
myeloma cells by DCs leads to enhanced induction of Th17-1 cells, which may be 
expanded in myeloma and correlate with bone disease197. 
There is further evidence of a role of IL-17 in MM bone disease: rhIL-17 treatment of 
monocytes produces TRAP+CD51+ multinuclear cells with actin ring formation (functional 
and phenotypic properties of osteoclasts), probably mediated via RANKL and TNFα198.  
Noonan et al. found reduced Treg and expanded Th17 cells in MM BM, and showed this 
cytokine environment mediated up-regulation of osteoclast activation with consequent 
lytic bone destruction199. Levels of certain Th17-inducing cytokines (IL-6, IL-1β, IL-17) 
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correlated closely with the extent of bone disease and marrow infiltrating lymphocytes 
activated under Th1-polarising conditions were able to reduce formation of mature 
osteoclasts. 
 
Oncolytic	virotherapy	
Observations of spontaneous regression of malignancies following naturally contracted 
viral infections date back to the turn of the nineteenth century and raised interest in the 
use of viruses as anti-cancer therapies.  However, early studies using viral infections in 
patients with cancer resulted either in arrest of viral infection by competent host immunity, 
or morbidity and mortality due to overwhelming infection and this line of research was 
largely abandoned in the 1950s (reviewed in 200).  More recently, advances in immunology 
and molecular cell biology have cast light upon the mechanisms by which naturally 
occurring and genetically engineered viruses might preferentially infect and lyse cancer 
cells and a number of these agents are under investigation in preclinical and early-phase 
clinical research. 
Oncolytic viruses are replication competent viruses with a predeliction for infection of or 
replication in cancer cells, and that are able to lyse cancer cells after infection.  In order to 
exert this differential effect against malignant cells this group of viruses necessarily rely 
upon differences in the cellular processes between normal and tumour cells, an effect 
which can be exploited to deliver anti-cancer therapy.  A crucial step forward in the field 
has been the recognition that the most significant effect of oncolytic virotherapy may 
result not from the infection and destruction of cancer cells per se, but rather through the 
consequent release of tumour antigens in a pro-inflammatory environment leading to 
priming of tumour antigen-specific secondary immune responses201-205.  In turn, this has 
lead us and others to combination of oncolytic virotherapy with other immunotherapeutic 
agents206,207. 
 
Reovirus	
Reovirus (derivation: respiratory enteric orphan virus) is a wild-type virus of the family 
reoviridae that is able to infect the human respiratory and gastrointestinal tracts, generally 
resulting in asymptomatic infection or mild influenza-like symptoms or diarrhoea.  The 
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virus is ubiquitous and seropositivity in the human population is virtually universal208.  
Reovirus is a dsRNA virus consisting of a non-enveloped icosahedral virion capsid with 
two layers of proteins encoded by 10 segments of RNA.   
 
Preclinical data 
The ability of the virus to replicate in tumour and transformed cell lines was noted in the 
1970s209; subsequent work identified amplified Ras signalling in such cells as the crucial 
sensitising event.  Reoviral infection of healthy cells results in activation of a 
serine/threonine protein kinase: double-stranded RNA-activated protein kinase (PKR) 210, 
which through activation of eIF2a induces an interferon response and shutdown of viral 
protein synthesis; Ras activation prevents PKR phosphorylation and thereby enables 
unchecked reoviral replication.  However, subsequent studies have demonstrated that 
Ras-activation is not the only enabling abnormality for reoviral replication as some cell 
lines with wild-type Ras also show susceptibility, for example cells with KRAS 
mutations211.  A wide range of malignant cell types have now been demonstrated to be 
susceptible to reovirus-induced oncolysis212,213.  Intratumoral injection of reovirus into both 
syngeneic tumours in immunocompetent animals, and xenografting tumours in 
immunodeficient animals results in tumour regression, for example in breast cancer214, 
colon215, ovarian215 and glioma animal models213.  The actual mechanism of cell death in 
reovirus-infected cells has been variously reported to be via apoptosis216-220 and by 
autophagy216,221. 
 
Clinical Trials 
Following from this work, a number of clinical trials have been completed with reovirus in 
solid malignancies, with a number more underway at present.  In keeping with the usual 
pattern of clinical exploration for new therapies, the early studies were of cautious dose 
escalation of single agent virotherapy, initially by intratumoural injection222.  Clinically 
significant responses were seen in some patients and side effects seen were mild flu-like 
illness and headaches; treatment was well-tolerated and grade 3/4 toxicities were not 
encountered.  On the basis of these data, intravenous administration was next appraised, 
in patients with advanced cancers of multiple histopathological subtypes: again flu-like 
illness was the dominant side effect, dose-limiting toxicities were not encountered and 
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viral delivery to tumour sites was demonstrated223.  Reovirus was next combined with a 
number of standard chemotherapeutic agents (reviewed in 224) and with radiotherapy225.  
A recent phase III trial in patients with platinum-refractory head and neck cancers, in 
combination with paclitaxel and carboplatin (REO 018) has shown improved PFS and OS 
vs. paclitaxel and carboplatin alone. 
One of the predominant concerns about the potential of oncolytic viruses for clinical 
meaningful immunotherapy stems from the development of rapid and potent anti-viral 
humoral responses.  Research has therefore been directed at combination strategies to 
attenuate anti-viral immune responses, through combination with immunosuppression226 
or chemotherapy227, and these strategies have seen some efficacy.  However, data from 
human trials delivering virus intravenous have revealed a fascinating phenomenon, that 
even in the presence of circulating neutralising anti-reovirus antibodies, the virus is able to 
‘hitch hike’ on leukocytes and platelets, allowing evasion of the immune response and 
access to the tumour bed228. 
 
Reovirus in haematological malignancy 
Building on the successes seen with solid tumours, and the obvious attractions of the 
potential for intravenous delivery, interest in oncoloytic virotherapy has been growing in 
the arena of haematological malignancy.  Preclinical data have pointed towards efficacy of 
reovirus against a range of haematological malignancies, including acute myeloid 
leukaemia229, lymphoma230, chronic lymphocytic leukaemia207 and MM216,231,232.   
The molecular landscape of MM has been increasingly thoroughly characterised over the 
preceeding decades but in fact RAS pathway mutations including N- and K-RAS 
mutations have long been known to be among the common disease-driving mutations in 
myeloma233-235; this oncogenic addiction makes myeloma a tempting target for oncolytic 
virotherapy.  Preclinical studies of reovirus in myeloma to date have demonstrated the use 
of reovirus to ‘purge’ autologous stem cell grafts of myeloma cells prior to re-infusion to 
NOD/SCID mice232, and that reovirus is able to induce ER stress, which can be 
augmented by combination with proteasome inhibition218.  A recent phase I trial has also 
concluded that reovirus monotherapy is well-tolerated and deliverable in patients with 
relapsed multiple myeloma, but concluded that combination therapy is required to 
achieve clinically useful disease responses236. 
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Murine	myeloma	models	
Considerable effort has been expended over many decades to generate in vivo models of 
human myeloma that will accurately recapitulate the human disease and allow dissection 
of the aetiology of the disease and testing of potential therapies.  The resulting range of 
approaches has led to a slew of disparate models, each with their own benefits and 
limitations.  The major categories of models will be briefly reviewed, and the reasons for 
ultimate model selection for the work presented in Chapter 5 will be explained. 
 
Chemical ly- induced plasmacytoma models 
These models rely on injection of pristane oil into the perineum of Balb/c mice237; the 
resulting chronic inflammatory granuloma typically results, after 120 days, in development 
of a plasmacytoma-like tumour localised to the injection site in 60% of mice.  Although 
these mice are immunocompetent the disease is localised and the model is therefore 
unsuitable for examination of bone disease or the BM microenvironment, or renal disease.  
In addition a long lag-time is needed between pristane injection and development of 
tumours, tumours do not produce IL-6 (which is a typical characteristic of human 
malignant plasma cells) and tumour outgrowth appears to be driven by t(12;15)(IgH/myc) 
in 90%, a defect seen in <5% of human myeloma.  A pan-European group have recently 
described a MOPC315.BM model238, derived through ex vivo selection and in vitro 
passage of cells from the original model, that does demonstrate bone marrow tropism 
and represents an improvement on the original model, but does not circumvent a number 
of the other drawbacks of this model.  In view of the limitations of this model it was not 
suitable for the work proposed here. 
 
SCID xenograft models 
Severe combined immunodeficient (SCID) mice exhibit complete inability to implement 
V(D)J recombination, resulting in failure of humoral and cellular immunity, and these mice 
are widely used as model organisms for a range of applications.  Due to marked 
immunodeficiency, human tumour cells can be grafted into these animals with 
subcutaneous or intravenous injection239, implantation of human (SCID-hu model240) or 
University of Leeds – School of Medicine Christopher Parrish 
- 40 - 
rabbit (SCID-rab model241) fetal bone chips, implantation of whole BM trephine biopsies 
(LAGλ-1 model242) or intratibial injection of human MM cell lines or primary plasma cell 
leukaemia samples243).  Some of these models do offer the potential of exploring a quasi-
human bone marrow microenvironment, and may replicate human disease faithfully in 
some respects (e.g. detectable paraprotein, bony deformity, no widespread organ 
involvement).  Nonetheless, these models are by definition devoid of competent immune 
effectors and are unsuitable for examination of immunotherapy. 
 
Transgenic models 
With the increasing understanding of the molecular underpinnings of myeloma has come 
a burgeoning of transgenic animal models of the disease.  A few of these appear able to 
reproduce many features of the human disease – for example the Vk*myc ORF model 
exhibits a slowly progressive monoclonal plasma cell proliferation, a serum paraprotein by 
20 weeks, anaemia, myeloma kidney disease, osteoporosis and rare bone lesions244.  
However, most exhibit features quite different from the typical pattern of human plasma 
cell dyscrasia – for example Eμ-xbp-1a shows prominent activation of proapoptotic 
tumour suppression mechanisms, which are quite unlike human disease245, c-MAF mice 
occasionally develop myeloma, but predominantly generate B cell lymphomas246, c-
Myc/Bcl-XL mice develop plasmablastic morphology and cytogenetic abnormalities 
dissimilar to human disease247,248 .  Of course, all animal models are by definition not 
exactly like their human counterpart, and many of these models will doubtless prove 
invaluable for studying certain aspects of myeloma pathogenesis and therapy; some 
would certainly be candidates for conducting the experiments reported here.  However, in 
addition to the concerns outlined, it is also now well-appreciated that human myeloma is 
a genetically diverse disease with marked intra-tumoral sub-clones which compete in a 
Darwininan manner under the selection pressures of therapy249-251  , meaning that models 
relying on a single genetic driver are likely to be limited in their ability to mirror the 
responses of human disease to therapy. 
 
5T l ineage models 
This group of models all derive from a spontaneous myeloma-like disease arising in 
ageing C57BL/KalwRij mice252; cells were subjected to serial autologous passage to 
evolve a range of cell lines which can be used in this syngeneic model253.  The 5T2, 5T7, 
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5T8, 5T13, 5T14, 5T21, 5T33, and 5T41 lines represent different clones isolated from 
these mice by serial transplantation253 and exhibit a range of growth characteristics.  
Stroma-independent subclones, such as 5TGM1 (derived from 5T33), were subsequently 
isolated and allow in vitro passage and thus considerable flexibility for ex vivo assays254-256.  
The disease in the 5TGM1 model is largely confined to BM (although spleen, which may 
represent a haematopoietic organ in adult mice, is also involved), secretes an IgG2bκ 
paraprotein and shows bone disease similar to humans (lytic lesions, decreased bone 
mineral density, hypercalcaemia etc.).  The 5T lines can develop into isotype-switch 
variants 257.  This immune competent model offers considerable flexibility to answer the 
questions posed here and was therefore adopted for this and subsequent work. 
 
 
Summary	
Multiple myeloma is an immunologically complex environment in which anti-tumour 
immune responses detectable early in the disease are gradually eroded and evaded by 
the tumour and its microenvironment, and ultimately fail in their battle to restrain the 
proliferating plasma cell clones.  An expanding body of experimental work has elucidated 
many of the mechanisms underlying these immune responses and their evasion, and 
characterised the immunomodulatory effects of agents and treatments with clinical activity 
against the disease.   
Evidence points towards an expansion of Th17 cells in myeloma, and is suggestive that 
this population may favour tumour growth and impede anti-tumour immunity; however 
these cells have not been characterised in great detail, and the potential for beneficial 
therapeutic manipulation of the responsible mechanisms remains to be explored.   
The oncolytic virus, reovirus, have demonstrated pre-clinical and clinical efficacy against a 
range of solid tumour types, and preliminary evidence also suggests potential against 
haematological malignancies.  The effects of this virus on myeloma cells, and on the host 
anti-myeloma immune response require further chararcterisation and the potential for 
combinatorial immunotherapy in this malignancy should now be explored. 
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Hypothesis,	Aims	and	Objectives	
The work contained in this thesis addresses two distinct but related strands of 
investigation, and the hypothesis, aims and objectives of these will be discussed 
separately. 
 
IL-17-secreting lymphocytes in multiple myeloma (Chapters 3 & 4) 
The hypothesis of this work is that tumour-immune system interactions in multiple 
myeloma give rise to dysfunctional T cell immunity, manifest as impaired protective 
immune responses and development of an immune microenvironment which favours 
tumour outgrowth. 
The objectives of this part of the project are to address 3 fundamental questions: 
• Do malignant plasma cells in multiple myeloma generate Th17 cells? 
• If so, how do they do this – what are the key events involved? 
• Are there phenotypic or functional differences between Th17 cells in health and in 
multiple myeloma? 
 
Oncolytic virotherapy in multiple myeloma (Chapter 5) 
The hypothesis of this section of work is that the oncolytic virus, reovirus, can induce 
direct and immune-mediated killing of myeloma tumour cells.  The work aims to address 
the following questions: 
• Can reovirus kill myeloma cells? 
• If so, what are the mechanisms? 
• Can this agent represent a useful treatment modality for human MM? 
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Chapter 2 – Materials and Methods 
Reagents	and	solutions	
Phosphate-buffered 
saline (PBS) 
Source: Sigma 
Fetal bovine serum (FBS) Source: PAA laboratories, heat inactivated for 30 minutes at 
56°C 
Complete medium (CM) RPMI-1640 (Sigma), 10% heat-inactivated FBS 
FACS buffer 490ml PBS, 5ml FBS, 5ml 5% Sodium azide (sterile, filtered) 
Hank’s buffered salt 
solution (HBSS) 
HBSS-CaCl2-MgCl2 (Sigma) 
 
Lymphoprep Source: Axis Shield, Norway 
MACS buffer 493ml PBS, 5ml FBS, 2ml 0.5M EDTA (sterile, filtered) 
Freezing medium 80% RPMI-1640 (Sigma), 10% FBS, 10% DMSO (Sigma) 
Brefeldin A Golgiplug (BD Biosciences, UK)  
Intracellular staining 
buffers 
Fixation-Permeabilisation and Permabilisation buffers, source: 
Miltenyi Biotec (Fixation and Dead Cell Discrimination Kit, 
130-091-163) 
Table 2.1: Reagents and solut ions. 
 
Sample	collection	from	healthy	volunteers	and	patients	
Approval was granted by the Local Research Ethics Committee for collection of samples 
from patients and healthy volunteers (REC: 12/YH/0364, LTHT R&D: HM12/10295).  
Informed consent was given by all patients and healthy donors.  Patients were recruited 
from the myeloma clinic at St James’s Institute of Oncology and gave consent for 
peripheral blood and, in some cases, bone marrow sample collection (Appendix 2 shows 
donor information sheets and consent forms).  Peripheral blood samples from healthy 
control donors were collected from both age-matched (relatives of patients) and non-age-
matched (University of Leeds staff) donors.  Healthy age-matched donor bone marrow 
samples were collected from patients undergoing hip arthroplasty without haematological 
comorbidities; matched peripheral blood samples were also taken from these donors.  
Patient and donor data, such as age, gender, date of diagnosis, and clinical parameters 
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were obtained and stored in a secure, anonymous manner according to ‘good clinical 
practice’ guidelines and the University of Leeds information governance policies. 
Venous blood and bone marrow aspiration samples were collected into sterile 
ethylenediaminetetraacetic acid (EDTA) tubes (Vacutainer, BD Biosciences).  Collection 
tubes were centrifuged at 350g for 15 minutes and the plasma was aspirated and stored 
at -80°C; the cell pellet was then resuspended in HBSS (twice the original sample volume) 
for mononuclear cell isolation.  Serum samples were collected simultaneously in clotted 
blood tubes, centrigued at 400g for 20 minutes and rapidly frozen and stored at 20°C 
until analysis. 
Apheresis cones from peripheral blood platelet donations were purchased from National 
Health Service Blood and Transplant, processed within 6 hours of the initial donation, and 
flushed out with 50ml of HBSS prior to mononuclear cell isolation (see below).   
 
Isolation	of	mononuclear	cell	fractions	
Cell solutions were divided into 30ml aliquots and layered onto 15ml of Lymphoprep (Axis 
Shield, Norway) in 50ml Falcon tubes.  The samples were centrifuged at 800g for 20 
minutes, with no brake.  The interface was aspirated with a wide bore pipette and the 
peripheral blood mononuclear cells (PBMC) washed twice in HBSS: centrifuging once at 
200g for 20 minutes, then once at 300g for 10 minutes.  If not required immediately, 
samples were suspended in freezing medium (107 cells per 1ml per cryotube), cooled at -
1°C/min and stored at -270°C in liquid nitrogen. 
	
T	cell	subset	enrichment	
Magnetic-assisted cell sorting 
For some experiments, CD4+ T cells were selected from PBMC by magnetic-assisted cell 
sorting (MACS), using CD4+ T cell Isolation Kit II (Miltenyi Biotec, UK).  In brief, PBMC are 
first incubated with a cocktail of biotin-conjugated monoclonal antibodies (against CD8, 
CD14, CD16, CD19, CD36, CD56, CD123, TCRγδ and glycophorin A) for 15 minutes, 
then anti-biotin monoclonal antibodies conjugated to magnetic beads are added.  The 
magnetically labelled non-CD4+ cells are then depleted by retention on a MACS column 
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(Miltenyi Biotec) in the magnetic field of a MACS separator (Miltenyi Biotec), while the 
unlabelled CD4+ cells pass through.  The kit was used as per the manufacturer’s 
instructions.  Purity checks by flow cytometry revealed >95% purity. 
For some experiments, purified naïve (CD45RA+) and memory (CD45RO+) T cell 
populations were required, which were isolated using the same method.  The Naïve CD4+ 
T Cell Isolation Kit II (Miltenyi Biotec, 130-094-131) contains biotin-conjugated monoclonal 
antibodies against CD8, CD14, CD15, CD16, CD19, CD25, CD34, CD36, CD45RO, 
CD56, CD123, TCRγδ, HLA-DR and glycophorin A.  The Memory CD4+ T Cell Isolation Kit 
(Miltenyi Biotiec, 130-091-893) uses biotin-conjugated monoclonal antibodies against 
CD8, CD14, CD16, CD19, CD36, CD45RA, CD56, CD123, TCRγδ and glycophorin A. 
For some coculture experiments, purified CD4+CD25- T cells were required.  These were 
isolated by first selecting CD4+ T cells from PBMC as described above.  Following this 
cells were labelled with anti-CD25 antibody conjugated to magnetic beads (CD25 
MicroBeads II, Miltenyi Biotec, 130-092-983), incubated for 15 minutes at 4-8°C and then 
washed.  The cells were then passed through a MACS column as before, resulting in 
depletion of CD25+ cells by retention within the magnetic field. 
Stimulation	of	T	cells	
A variety of T cell stimulation modalities were investigated.   
Phorbol 12-myristate 13-acetate & ionomycin 
The phorbol ester, phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, UK), causes 
direct activation of Protein Kinase C.  Ionomycin (ION, Sigma-Aldrich, UK), an ionophore 
produced by the bacterium Streptomyces conglobatus, induces a rise in intracellular 
calcium.  The combination of these two agents has been widely used to induce T cell 
stimulation.  Unless otherwise stated, cells were suspended at 106/ml in complete 
medium (CM), PMA was added at 25ng/ml and ION at 1μg/ml and cells were incubated 
for 3 hours at 37°C, 5% CO2.  Golgiplug (BD Bioscience) was then added at 1μl/ml and 
the cells incubated for a further 3 hours. 
T cell activation/expansion kit 
This kit is intended for expansion and activation of human T cells by mimicking antigen-
presenting cells.  Anti-biotin MACSiBead particles (Miltenyi Biotec) were loaded with 
combinations of biotinylated antibodies against CD3, CD28 (included in the kit), CD5 (BD 
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Biosicence) and ICOS (eBioscience), under aseptic conditions as follows:  MACSiBead 
particles were first re-suspended by vortexing; 108 particles (500μl) were then removed 
and placed in a sealable 2ml tube.  100μl of each antibody was added, and the mixture 
was then made up to a total volume of 1ml with MACS buffer.  The mixture was 
incubated at 2-8°C under constant rotation at 4rpm.  The loaded particles were then 
stored for up to 4 weeks at 2-8°C. 
MACSiBead particles were added to mononuclear or T cells at ratio of 1 bead : 2 cells.  
When used for T cell restimulation (to induce cytokine secretion), cells were incubated for 
6 hours, with Golgiplug added at 1μl/ml for the last 3 hours, as per the PMA/ION 
protocol.  
Cytostim 
Cytostim is an antibody-based reagent that stimulates T cells by crosslinking T cell 
receptors (TCR) with major histocompatibility complex (MHC) molecules; it acts similarly 
to a superantigen (although independently of certain Vβ domains of the TCR).  Cells were 
suspended at 106ml-1 in CM, Cytostim was added at 20μl per ml and the mixture was 
incubated for 6 hours at 37°C, 5% CO2; Golgiplug was added for the last 3 hours. 
Candida albicans antigens 
The Peptivator Candida albicans MP65 reagent (Miltenyi Biotec, UK) is a lyophilised pool 
of 15aa peptides (with 11aa overlap) covering the sequence of the Candida albicans cell 
wall mannoprotein MP65.  Cells were suspended at 106ml-1 in CM, Peptivator was added 
at 20μl per ml and the mixture was incubated for 6 hours at 37°C, 5% CO2; Golgiplug 
was added for the last 3 hours. 
 
Flow	cytometry	
Principles of flow cytometry 
Flow cytometry, a technique widely employed in immunobiology, allows high-throughput 
multiparametric analysis of the physical and chemical characteristics of multiple individual 
cells within a single cell suspension by measurement of their light absorption, scattering 
and emission characteristics.  Through the use of antibodies conjugated to fluorophores 
(fluorescence chemicals which absorb light of one wavelength and then re-emit light of a 
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longer wavelength) the method allows assessment of the expression of proteins both on 
the surface of, and within cells. 
In brief, a flow cytometer comprises three components: a fluidic system, an optical 
system and a computer system.  The fluidic system employs hydrodynamic focusing to 
force cells into a single cell stream, which is then passed at a known speed through the 
optical system.  Here, one or more lasers interrogate the particle stream in turn, causing 
excitation of fluorophores responsive to that wavelength.  A series of dichroic mirrors, 
bandpass filters and photomultiplier tubes (PMT) then allow detection of transmitted, 
reflected and re-emitted light within pre-determined ranges of wavelengths during the 
passage of each particle through each laser.  Low angle forward scattered light (forward 
scatter: FSC, collected at an angle of 15° to the incidence beam, usually measured using 
the ‘blue’ laser at 488nm) is detected by a PMT aligned to the laser stream (with an 
obscuration bar to exclude transmitted light) and is approximately proportional to cell 
diameter.  Light scattered at wide angles (measured at 90° to the incident beam, again 
usually on the 488nm laser) provides a measure of the granularity of the cell (side scatter: 
SSC).  The remaining PMTs collect light at 90° to their respective incident laser at ranges 
of wavelengths longer than the excitation laser and therefore allow measurement of light 
emitted by stimulated antibody-conjugated fluorophores and thus quantitation of the 
cognate antigen.  Since fluorophores emit light across a range of wavelengths and may 
therefore be detected by more than one detector, a panel of control samples, each 
stained with only a single fluorophore, is used to compensate for spectral overlap across 
fluorophores. 
 
Fluorochome-conjugated antibodies 
The antibody-fluorochrome conjugates and DNA dyes employed in these experiments 
were as follows: 
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Live/Dead 
discriminator 
PI-like Blue (488) 625 Miltenyi 
Biotec 
(130-091-163) 
CD4 FITC Blue (488) 520 BD RPA-T4 (555346) 
CD4 APC-Cy7 Red (633) 785 BD RPA-T4 (557871) 
CD8 APC-Cy7 Red (633) 785 Biolegend SK1 (344714) 
CD161 APC Red (633) 660 BD DX12 (550968) 
CD25 PE-Cy7 Blue (488) 785 BD M-A251 (557741) 
CD183  
(CXCR3) 
PE-Cy7 Blue (488) 785 BD 1C6/CXCR3 
(560831) 
CD184  
(CXCR4) 
PE-Cy7 Blue (488) 785 BD 12G5 (560669) 
CD194  
(CCR4) 
AF647 Red (633) 668 BD 1G1 (557863) 
CD196  
(CCR6) 
PE Blue (488) 578 BD 11A9 (559562) 
IL-17 V450 Violet (405) 448 BD N49-653 (560610) 
IFNγ V500 Violet (405) 500 BD B27 (561980) 
RORγt PE Blue (488) 578 BD Q21-559 (563081) 
RORγt PE Blue (488) 578 eBioscience AFKJS-9 (12-6988) 
T-bet PE Blue (488) 578 BD O4-46 (561268) 
FoxP3 AF488 Blue (488) 495 BD 236A/E7 (561181) 
FoxP3 APC Red (633) 660 eBioscience 236A/E7 (17-4777) 
Table 2.2: F luorochrome-conjugated ant ibodies for f low cytometry.  IL-17: 
interleukin 17, IFNγ: interferon gamma, RORγt: retinoic acid-related orphan receptor 
gamma t, T-bet: T-box gene expressed in T cells, FoxP3: forkhead box P3, PI: Propridium 
iodide, FITC: Fluorescein isothiocyanate, APC-Cy7: Allophycocyanin-cyanine dye 7, APC: 
Allophycocyanin, AF488: Alexa Fluor 488, AF647: Alexa Fluor 647, PE: R-phycoerythrin, 
PE-Cy7: phycoerythrin-cyanine dye 7, BD: Becton Dickinson,  
Cell staining and assay protocol 
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Live cells were transferred to U-bottomed 96 well plates (Corning Incorporated, USA) at 
≤106 in 100μl per well and the plate was centrifuged at 300g for 3 minutes (all further 
spins used these settings).  After removal of supernatant, cells were resuspended in 50μl 
of FACS buffer per well and 1μl of Dead Cell Discriminator (Miltenyi Biotec, UK) was 
added.  The plate was then incubated on ice under a 60W tungsten filament bulb for 10 
minutes to photo-label cells.  From this point onwards, all incubations were performed in 
the dark and on ice.  Thereafter conjugated monoclonal antibodies against surface 
proteins, or their corresponding isotypes, were added and cells were incubated for 30 
minutes.  Wells were then washed with 200μl of Fixation-Permeabilisation buffer (Miltenyi 
Biotiec).  1μl of Dead Cell Discriminator stop (Miltenyi Biotec, UK) was added and cells 
incubated for 10 minutes.  Cells were then washed once in 100μl of FACS buffer and 
once in 100μl of Permeabilisation buffer (Miltenyi Biotec, UK), before resuspension in 
100μl of permeabilisation buffer.  Conjugated monoclonal antibodies against intracellular 
proteins, or their corresponding isotypes, were then added and cells incubated for a 
further 30 minutes.  Finally, cells were washed in FACS buffer, and resuspended in either 
200μl FACS buffer per well in the 96 well plate, or 300μl in 5ml polypropylene FACS 
tubes, and analysed immediately on the BD LSR II flow cytometer. 
Analysis, gating strategy and fluorochrome compensation 
Analysis was performed with FACS DIVA versions 6 and 7 (BD Biosciences).  The 
lymphocyte population was identified by forward and side scatter characteristics and 
dead cells were excluded using fluorescence in the dead cell discriminator channel.  
Where there was spectral overlap between fluorochromes, this was corrected using 
compensation values calculated from single stain controls.  When all compensation was 
completed, CD4+ T cells were gated on and categorised as Th17, Th1 or Th17-1 on the 
basis of expression of IL-17, IFNγ or both respectively.  The phenotype of these subsets 
was then characterised by their expression of additional markers. 
Flow cytometric cell sorting 
Flow cytometric sorting was performed by the University of Leeds Core Facilities FACS 
sorting service using a BD FACS Aria cell sorter.  In principle this machine is a standard 
flow cytometer, which has in addition a vibrating mechanism able to fracture the single 
stream of cells into individual droplets after it has passed through the flow cell, with each 
droplet containing a single cell .  An electrostatic charge is then applied to each droplet, 
which subsequently passes through an electrostatic deflection system which directs each 
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drop into a selected collection tube.  In this way, each individual cell can be directed to a 
particular collection tube according to gating on their flow cytometric characteristics, 
allowing collection of one or more specific populations of cells.  For cell sorting 
experiments, cell staining was performed according to the same protocols described 
above. 
 
Luminex®	assays	
A Luminex assay (R&D Systems: Human HS Cytokine B Pre-Mixed Mag Luminex 
Performance Assay) was employed for multiplex cytokine assays, and was used 
according to the protocol supplied with this propriety kit.  The selection of beads used is 
detailed in the Chapter 3 methods section.  In brief, donor plasma samples were loaded 
into 96-well plates and incubated with spectrally encoded beads conjugated with 
antibodies against the analytes of interest.  Serial dilutions of control samples were loaded 
into the same plate and treated similarly.  Secondary biotinylated detection antibodies 
specific for the same analytes were then added, followed by phycoerythrin (PE)-
conjugated streptavidin.  The plate was then read using a Luminex 100 flow cytometry 
analyser, which employs dual lasers to simultaneously classify the bead and determine 
the magnitude of the PE-derived signal.  The results were subsequently analysed using 
Luminex IS software.  By comparison of the PE-derived signal associated with each bead 
in each sample against a standard curve, determination of the concentration of each 
analyte in each sample can be determined. 
 
Human	myeloma	cell	(HMCL)	&	bone	marrow	stromal	cell	
lines	(BMSC)	
The human myeloma cells H929, JIM1, JIM3, JJN3, KMS11, KMS18, OPM2, RPMI8226, 
U266B (in house), the human bone marrow stromal cells HS-5 and HS-27, the murine 
bone marrow stromal cell M2-10B4, the CD40L-transduced human fibroblast line L929 
and the Epstein Barr virus-transformed B cell line IM9, were maintained in CM in 
ventilated tissue culture flasks at 37°C and 5% CO2 in a humidified incubator.  CM was 
replaced every 3 to 4 days.  1% trypsin was used to loosen the plastic-adherent BMSC 
lines prior to passage.  HMCL characteristics are shown in Appendix 3. 
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PBMC	/	HMCL	co-cultures	
All tissue culture work was performed under sterile conditions in laminar flow hoods.  
Proliferation of myeloma cell lines was reduced by treatment with mitomycin-C at a 
concentration of 50μg/ml for 30 minutes.  Cells were then washed twice in CM, 
centrifuging at 300g for 10 minutes.  PBMC and HMCLs were mixed at a 1:1 ratio at a 
concentration of 106ml-1 in CM.  Unless indicated, cocultures were incubated for 7 days at 
37°C, 5% CO2 before cells were harvested for analysis by flow cytometry. 
For cultures where HMCL lysates were used, 106 HMCL were resuspended in 100μl of 
PBS and subjected to 5 freeze-thaw cycles, alternating between -80°C for 20 minutes 
and 37°C for 10 minutes.  100μl of this solution was then added to 106 PBMC.  Cultures 
were then treated and analysed as above. 
 
Western	blotting	
Loading buffer, running buffer and blot transfer buffer were made as listed in Appendix 4.  
Cell cultures were harvested and then centrifuged in a 15ml Falcon tube at 1000g for 10 
minutes.  The supernatants were removed and the cell pellet resuspended in 50μl of 
loading buffer, mixed thoroughly and transferred to 1.5ml Eppendorf tubes. 
A 10% SDS-PADE resolving gel with a 5% stacking gel was prepared and immersed in 
running buffer.  25μl of pre-stained standard protein ladder (Invitrogen) was placed in the 
first well.  Protein samples were heated to 100°C for 5 minutes before being placed on 
ice, and 25μl of each sample was then loaded into well.  A potential difference of 200V 
was applied across the gel for 3 hours. 
A piece of polyvinylidene difluoride membrane (Hybrid P, Sigma) was activated in 
methanol for 20 seconds and then immersed in transfer buffer.  The SDS-PAGE gel was 
then placed on top, the two sandwiched in blotting paper (Whatman paper, 3M), placed 
within a transferred cassette and 120mA current was applied across the cassette for 12 
hours. 
The membrane was first blocked in PBS/TWEEN containing 10% Marvel for 1 hour at 
room temperature with continuous rocking.  The membrane was then transferred to 
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PBS/TWEEN containing 1% Marvel, and the primary antibody (rabbit anti-bcl2, 50E3, Cell 
Signalling Technologies) was added at 1:1000 before incubation for 3 hours at room 
temperature with continuous rocking.  The membrane was next washed 3 times in 
PBS/TWEEN (10 minutes per wash, with continuous rocking) and then placed in 
PBS/TWEEN containing 0.1% Marvel; secondary antibody was then added (HRP-
conjugated anti-rabbit, Cell Signalling Technologies) at 1:3000 and the membrane 
incubated for 1 hour at room temperature with continuous rocking.  The membrane was 
then washed 3 times in PBS/TWEEN (10 minutes per wash, with continuous rocking) 
before electrochemiluminescence ECL solutions 1 and 2 were added at a ratio of 1:1, and 
the blot transferred to a light-proof cassette.  In a darkroom, CL-XPosure film (Thermo 
Scientific) was then inserted into the cassette and exposed for a variety of times, before 
being developed using an automated developer. 
 
Statistical	analysis	
Statistical analysis was performed using Graphpad Prism version 6.  Unless stated 
otherwise a p value of <0.05 was considered statistically significant.  Cell phenotyping 
data is expressed as median values and co-culture readouts as mean values, unless 
otherwise stated. 
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Chapter 3 – Th17 cells in multiple myeloma 
Introduction	
As reviewed in detail in Chapter 1, the role played by Th17 cells in cancer remains the 
subject of debate.  Considerable discrepancy exists between published experimental 
findings and a range of reasons might account for this.  Firstly, there are likely to be true 
differences in the prevalence and biological roles of these T cells between different types 
of cancer; clearly their contribution is potentially complex, with both pro- and anti-tumour 
roles ascribed.  However, in addition, variations in experimental approach may contribute 
to the disparate findings.  For example, these cells are defined by secretion of IL-17, 
however since this is often a difficult property to assay, a range of surrogate markers have 
been used to identify the cells, ranging from expression of their signature transcription 
factor, RORC, to cell surface markers said to be characteristic of the subset; IL-17 is also 
sometimes quantified and a T cell source inferred258-260. 
This chapter of work aims firstly to develop a robust methodology for identification, 
quantitation and phenotypic assessment of Th17 cells in peripheral blood and bone 
marrow samples, and then to employ this protocol to assess the prevalence, phenotype 
and function of Th17 cells in healthy donors and patients with plasma cell dyscrasia. 
 	
University of Leeds – School of Medicine Christopher Parrish 
- 54 - 
Materials	and	Methods	
Patients and normal donors 
Samples from newly diagnosed patients were taken prior to any treatment of disease; 
samples from patients with relapsed disease were taken prior to any treatment of relapse.  
All patients on maintenance therapy were taking lenalidomide, with or without 
dexamethasone.  Donor characteristics are shown in Table 3.1. 
 
Luminex assay 
A Luminex assay (R&D Systems: Human HS Cytokine B Pre-Mixed Mag Luminex 
Performance Assay) was employed for cytokine assays.  Microparticles used are shown in 
Table 3.2. 
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N 22 10 14 5 5 4 4 
Gender male:female 10:12  8:6 3:2 2:3 2:2 2:2 
Age 
(range) 
46 
(22-79) 
 
74 
(46-90) 
66 
(55-81) 
71 
(58-88) 
68 
(59-74) 
68 
(63-75) 
Paraprotein type 
 IgG 
 IgA 
 IgM 
 LC 
 NS 
  
 
12 
1 
0 
1 
0 
 
4 
0 
0 
0 
1 
 
4 
1 
0 
0 
0 
 
4 
0 
0 
0 
0 
 
3 
0 
0 
1 
0 
Paraprotein level  
/gl-1 (range) 
  8 
(0-38) 
16 
(0-58 
4 
(0-10) 
1 
(0-5) 
18 
(10-27) 
 
Table 3.1: Donor character ist ics.  PB: peripheral blood, MGUS: monoclonal 
gammopathy of uncertain significance, AMM: asymptomatic myeloma, LC: light chain 
disease, NS: non-secretory disease 
 
Analyte Sensitivity 
/pgml-1 
High standard 
value /pgml-1 
Microparticle 
region 
IFNγ 0.029 260 30 
IL-1β 0.146 4,240 20 
IL-2 0.386 4,850 19 
IL-6 0.135 2,650 25 
IL-17A 0.349 10,370 36 
IL-17F 4.54 36,750 37 
IL-22 0.529 6,700 38 
IL-23 9.52 70,000 39 
TNFα 0.551 4,920 12 
 
Table 3.2: Luminex micropart ic les used for cytokine assays on serum 
samples. 
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Results	
Quantitation and phenotyping of Th17 cells in normal individuals – 
stimulation of cytokine secretion 
Since cytokine secretion must be induced to identify the Th17 population, IL-17 production 
by CD4++ T lymphocytes was assayed after a range of polyclonal stimulation modalities: 
PMA and ION, anti-CD3/28 MACSiBeads and Cytostim.  As reported in the published 
literature, Th17 cells represented only a very small proportion of T cells, often less than 1%; 
representative dot plots are shown in Figure 3.1.  The combination of PMA and ION 
(PMA/ION) was optimal for stimulation of IL-17 secretion, however, PMA also resulted in 
loss of CD4 from the cell surface in a time-dependent manner (Figure 3.2).  Use of lower 
concentrations impaired cytokine secretion but did not satisfactorily abrogate loss of CD4 
(data not shown).  Phosphorylation and modulation of cell surface expression of CD4 in 
response to PMA has been reported previously261 and result in internalisation and 
lysosomal degradation of the protein262.  CD8 was also affected (Figure 3.2).  Addition of 
fluorochrome-conjugated anti-CD4 antibody at the intracellular staining stage reliably 
identified cells having internalised CD4 in response to PMA and this protocol was 
therefore adopted for the remainder of the project. 
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F igure 3.1.  Representat ive dot plots of IL-17 and IFNγ  secret ion by CD4+ T 
cel ls.  PBMC from a healthy donor were stimulated for 6 hours with PMA and ION, ION 
alone, anti-CD-3/28 MACSiBeads or Cytostim.  All cells were treated with Golgiplug for 
the last 4 hours of stimulation.  Percentages of total CD4+ cells shown. 
 
F igure 3.2.  Representat ive dot plots of surface CD4 and CD8 stain ing on 
CD3+ cel ls after incubat ion of unselected PBMC with PMA for 6, 4 or 3 
hours at 25ng/ml.  All conditions were treated with Golgiplug for the last 3 hours of 
incubation.  Percentages are the proportion of CD3+ cells expressing CD4 and CD8 on 
their surface. 
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Circulating Th17 cells in healthy donors 
PBMC were isolated from healthy volunteers (n=22, median age 46.9 years) and stained 
to quantify and phenotype CD4+ T cell subsets, as described above.  The median 
frequency of CD4+ T cell subsets was as follows (Figure 3.3): Th17 cells: 0.21% of CD4+ 
cells (range 0-2.94), Th17-1: 0.04% (0-0.85), Th1: 11.39% (0.08-49.67). 
CD4+ T cell subsets from peripheral blood apheresis cones (n=10) were also analysed and 
showed: Th17: 0.64% (0.20-2.852), Th17-1: 0.13% (0-1.06), Th1: 28.27% (10.99-43.42). 
When peripheral blood (PB) and apheresis cone (AC) samples were compared (Figure 
3.4), there was no significant difference between the frequency of any measured T cell 
subsets in peripheral blood donors and apheresis cone cells (unpaired student t test, 
p=NS).  These results indicate that apheresis cones are a suitable substitute for peripheral 
blood samples, and the two sources of mononuclear cells were thereafter considered 
equivalent and apheresis cones were used where large numbers of cells were required. 
There was a small, but significant, negative correlation between donor age and Th17 cells 
as a percentage of CD4+ cells (r2=0.19, p=0.04, Figure 3.5A).  However, there was no 
significant correlation between donor age and Th1 (Figure 3.5B) or Th17-1 cell prevalence 
(Figure 3.5C).  Since MM is predominantly a disease of the elderly, these results indicate 
age-matched healthy donors are required as a control for assessing Th17 in patients with 
MM. 
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F igure 3.3.  Th17, Th1 and Th17-1 subsets as a percentage of CD4+ cel ls in 
per ipheral b lood samples from healthy donors.  Horizontal lines show mean and 
standard deviation (which crosses the x axis for the Th17 and Th17-1 groups).  N=22 
 
F igure 3.4. Comparison of T cel l  subsets in per ipheral b lood (PB) of healthy 
donors and apheresis cone der ived cel ls.  Horizontal lines show mean and 
standard deviation.  There was no difference in the numbers of Th17, Th1 or Th17-1 cells 
between PB and Cones (unpaired t test, p=NS).  There was also no difference in the 
expression of CD161, CCR4 of CCR6 on Th17 cells from PB or Cones (data not shown).  
Healthy donors n=22, cones n=10. 
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F igure 3.5.  Th17 (panel A),  Th1 (B) and Th17-1 (C) cel ls as a percentage of a l l  
CD4+ cel ls as a funct ion of donor age.  The red lines show linear regression fits 
and the dotted lines show the 95% confidence intervals.  There was a small but significant 
correlation (r2=0.19, p=0.04) between age and percentage of Th17 cells, but no significant 
correlation between age and percentage of Th1 cells (r2=0.045, p=NS), or Th17-1 cells 
(r2=0.13, p=0.09).  N=22. 
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Th17 cell phenotype in health 
Since retinoic acid-related orphan receptor gamma t (RORC) is the signature transcription 
factor for the Th17 lineage, it was assumed that this would represent a sensitive and 
specific marker of the population by flow cytometry.  Unfortunately only two commercial 
antibodies against RORC (the human homologue of RORγt) are currently available.  
Despite testing with a range of staining protocols and reagents these antibodies were 
found to be nonspecific, staining almost all CD4+ cells, with no significant difference seen 
in either percentage positivity or median fluorescence intensity between those CD4+ cells 
producing IL-17 and those not (data not shown).  The cell surface and functional 
properties of Th17 cells were therefore investigated, in order to attempt to define a 
phenotypic profile for this rare set of T cells. 
Th17 cells from PB and AC samples were examined for their expression of cell surface 
proteins (CCR6, CD161, CD127, CXCR4, CXCR3, CCR7, CCR4, CD25), cytokines (IL-
17, IFNγ, IL-10) and transcription factors (RORγt, T-bet, FoxP3).   
Representative flow cytometry plots of CD161 expression on T cell subsets is shown in 
Figure 3.6, collated data for multiple donors in Figure 3.7.  Although there was a 
significant difference in CD161 expression between Th17 and Th1 cells (p=0.0001) and 
between Th17 cells and CD4+IL-17-IFNg-FoxP3- T cells (p=0.0001), there was no 
difference between Th17 cells and either Th17-1 or TReg cells (p=NS).  Furthermore, CD161 
was expressed to some extent on all subsets (by comparison to isotype control staining), 
with wide variation in the degree of expression in all subsets.  Consequently, gating on 
CD4+CD161+ cells yielded a population considerably enriched for IL-17-producing 
lymphocytes (5.1% vs. 1.2% in the un-gated population for the donor shown), but which 
still contained Th1 cells, as well as CD4+ cells producing neither cytokine (Figure 3.8).   
Expression of CCR6 was seen on a median of 93.4% of Th17 cells, although once again 
expression was noted in a subpopulation of Th1 cells (Figures 3.9 & 3.10); CCR4 
expression was recorded in median 80.6% of Th17 cells, but expression of the marker was 
found to be even less specific for the subset (Figure 3.11).  As with CD161, neither of 
these markers was therefore suitable as a surface marker for Th17 cells in isolation.  The 
remaining markers examined were found to be minimally expressed on Th17 cells (data not 
shown).   
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F igure 3.6.  Representat ive dot plots of CD161 expression in T cel l  subsets 
in a healthy donor.  The left panel shows IL-17 and IFNγ secretion in CD4+ cells after 
stimulation with PMA & ION and Golgiplug.  The 4 panels on the right show CD161 
expression on Th17, Th17-1, Th1 and IL-17-IFNγ- CD4+ cells. 
 
F igure 3.7.  Expression of CD161 on Th17, Th1, Th17-1 and Treg 
(CD4+CD25+FoxP3+) cel ls in healthy donors.  CD161 expression on CD4+IL-17-
IFNg-FoxP3- cells is shown for comparison (n=6).  Median percentages of cells expressing 
CD161 were: Th17: 54.0% (range 0-77.2%), Th1: 31.0% (0.4-59.4%), Th17-1: 58.1% (0-
83.3%). TReg (CD4+CD25+FoxP3+): 34.3% (0-100%), CD4+IL-17-IFNg-FoxP3-: 10.35% (7.4-
16.3%).  Plots show mean and standard deviation.  p values are two-tailed paired t tests.  
N=22. 
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F igure 3.8.  Representat ive dot plots of cytokine product ion in CD161+ 
cel ls.  The left hand plot shows CD161 vs. side scatter, with the red square indicating a 
gate on CD161+ cells (gate set according to corresponding isotype control).  The right 
plot shows IL-17 and IFNγ production in the gated population.   
 
 
 
F igure 3.9.  Representat ive dot plots of CCR6 expression in T cel l  subsets 
in a healthy donor.  The left panel shows IL-17 and IFNγ secretion in CD4+ cells after 
stimulation with PMA & ION and Golgiplug.  The 4 panels on the right show CCR6 
expression on Th17, Th17-1, Th1 and IL-17-IFNγ- CD4+ cells. 
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F igure 3.10.  CCR6 expression on T cel l  subsets in healthy donors.  Mean 
and standard deviations shown.  P values are for two-tailed paired t tests.  N=18. 
 
 
F igure 3.11.  Representat ive dot plots of CCR4 expression in T cel l  subsets 
in a healthy donor.  The left panel shows IL-17 and IFNγ secretion in CD4+ cells after 
stimulation with PMA & ION and Golgiplug.  The 4 panels on the right show CCR4 
expression on Th17, Th17-1, Th1 and IL-17-IFNγ- CD4+ cells. 
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These results indicated that none of the cell surface markers used individually were 
sufficiently selective or specific for Th17 cells to be used to reliably identify the population.  
Staining for combinations of these proteins was therefore evaluated.  Figure 3.12 shows a 
representative example of this gating strategy.  Here, PBMC from a healthy donor were 
stimulated as previously, and the production of IL-17 and IFNγ by live CD4+ cells is shown 
in the left panel – 0.3% of this population produced IL-17.  In the right panel an alternative 
gating is shown whereby the live CD4+CD161+CCR6+ population was assessed for 
production of IL-17 and IFNγ – 1.4% of this population produced IL-17.  Therefore, 
combination of markers in this way resulted in an approximately five-fold enrichment for 
Th17 cells, although an increase in the proportion of cells producing IFNγ was also seen 
and the vast majority of cells produced neither cytokine.  Addition of CCR4 to the gating 
strategy did not improve purity.  For these reasons, it was not possible to use staining of 
the available surface antigens to define Th17 cells, and for the remainder of this thesis Th17 
cells are therefore identified by their determining characteristic – production of IL-17 (i.e. 
CD4+IL-17+ cells). 
In light of the correlation seen between Th17 prevalence and age, the interplay of age and 
expression of CD161 and CCR6 was examined; linear regression analysis indicated no 
significant correlation in both cases (data not shown). 
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F igure 3.12.  Representat ive example of two gat ing strategies for 
ident i f icat ion of Th17 cel ls.  PBMC from a healthy donor was stimulated as described 
and flow cytometric gates were used to identify live CD4+ cells.  In the left panel, the 
production of IL-17 and IFNγ by these cells in shown.  In the right panel, the CD4+ cells 
were further selected for expression of both CD161 and CCR6, and production of IL-17 
and IFNγ by this subpopulation is then shown in the bottom right panel. 
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Quantitation of Th17 cells in the peripheral blood of myeloma 
patients 
Th17 cells (CD4+IL-17+) were enumerated in the peripheral blood of patients with MM and 
MGUS and compared to healthy controls; a significant reduction in Th17 cells was noted in 
the patient group compared to healthy donors: 0.39% (range 0-2.94%) vs. 0.69% (range 
0-1.86%), p=0.0331; Figure 3.13.  This is in contradiction to published data also 
comparing with non-age-matched healthy donors74.  In contrast, Th1 cells and Th17-1 cells 
were not significantly different between health and disease (p=NS, student t-test, data not 
shown).   
 
Impact of Age 
Since donor age had been shown to correlate inversely with prevalence of Th17 cells in the 
peripheral blood of healthy donors, comparisons were next made between patients with 
plasma cell dycrasias (median age 73, range 46-90) and a cohort of age-matched healthy 
donors (median age 70 years, range 47-79).  In this age-matched cohort, 0.1% of CD4+ T 
cells produced IL-17 – significantly less than the 0.39% seen in the patient samples 
(p=0.05, Figure 3.14) 
The effect of age on prevalence of Th17 cells in the peripheral blood of patients with 
plasma cell dyscrasias was next examined (Figure 3.15).  Surprisingly, unlike in the case 
of healthy donors, the age of patients did not correlate with the prevalence of Th17 cells in 
their peripheral blood (r2=0.0005, p=0.9009); when the impact of age was assessed in the 
age-matched healthy donor cohort (shown in blue on Figure 3.15), there was no 
significant correlation (r2=0.0001, p=0.9766). 
These data indicate that although Th17 cell frequency was lower in peripheral blood of MM 
patients than in an unselected healthy donor population, when a more appropriate age-
matched healthy donor cohort was used, levels were actually found to be higher in MM 
than in health.  An age-matched healthy donor cohort was therefore included for the 
proceeding work. 
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F igure 3.13.  Th17 cel l  f requency in the per ipheral b lood of healthy donors 
and pat ients with plasma cel l  dyscrasias.  Healthy donors: n=32, Patients: n=32.  
Mean and standard errors of the mean shown. Two-tailed student t-test shown. 
 
 
F igure 3.14.  Th17 cel l  f requency in the per ipheral b lood of age-matched 
healthy donors and pat ients with plasma cel l  dyscrasias.  Healthy donors: n=8, 
Patients: n=32.  Mean and standard errors of the mean shown. Two-tailed student t-test 
shown. 
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F igure 3.15.  Th17 cel l  f requency as a percentage of a l l  CD4+ cel ls in the 
per ipheral b lood of pat ients with plasma cel l  dyscrasias (red, n=32), and 
age-matched healthy controls (b lue, n=8), p lotted as a funct ion of age.  The 
solid lines show linear regression fits, and the dotted lines 95% confidence intervals for 
the linear regressions. 
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Subdivision by disease stage 
When patients were subdivided by disease category (for disease category classifications, 
see Appendix 1), differences in the prevalence of IL-17- and IFNγ-secreting CD4+ T cells 
were noted between stages of disease (Figures 3.16-18).  Interestingly, although all 
patient groups had higher levels of Th17 cells than age-matched controls, the highest 
levels were seen in patients with pre-symptomatic disease (MGUS and asymptomatic 
myeloma), and the lowest in those with ‘active’ disease (newly diagnosed or relapsed). 
When analysed by disease classification, Th17-1 cells were significantly increased in 
patients with MGUS & asymptomatic MM compared to age-matched healthy controls; 
there were no other significant differences (Figure 3.17).  Th1 cells were increased in 
patients at relapse compared to healthy donors (age-matched or of all ages), newly 
diagnosed myeloma and patients in remission, but no other significant differences 
between groups were found (Figure 3.18). 
These data show differences in the relative prevalences of Th17 and Th1 cells, with Th17 
cells being raised in MGUS/AMM and falling to the lowest levels in relapsed disease 
where Th1 cells in contrast reached the highest levels in relapsed MM.  These findings are 
novel and indicate that the loss of Th17 cells with disease progression is not merely a 
consequence of disease- or treatment-related lymphopenia but instead suggests a 
specific depletion of the T cell subset in active disease. 
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F igure 3.16.  Th17 cel l  f requency in the per ipheral b lood of healthy donors 
and pat ients.  Mean frequencies were as follows: healthy donors of all ages: 0.69% 
(range 0-2.94%, n=32), age-matched healthy donors: 0.10% (0-0.42%, n=8), MGUS & 
asymptomatic MM: 0.48% (0.04-1.86%, n=14), newly-diagnosed MM: 0.233% (0.002-
0.63%, n=5), MM on maintenance therapy: 0.45% (0-0.74%, n=5), MM in remission: 
0.45% (0.33-0.50%, n=4), relapsed MM: 0.10% (0-0.23%, n=4). Mean and standard 
errors of the mean shown.  P values shown are for unpaired student t tests with Welch’s 
correction; where not shown, p=NS. 
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F igure 3.17. Th17-1 cel l  f requency in the per ipheral b lood of healthy donors 
and pat ients.  Healthy donors: n=32, Age-matched healthy donors: n=8, MGUS & 
asymptomatic MM: n=14, newly diagnosed MM n=5, MM on maintenance therapy n=5, 
remission n=4, relapse n=4.  Mean and standard errors of the mean shown.  P values 
shown are for unpaired student t tests with Welch’s correction. 
 
F igure 3.18. Th1 cel l  f requency in the per ipheral b lood of healthy donors 
and pat ients. Healthy donors: n=32, Age-matched healthy donors: n=8, MGUS & 
asymptomatic MM: n=14, newly diagnosed MM n=5, MM on maintenance therapy n=5, 
remission n=4, relapse n=4.  Mean and standard errors of the mean shown.  P values 
shown are for unpaired student t tests with Welch’s correction. 
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Quantitation of Th17 cells in bone marrow of myeloma patients 
Bone marrow samples from age-matched healthy donors and patients with plasma cell 
dyscrasias were examined for Th17 cell frequency; figure 3.19 shows representative flow 
cytometry dot plots from analysis of the bone marrow of a healthy donor and a patient 
with newly-diagnosed MM.  Although a rare subset in all marrow samples examined, there 
was a significantly higher frequency of Th17 cells in patients than in healthy donors (mean 
0.69% vs. 0.12%, p=0.0185, Figure 3.20A).  Th1 cells were increased in patients 
compared to healthy donors (mean 22.24% vs. 6.28%, p=0.0426, Figure 3.20B), 
whereas Th17-1 cells were not significantly different between the two populations (mean 
0.45% vs. 0.14%, p=NS, Figure 3.20C).  The ratio of Th17:Th1 cells was not significantly 
different between the groups (Figure 3.20D).   
These results indicate that Th17 cells are expanded in the bone marrow as well as the 
peripheral blood of patients with plasma cell dyscrasias.  Since the bone marrow is the 
tumour bed in MM this is further evidence to suggest the expanded Th17 cells derive from 
interactions between the tumour and the host immune system.  Th1 cells were also 
expanded in the bone marrow, but since the number of samples was insufficient for 
meaningful subdivision of patients by disease stage, it is not clear whether this reflects an 
increase in Th1 cells in association with disease relapse, as was seen in the peripheral 
blood. 
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F igure 3.19.  Representat ive dot plots of IL-17 and IFNγ  expression in CD4+ 
cel ls from bone marrow of a healthy donor (A) and a pat ient with newly 
diagnosed MM (B).   
 
 
 
F igure 3.20.  Th17 (panel A),  Th1 (B),  Th17-1 (C) cel l  and Th17:Th1 rat io (D) in 
the bone marrow of healthy donors and pat ients with plasma cel l  
dyscrasias.  Healthy donors: n=6, Patients: n=11.  Mean and standard errors of the 
mean shown. Two-tailed student t-tests shown. 
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Impact of disease-specific variables 
A number of disease-specific variables were next examined for their effect on the 
frequency of Th17 cells.  Patients whose paraprotein was of lambda isotype were found to 
have a higher frequency of Th17 cells than those with a kappa paraprotein (0.59% vs. 
0.28%, p=0.0301).  Those with an IgG heavy chain had a lower frequency of Th17 cells 
than those with an IgA paraprotein (0.25% vs. 0.56%, p=0.02) or light chain disease 
(0.69%, p=0.02).  Level of paraprotein, number of prior lines of therapy, previous 
exposure to thalidomide, lenalidomide or bortezomib, prior stem cell transplant, 
percentage of normal or malignant plasma cells in the bone marrow, serum creatinine, 
myeloma plasma cell phenotype (CD56, CD27 and CD45 expression) and myeloma 
cytogenetic and molecular abnormalities (del 13q and IgH rearrangement) were 
uncorrelated with Th17 frequency.   
Caution is warranted in making inferences from these results, since the numbers of 
patients falling into some subgroups was small, and multivariate analysis was therefore 
not undertaken.  Results for these analyses are shown in Appendix 5. 
 
Functional phenotype of Th17 cells in MM patients – IL-17 
production 
The mean fluorescence intensity (MFI) of Th17 cells for IL-17, which can be considered a 
surrogate marker of IL-17 production, was compared across healthy and disease states 
(Figure 3.21A).  Since MFI varies between experiments according to the flow cytometer 
setup and calibration, it was necessary to normalise data in order to compare samples 
analysed at different points throughout the project.  In order to achieve this the MFI of Th17 
cells for IL-17 was divided by the MFI of IL-17-negative CD4+ lymphocytes for IL-17, 
measured in the same sample.   
When patient peripheral blood Th17 cells were compared to healthy donor Th17 cells they 
were found to have significantly lower expression (student t-test, p=0.0181).  However, 
when the MFI of Th1 cells for IFNγ (similarly normalised to IFNγ- CD4+ cells) was compared 
between health and disease, this was also found to be reduced in patients with plasma 
cell dyscrasias compared to healthy donors (Figure 3.21B).  When BM samples were 
compared, no significant difference was seen in MFI of either Th17 cells for IL-17 or Th1 
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cells for IFNγ between healthy donors and those with plasma cell dyscrasia (data not 
shown). 
 
 
 
F igure 3.21.  Normal ised mean f luorescence intensity of Th17 cel ls for IL-17 
(panel A) and Th1 cel ls for IFNγ  (panel B) in healthy donors and pat ients 
with MM.  P values are for unpaired two-tailed t tests.  N=17 each.   
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These data suggest that Th17 cells in MM are abnormal not only in frequency, but also in 
their ability to produce IL-17 upon stimulation.  In order to further examine this issue, 
concentrations of a range of cytokines were next examined in serum samples from 
patients with multiple myeloma and age-matched healthy donors, using a Luminex® 
assay. 
Firstly, cytokines produced by Th17 cells were assessed: IL-17A, IL-17F, IL-22, IL-23 and 
TNFα.  Median levels of IL-17A, IL-17F and IL-22 are shown in Figure 3.22, TNFα in 
Figure 3.23.  IL23 was below the limit of detection in almost all samples (<9.52pg/ml).  No 
significant differences between healthy donors and patients were noted for any of these 
cytokines (unpaired t tests). 
Cytokines implicated in the generation of Th17 cells were next assessed: IL-1β, IL-2 and 
IL-6 (Figure 3.24).  IFNγ was also assessed, but was below the limit of detection in the 
majority of samples (<0.029pg/ml).  No significant differences were noted between 
healthy donors and patients in any of these cytokines (unpaired t tests). 
In summary, the levels of cytokines detected in all samples were low, and whilst median 
levels of Th17 cytokines were lower in the patient samples in keeping with the flow 
cytometry data, the differences between patient and healthy donor samples did not reach 
significance.  
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F igure 3.22  Concentrat ions of Th17 cytokines in the serum of healthy 
donors (n=8) and pat ients with MM (n=18).  Median levels in healthy donors and 
patients were as follows: IL-17A: 1.030pg/ml (range: 0.5-7.97) vs. 0.75pg/ml (0.44-2.29), 
IL-17F: 5.32 pg/ml (0.38-7.34) vs. 2.44pg/ml (0.83-11.54), IL-22: 0.51pg/ml (0.01-7.86) 
vs. 0.62pg/ml (0.15-1.43).  Mean and standard deviations shown.  p values are for 
unpaired student t tests.   
 
F igure 3.23  Concentrat ion of TNFα  in the serum of healthy donors (n=8) 
and pat ients with MM (n=18).  Median levels in healthy donors and patients were as 
follows: TNFα: 5.25pg/ml (2.61-99.4) vs. 9.15pg/ml (2.08-24.9).  Mean and standard 
deviations shown.  p value is for unpaired student t test.   
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F igure 3.24  Concentrat ions of cytokines impl icated in induct ion of Th17 
cel ls, in the serum of healthy donors (n=8) and pat ients with MM (n=18).  
Median levels in healthy donors and patients were as follows: IL-1β: 0.83pg/ml (range 
0.46-3.31) vs. 0.73pg.ml (0.27-3.77), IL-2: 0.54pg/ml (0.29-3.67) vs. 0.37pg/ml (0.04-
1.83), IL-6: 1.02pg/ml (0.56-1.69) vs. 2.24pg/ml (0.63-62.15).  Mean and standard 
deviations shown.  p values are for unpaired student t tests.   
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Cell surface proteins, transcription factors and other cytokines 
The phenotype of Th17 cells in patients with myeloma and related disorders was 
compared to that of healthy donors with respect to CD161, CCR4, CCR6, CD127, 
CXCR4, CXCR3, CCR7, RORC, FoxP3, T-bet, IL-10 and IFNγ expression.  Expression of 
CD161 and CCR6 were significantly reduced on Th17 cells from patients compared to 
healthy donors (Figure 3.25).  Furthermore, subgroup analysis of CD161 and CCR6 
expression by disease status revealed an association between advancing disease and 
progressive loss of cell surface expression (Figures 3.26 & 3.27).  CCR4, CD127, CXCR4, 
CXCR3, CCR7, RORC, FoxP3, T-bet and IL-10 expression were not found to be 
significantly different between patients and healthy donors (data not shown). 
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F igure 3.25.  CD161 and CCR6 expression on PB Th17 cel ls in healthy 
donors (n=21) and pat ients with plasma cel l  dyscrasias (n=27).  CD161: 
patients 25.54% (range 0-82.8%), healthy controls: 54.26% (0-77.2%) p<0.0001; CCR6: 
patients 68.18% (0-100%), healthy controls: 91.78 (74.4-100%), p=0.0019.  Medians and 
standard errors of the mean indicated.  P values are for unpaired, two-tailed t tests. 
 
F igure 3.26. CD161 expression on PB Th17 cel ls in healthy donors (n=21), 
MGUS & asymptomatic MM (n=12), newly diagnosed MM (n=4), MM on 
maintenance therapy (n=4), MM in remission (n=4) and re lapsed MM (n=3).  
Medians and standard errors of the mean indicated.  P values are for unpaired, two-tailed 
t tests. 
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F igure 3.27.  CCR6 expression on PB Th17 cel ls in healthy donors (n=21), 
MGUS & asymptomatic MM (n=12), newly diagnosed MM (n=4), MM on 
maintenance therapy (n=4), MM in remission (n=4) and re lapsed MM (n=3).   
Medians and standard errors of the mean indicated.  P values are for unpaired, two-tailed 
t tests. 
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Expression of CD161 and CCR6 on Th17 cells in the BM of healthy donors and patients 
were next examined.   Th17 cells in the BM of healthy donors expressed CD161 at a lower 
level than in the PB of the same donors (mean ± SD: 14.02% ± 10.65% vs. 42.32% ± 
10.61%, p=0.0245, representative single patient flow cytometry plots shown in Figure 
3.28, collated data in figure 3.29).  A similar pattern was seen when CCR6 was examined 
(43.34% ± 20.25% vs. 80.58% ± 11.41%, p=0.0294, Figures 3.28 and 3.29). 
When expression of CD161 and CCR6 on Th17 cells from BM and PB of patients was 
compared, CD161 expression was not significantly different (23.14% ± 24.12% vs. 
17.39% ± 14.31%, p=NS) whereas CCR6 expression was lower in BM than PB (38.48% 
± 33.49% vs. 68.66% ± 22.38%, p=0.047); representative flow cytometry plots for a 
single patient shown in Figure 3.30, collated data from all donors in Figure 3.31. 
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F igure 3.28.  Representat ive histograms of CD161 and CCR6 expression on 
Th17 cel ls from PB and BM of a s ingle healthy donor.   
 
 
F igure 3.29.  CD161 and CCR6 expression on Th17 cel ls in the BM and PB 
of healthy donors.  N=5.  P values are for paired student t tests.  Histogram shows 
means ± SEM. 
CCR6$
PB$Th17$
BM$Th17$
CD161$&$CCR6$in$BM$vs$PB$–$healthy$donor$
$
CD161$
University of Leeds – School of Medicine Christopher Parrish 
- 85 - 
 
 
 
F igure 3.30.  Representat ive histograms of CD161 and CCR6 expression on 
Th17 cel ls from PB and BM of a s ingle pat ient with newly-diagnosed MM.   
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Figure 3.31.  CD161 and CCR6 expression on Th17 cel ls in the BM and PB 
of pat ients with plasma cel l  dyscrasias.  N=9.  P values are for paired student t 
tests.  Histogram shows means ± SEM. 
 
Expression of neither CD161 nor CCR6 on BM Th17 cells was significantly different 
between healthy donors and patients (mean and SD): CD161: 14.0 ± 10.7% vs. 23.1 ± 
24.1%, CCR6: 43.3 ± 20.3% vs. 38.5 ± 33.5% (Figure 3.32). 
Since CD161 expression on PB Th17 cells and MFI for IL-17 in PB Th17 cells were both 
reduced in patients in a disease stage-dependent manner, these two variables were next 
assessed for correlation.  Linear regression analysis revealed no significant correlation 
between the two: r2=0.048, p=NS (Figure 3.33). 
These findings reveal a complicated pattern of antigen loss in MM.  Both CD161 and 
CCR6 were found to be lost in MM, in a disease stage-related manner.  Nonetheless, 
CCR6 expression on Th17 cells in MM shows the normal overall pattern in terms of higher 
level expression on PB than BM, albeit it at lower absolute levels in both sites.  In contrast 
CD161 expression is specifically reduced in the PB compared to BM. 
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F igure 3.32  CD161 and CCR6 expression on Th17 cel ls in the BM of healthy 
donors and pat ients with plasma cel l  dyscrasias, n=5 healthy donors, n=9 
pat ients.  P values are for paired student t tests.  Histogram shows mean ± SEM. 
 
F igure 3.33  Normal ised MFI of Th17 cel ls for IL-17 as a funct ion of fract ion 
of Th17 cel ls expressing CD161.  The solid line shows a linear regression (r2=0.048, 
p=0.26) and the dotted lines the 95% confidence interval for the linear regression. 
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Th17 cell responses to fungal antigens in health and disease 
The IL-17 family of cytokines has a well-described role in the immune response to fungal 
infections, and Th17 cells are able to respond to fungal peptides.  The proportion of Th17 
cells able to respond in this way in the peripheral blood of healthy donors and patients 
was therefore assessed using a pool of lyophilised peptides, consisting mainly of 15-mer 
sequences with 11 amino acid overlap, covering the sequence of the Candida albicans 
mannoprotein MP65 protein (Miltenyi Biotec, UK), hereafter referred to as MP65.  0.7% of 
healthy donor CD4+ T cells produced IL-17 in response to stimulation with PMA/ION (SD: 
0.205%, n=7).  Surprisingly, a mean of 0.15% (SD: 0.156%) of CD4+ T cells from the 
same donors produced IL-17 in response to stimulation for 6 hours with MP65, indicating 
that 21.4% ± 20.7% of Th17 cells responded to this oligoclonal stimulus (representative 
flow cytometry plots: Figure 3.34, collated data: Figure 3.35).  As anticipated in view of 
the reduced frequency of total Th17 cells in patients compared to controls, there were 
fewer cells able to produce IL-17 in response to MP65 (mean 0.13% vs. 0.15% in 
controls, p=NS, n=3 patients, representative flow cytometry plots: Figure 3.34).  However, 
interestingly there was also a trend towards a reduction in the percentage of total Th17 
cells apparently able to respond to the oligoclonal stimulus, although this did not reach 
significance (7.4% ± 10.5% in disease vs. 21.4% ± 20.7% in health, p=NS, Figure 3.35). 
These data indicate that in addition to being aberrant in frequency and in their level of IL-
17 secretion, Th17 cells in myeloma are additionally compromised in their ability to 
respond to a physiologically appropriate stimulus and are therefore functionally impaired.  
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F igure 3.34.  Representat ive dot plots of IL-17 and IFNγ  secret ion by PB 
Th17 cel ls from a healthy donor ( left )  and a pat ient with MM (r ight)  after 
st imulat ion with PMA and ION (top) or MP65 (bottom).   
 
F igure 3.35.  Proport ion of Th17 cel ls producing IL-17 after st imulat ion with 
MP65 (expressed as a percentage of cel ls from the same sample producing 
IL-17 after st imulat ion with PMA & ION) in healthy donors (n=7) and 
pat ients (n=2).  All cells were stimulated for 6 hours and treated with Golgiplug for the 
last 3 hours.  P value is for an unpaired two-tailed t test. 
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Discussion	
Testing a range of methods of T cell stimulation revealed PMA with ION to be most potent 
for induction of IL-17 secretion from the very small percentage of CD4+ T-cells able to 
produce it, and in combination with intracellular staining for CD4, this allows reliable 
identification of Th17 cells.  An optimised protocol of stimulation and flow cytometric 
staining was thereby devised for the identification and phenotypic characterisation of Th17, 
Th17-1 and Th1 cells in health and disease.  Th17 and Th17-1 cells were found to comprise 
median 0.21% (range 0-2.94%) and 0.04% (range 0-1.06%) of CD4+ T-cells in a cohort of 
healthy donors, which is in keeping with published work171, thus validating the method. 
When the prevalence of T cell subsets in healthy donors was examined as a function of 
age, a weak but significant negative correlation was noted between age and Th17 
frequency, whereas when Th1 and Th17-1 cells were examined the effect of age was 
smaller and not significant.  In the context of myeloma, a disease with a median age of 
presentation of around 70 years, this is clearly an important observation.  Nonetheless, 
linear regression analysis yielded r2=0.19, p=0.04, indicating that only 19% of the variance 
seen in Th17 frequency is expected to be accounted for by age alone.  Interestingly, one 
previous study reported an association between increasing age and increased incidence 
of CD4+IL23R+ cells (employed in that study as a surrogate marker for Th17 cells), but 
decreased production of IL-17 by CD4+ cells after stimulation263.  It is therefore tempting 
to speculate that the changes in immune responses associated with ageing might include 
an impaired ability of RORC+CD4+ cells to produce IL-17 upon stimulation; further work 
would be required to clarify this issue.   
Experiments were next undertaken to examine the phenotype of Th17 cells in health, 
which as discussed previously has been extensively reported to be 
CD4+RORC+CD161+CCR4+CCR6+.  When assessed by flow cytometry, expression of 
RORC, the signature transcription factor for Th17 cells was found to be non-specific for 
the subset, staining almost all CD4+ cells to some extent.  Clearly, RORC is extremely well 
characterised in this role by multiple publications.  The failure of this method might then 
represent a problem associated with the specificity and sensitivity of the available 
antibodies, but might also reflect the presence of RORC at a range of concentrations in a 
range of CD4+ cells, the cytokine secretion phenotype of which depends on the relative 
concentrations of other lineage-determining transcription factors (e.g. T-bet, GATA-3).  It 
does not appear to be a technical issue with detecting nuclear proteins as both T-bet and 
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FoxP3 staining yielded expected results.  Alternative methods (e.g. PCR, Western 
blotting) would be needed if this were to be examined further.  Nonetheless, the 
fundamental defining characteristic of Th17 cells is their ability to produce IL-17 upon 
stimulation, and this more basic, functional definition was therefore adopted for the 
remainder of the work presented here. 
CD161 was expressed on a significantly higher proportion of Th17 cells than Th1 or 
CD4+IL-17-IFNγ-FoxP3- cells.  However, two important caveats exist.  Firstly, despite 
previous reports165, by flow cytometry at least, this marker was not expressed on all IL-
17-producing CD4+ cells – indeed only 54% of these cells expressed the marker in 
healthy donors, with considerable inter-donor variability seen; importantly age was not 
found to be correlated with CD161 expression on Th17 cells.  Three different fluorophore-
conjugated antibodies were tested, with similar results, suggesting this is not a reagent-
related problem.  Secondly, CD161 was also expressed on Th17-1 and TReg cells and the 
level of expression by these cells was not significantly different from that of Th17 cells.  
When flow cytometry gating was employed to focus on CD4+CD161+ cells for analysis, a 
relative enrichment in Th17 cells was seen, but the effect was modest and unfortunately 
these data indicate that despite a great deal of enthusiasm in the published literature165, 
CD161 is unsuitable for selection of un-stimulated Th17 cells e.g. by FACS sorting.  CCR6 
and CCR4 were similarly found to be expressed at higher levels on Th17 cells than on Th1 
cells, but did not allow differentiation between Th17 cells and Th17-1 or TReg cells.  
Combinations of these markers did not greatly improve specificity or sensitivity for Th17 
cells, leading to the conclusion that it is presently not possible to identify Th17 cells reliably 
without redress to stimulation and functional assay – i.e. measurement of IL-17 
production. 
When patient and healthy donor PB samples were compared, a significant reduction in 
Th17 cells was seen, below even the low levels seen in healthy donors.  However, in view 
of the correlation between age and Th17 frequency in healthy donors, patient samples 
were then compared to an age-matched cohort and were found to have a significantly 
higher level of Th17 cells than this, more appropriate control group.  When patient samples 
were subdivided according to clinical disease stage, those with MGUS and asymptomatic 
disease (who had the highest levels), MM on lenalidomide maintenance therapy and MM 
in remission showed significantly raised Th17 levels compared to age-matched controls, 
whereas those with newly diagnosed and relapsed disease had levels not significantly 
different from age-matched controls.  Th17-1 cells were increased only in those with MGUS 
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& asymptomatic MM compared to age-matched controls and Th1 cells were raised only at 
relapse – significantly by comparison to almost all other groups including age-matched 
controls.   
The MM disease stage-related differential in IL-17-secreting T cells has not been reported 
previously, and the high levels of Th17 and Th17-1 cells seen in those with MGUS and 
asymptomatic MM are of particular interest and warrant further exploration.  Th17 
cytokines such as IL-17 and IL-21 have certainly been reported to serve as growth factors 
for MM cells74,196  (although attempts to recapitulate those experiments have not been 
successful to date; data not shown), however levels of Th17 cells were actually lower in 
newly diagnosed, symptomatic MM than in MGUS & asymptomatic MM, suggesting the 
relationship between malignant plasma cells and Th17 cells is more complex than a simple 
positive feedback loop.  In addition, the role of Th17-1 cells is unclear: these cells have 
been linked with effective anti-tumour responses in adoptive transfer models164 – an effect 
which is critically dependent on both Th17 polarisation and secretion of IFNγ, and it may 
be that the ability to traffic according to a Th17 cell surface phenotype but deliver IFNγ 
confers a particular significance on these cells; unfortunately numbers of these cells were 
so small that detailed ex vivo characterisation was not possible.  The significance of the 
raised levels of Th1 cells seen at relapse is also unknown, although clearly in the past IFNγ 
immune responses have been widely associated with anti-cancer effects.  On the basis of 
these results, and the known presence of anti-tumour immune responses in MM 45,47 , it is 
tempting to speculate that Th17 or Th17-1 cells might be playing a role in anti-cancer 
immunity in early disease, but a large number of further experiments are required to 
examine this question. 
Th17 cells in MM were also noted to have a lower normalised MFI for IL-17 in MM, and 
serum levels of IL-17A, IL-17F, IL-22 and TNFα were lower in MM samples than healthy 
donors, although the differences in cytokine levels did not reach significance.  Low levels 
were expected in all samples in view of the rarity of Th17 cells, and are in keeping with the 
levels reported in other malignancies 264,265 , though they are significantly lower than those 
reported in the only paper to examine this in myeloma 74 and this might reflect differences 
in sample storage and assay protocols.  When BM samples were examined, Th17 cells 
were increased in patients compared to healthy donors, as were Th1 cells; the Th17:Th1 
ratio, employed as a surrogate for the balance of T cell polarisation towards Th17 cells, 
was not significantly different.  However, Th17 cells in MM did exhibit reduced 
responsiveness to a more physiologically relevant stimulus – Candidal wall proteins, 
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suggesting a physiologically relevant functional defect.  Since Th17 cells have been 
ascribed roles in immune responses against not only fungal infections 180,266 , but also 
extracellular bacteria 174,175,267,268    and intracellular bacteria 176, the loss of Th17 cells with 
disease progression may be contributory to the increased risk of a range of infections 
seen in MM. 
These data are not directly in line with published work.  Prabhala et al. examined PB from 
11 newly-diagnosed MM patients and 12 healthy donors (not age-matched) and BM from 
4 patients and 3 healthy donors, and noted expansion of the Th17 population in both the 
PB and BM of patients compared to controls74.  These authors report considerably higher 
levels of Th17 cells in both health and disease than those seen here – for example 2.05% 
± 0.3% of T cells are Th17 in normal donors and 4.49% ± 0.78% in MM patients.  
Prabhala et al. also report increased levels of IL-17, IL-21, IL-22 and IL-23 in the serum of 
patients with MM, in contrast to the data presented here. 
Some of this discrepancy might be accounted for by differences in the gating strategies 
employed.  For example, the FACS protocol used here incorporates a dead cell 
discriminator stain to allow exclusion of dead cells, which otherwise appear to produce IL-
17 due to autofluorescence.  This is of considerable importance when dealing with such a 
small population and may account for the lower numbers of Th17 cells in my data – the 
exemplar FACS plots in the published paper do suggest a degree of autofluorescence 
which might artificially increase Th17 numbers74.  Cytokine levels measured by Luminex 
here were low, and it is possible that the blood collection or sample freezing procedure 
employed was not optimal for preservation of cytokines, although the same technique 
was used for all samples, including healthy donors.  The levels of Th17 signature 
cytokines in health and disease might be further examined through qRT-PCR, and RNA 
from relevant samples has been isolated and stored for this purpose. 
Surprisingly, unlike with healthy donors, no correlation was seen between age and Th17 
frequency in MM patients, strengthening the assertion that Th17 changes are a 
consequence of disease.  Interestingly, the prevalence of Th17 cells did vary according to 
some disease-specific variables, with lower levels seen in those with kappa light chains, 
and with IgG paraproteins; the causes and significance of these observations is unknown 
and since multivariate analysis could not be conducted, caution is warranted in avoiding 
over-interpretation.  Nonetheless, the data highlight the importance of the use of age-
matched controls, which has been overlooked by a number of the published studies of 
Th17 cells in myeloma and cancer more widely. 
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The increased levels of Th17 cells in BM raises the possibility that myeloma cells are able 
to induce Th17 cell differentiation or survival – a number of the cytokines required for Th17 
polarisation (e.g. IL-1β, TGFβ, IL-6) are known to be abundant in the bone marrow 
microenvironment 12,269 and it is possible these mediators might lead to expansion of Th17 
cells in MM; this issue will be explored in the following results chapter.  It is uncertain why 
Th17 cells should be increased in the BM to a considerably greater extent than in the PB; 
alterations in trafficking, sensitivity to stimulation, longevity, peripheral plasticity or other 
mechanisms might account for this, and again warrant further evaluation.  Of potential 
relevance is the fact that IL-1β, IL-2 and IL-6 were not found to be raised in the peripheral 
blood of MM patients compared to healthy controls, strengthening the hypothesis that 
microenvironmental changes may be responsible for the localized expansion of Th17 cells 
in the bone marrow. 
When examining patient samples it was noted that CD161 is absent on a large portion of 
Th17 cells, in a disease-stage dependent manner.  A 2011 publication reported reduced 
CD161 expression on Th17 cells from patients with head and neck cancer169, at all 
sampled sites but particularly in metastatic lymph nodes, suggesting this may be a more 
generalised cancer-related phenomenon.  It remains to be clarified whether CD161 has 
functional importance in this context, or indeed in general, as the role of the protein is 
unknown, although PILAR-signalling through CD161 has been shown to support CD3 
antibody-dependent and antigen specific T-cell proliferation167, meaning it is possible loss 
of CD161 might contribute to the relative paucity of Th17 cells in the peripheral blood of 
MM patients.  A weak correlation was noted between expression of CD161 and MFI for 
Th17.  In interpreting this finding it should be borne in mind that for the reasons discussed 
earlier IL-17 secretion was here assessed by supra-physiological, antigen-independent 
activation of T cells by PMA and ionomycin.  If CD161 does indeed function as a 
costimulatory receptor or other mediator in the context of normal immune synapse 
formation, the effect of loss of CD161 might reasonably be expected to exert a far more 
profound effect on the ability of Th17 cells to respond appropriately to stimulation in vivo.  
Experiments using T cell re-stimulation using MACSiBeads loaded with and without a 
stimulating anti-CD161 antibody might be used to examine this issue further. 
Since Th17 cells are thought to derive only from CD161+ precursors in health, two 
possibilities exist to explain the presence of significant numbers of CD161- Th17 cells in 
MM: either CD161+ Th17 cells lose expression of CD161 through interactions with MM or 
the microenvironment, or CD161- T cells are abnormally induced to become Th17 cells 
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through such interactions.  This issue will be addressed in the subsequent results 
chapter.  Further characterisation of the phenotypic and functional properties of CD161+ 
and CD161- Th17 cells may also be illuminating, and many basic immunology and 
translational questions remain to be explored in this area.  For example, does ligation of 
CD161 affect production of IL-17 after a physiological stimulus such as Candidal antigen?  
If so, are the CD161+ and CD161- cells different in terms of their capacity to conduct their 
normal physiological antifungal role or to upregulate neutrophil migration and epithelial 
immune responses270-272?  Further examination of some of these issues may cast light on 
the basic immunological questions about the natural role of CD161.  Of course, in the 
context of myeloma it will also be of interest to know whether these cells respond 
differently to immune synapse formation with MM plasma cells, and whether CD161- Th17 
cells either lose anti-tumour efficacy or can even support the tumour clone.  The latter 
point is of interest, since Prabhala et al. have reported an ability of IL-17 to augment 
growth of HMCLs in culture74, although as mentioned previously, attempts to reproduce 
these experiments have thus far failed. 
CCR6 expression was also reduced on patient Th17 cells.  This protein mediates attraction 
of Th17 cells to CCL20 and human β-defensin273, thereby mediating homing to skin and 
mucosal tissues where Th17 cells have an increasingly well-described role in mucosal 
immunity270,272,274.  CCR6-expression has been reported in high proportions of CD4+ cells 
in inflamed sites in juvenile arthritis171, and CCR6+ γδ T cells are more responsive to TCR-
stimulation than their CCR6- counterparts273, suggesting the loss of CCR6 expression in 
MM might contribute to the increased risk of infections in MM.   
Restimulation with Candidal antigens revealed that, surprisingly, 20% of Th17 cells in 
healthy donors were able to respond to this oligoclonal stimulus.  Although previous 
studies have demonstrated T cells with TCR specificity for C. albicans antigen are 
preferentially or exclusively present in the CCR6+ subset171, the experiments presented 
here were performed in the absence of antigen presenting cells (APCs), implying TCR-
mediated antigen specificity is not the mechanism of response.  This raises the possibility 
that Th17 cells might instead be stimulated via pathogen-associated pattern recognition 
receptors such as C-type lectins275,276, or even CD5134.  In light of the loss of CD161, a C-
type lectin receptor, in patient-derived Th17 cells this is an exciting possibility and requires 
exploration, particularly in light of the decreased responsiveness to MP65 seen in patient 
Th17 cells.   
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A large number of additional avenues of further investigation could follow from this work.  
The TCR specificity of the Th17 cells has not been addressed by the preceding studies 
and T cell priming/recall experiments might be used to examine this issue further.  
Development of further functional assays of Th17 cell function are another natural 
extension of this work – for example neutrophil migration assays (since Th17 cytokines are 
chemoattractant to neutrophils during normal immune responses277) or examination of 
innate endothelial and epithelial immune responses such as upregulation of defensins270 
or cytokine secretion178.  Th17 cell localisation within the BM has not yet been assessed, 
and the interplay between tumour cells, immune cells, hypoxia and the tumour niche 
warrants examination, perhaps initially by immunohistochemical appraisal of myeloma BM 
trephine samples.  Th17 cells, through their cytokine mediators, may also favour growth of 
the malignant clone.  Th17 cells may therefore play a contributory role in both the 
pathogenesis and manifestations of the disease and represent a rational therapeutic 
target.  The ability of established immune-active and immunomodulatory MM therapies to 
interrupt and reverse the generation of Th17 cells could next be investigated.  Monoclonal 
antibodies targeting IL-17278-281  and IL-23282 have been used in clinical trials for 
inflammatory diseases in humans, and an anti-IL-21R antibody is similarly under 
investigation283, and the potential for these drugs to disrupt Th17-MM interactions might 
also be explored.  Th17 cells and their mediators are therefore clinically viable targets and 
further characterisation of the derangements in MM is warranted.  
The work presented here points towards an impairment of Th17 immune function in MM, in 
terms of prevalence, phenotype and function, and this may contribute to the risk of 
infection in the disease.  The following results chapter will employ an in vitro model to 
address a number of the questions arising from this work: do myeloma plasma cells 
induce formation of Th17 cells, and if so how?  What are the precursor cells, and what 
effect do tumour interactions have on the expression of CCR6 and CD161?  And 
importantly, what role does the bone marrow microenvironment play in these processes? 
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Chapter 4 – In vitro modelling of Th17 
generation in multiple myeloma 
 
Introduction	
The data presented in Chapter 3 demonstrate that Th17 cells are expanded in the 
peripheral blood and bone marrow of patients with multiple myeloma, have an abnormal 
cell surface phenotype and are compromised in their ability to respond to stimulation.  A 
number of possibilities might account for the abnormal numbers and phenotypes of Th17 
cells in MM.  For example, Th17 cells might be induced in the bone marrow through 
interactions with tumour cells, either directly or via other cellular/chemical mediators such 
as bone marrow stromal cells (BMSCs), cytokines and chemokines.  Alternatively, Th17 
cells from peripheral blood might traffic to the bone marrow microenvironment (BMME) 
through BM-expressed surface proteins or chemokines, and be retained there.  A 
considerable body of evidence points to plasticity between Th17 cells and regulatory T 
cells (Treg), which have been shown to be expanded in patients with MM67 and might serve 
as a reservoir for peripheral Th17 generation.  The longeivity of Th17 cells is also unknown; 
if Th17 cells are not generated per se by myeloma, it is possible they may be protected 
from apoptosis by the BMME or MM-produced cytokines. 
The cell surface marker CD161 a C-type lectin receptor, induced by RORC2 and 
previously reported to be present on all human IL-17-producing cells, be they Th17 cells or 
others (e.g. CD8+TCRαβ+, CD4-CD8-TCRαβ+ and CD4-CD8-TCRγδ+)166, was found in the 
previous chapter to be downregulated on the surface of Th17 cells in MM.  Two likely 
explanations exist for this: either these Th17 cells might have arisen via an abberant 
pathway from CD161- precursors (which should normally be unable to give rise to IL-17-
producing cells), or the Th17 cells may have developed normally and subsequently lost 
their expression of CD161 due to interactions with the tumour microenvironment.  Since it 
has been proposed that CD161 can act as a co-activating receptor, allowing antigen-
dependent T cell proliferation upon engagement by its ligand, the loss of this antigen may 
have functional repercussions for immunity in MM.  
In the work reported in this chapter, a co-culture model is developed to examine the 
cellular interactions between T cells, peripheral blood immune subsets and tumour cells 
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that might give rise to the expanded Th17 cell population identified in patients.  This model 
is then developed to examine the contribution of bone marrow stromal cells and the 
impact of CD4+ starting populations, including the importance of initial CD161 expression.  
Finally, a protocol is developed for in vitro generation of Th17 cells to examine the 
propensity to Th17 generation in health and in MM, and factors that may affect this. 
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Materials	and	Methods	
Preparation of cells for co-culture 
PBMC and Mitomycin C-treated HMCL were isolated and maintained as described in 
Chapter 2, before mixing at a 1:1 ratio.  Where HS-5 and HS-27 were used in cocultures, 
these were seeded in 24 well plates at 105 cells/well for 24 hours at 37°C, 5% CO2 before 
washing the plates to remove dead or non-adherent cells prior to addition of HMCL and T 
cells.  BMSCs were added at a BMSC:T cell ratio of 1:10. 
 
Flow cytometric cell sorting 
For the experiments described under ‘characterisation of parental population’, flow 
cytometric sorting of CD4+ cells according to expression of CD161 and CCR6 was 
undertaken.  CD4+ T cells were first isolated using MACS, and then stained with CCR6-
PE and CD161-APC, as described in Chapter 2.  Cells were then resuspended at 107/ml 
in MACS buffer and sorting using a BD Influx 5 laser cell sorter (principles described in 
Chapter 2) into CM at 37°C.  Samples of sorted populations were re-examined by flow 
cytometry and were found to be >90% pure in all cases. 
 
T cell stimulation protocols 
TCR and signal 2 stimulation was provided using a T Cell Activation/Expansion Kit 
(Miltenyi Biotec: 130-091-441), modified to provide alternative signal 2 stimuli.  In brief, 
108 anti-biotin MACSiBead particles in 500μl MACS buffer were mixed with combinations 
of 100μl of 100μg/ml each of anti-CD3-Biotin (included in kit), anti-CD28-Biotin (included 
in kit), anti-CD5-Biotin (BD Biosciences) and anti-ICOS-Biotin (eBIosience), the total 
volume made up to 1ml with further MACS buffer, and incubated for 2 hours at 4°C under 
constant gentle rotation, yielding MACSiBead particles at 108ml-1 and a final antibody 
concentration of 10μg per antibody per ml.  Loaded MACSiBead particles were then 
added to T cells at a 1:1 ratio. 
Recombinant human cytokines and cytokine-neutralising antibodies were obtained and 
used as shown in Table 4.1.  All cytokines were certified endotoxin level <0.1ng/μg of 
protein. 
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Cytokine Manufacturer Source Final 
concentration 
Product ID & Lot 
IL-1β Peprotech E. coli 10ng/ml 200-01B 1202B95R1 
IL-2 Peprotech E. coli 200IU/ml 2002-02 020812ST 
IL-6 Peprotech E. coli 20ng/ml 200-06 090916 
TGFβ1 Peprotech HEK 293 5ng/ml 100-21 1012209 
Anti-IL-12 eBioscience Mouse 1ng/ml BMS152   B-T21 
 
Table 4.1.  Recombinant cytokines and cytokine-neutra l is ing ant ibodies. 
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Culture conditions for Th17 polarisation 
Unless otherwise stated, incubations were performed in CM at 37°C, 21% O2 and 5% 
CO2 in a humidified tissue culture incubator.  Hypoxic cultures were incubated at 37°C, 
5% O2 and 5% CO2 in a humidified tissue culture incubator (Galaxy R CO2 Incubator; 
Scientific Laboratory Supplies Ltd.).  Where Iscove’s modified Dulbecco’s medium (IMDM, 
Sigma: I3390) was used, this was supplemented with 10% heat-inactivated FBS).  Where 
stated, 11μg/ml ι-tryptophan was added to culture media prior to incubations.  For 
experiments where ‘dark’ was specified, culture media and culture vessels were stored in 
opaque containers and exposure to natural and artificial light minimised. 
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Results	
Development of a co-culture model 
Since Th17 cells were expanded in bone marrow samples from myeloma patients, relative 
to peripheral blood, and published work reports expansion of Th17 cells in bone marrow 
from myeloma patients compared to normal marrow, a simple in vitro model was 
developed to allow examination of the requisite cellular interactions.  Initial attempts to 
culture HMCLs with negatively-selected CD4+ T cells at ratios ranging from 1:16 to 1:1 
resulted in high levels of cell death in the cultured T cells, and absence of cytokine 
secretion (data not shown).  Since this was associated with, and presumably consequent 
upon, marked expansion of the HMCL population and acidic cell cultures (determined by 
phenol red), the model was modified to incorporate mitomycin C (MitC) treatment of 
HMCLs prior to co-culture.  PBMC and MitC-treated HMCL were mixed at a 1:1 ratio and 
the timescale of interactions between CD4+ T cells and HMCLs was examined. 
As discussed in the previous results chapter, considerable inter-donor variability is seen in 
terms of the prevalence of Th17 cells in the peripheral blood.  In order to correct for this 
variation, cocultures were repeated 5 times, and the percentages of CD4+ cells producing 
IL-17 throughout coculture were normalised to the pre-coculture levels for that donor, and 
thus expressed as a fold change.  IL-17 production by CD4+ cells was found to increase 
throughout the culture, whereas IFNγ secretion decreased (dot plots for a single donor 
are shown in Figure 4.1, collated data: Figure 4.2).  After 4 days of isolated culture of 
CD4+ cells alone, the fraction of cells producing IL-17 was unchanged (95.6% of 
baseline), whereas when cocultured with U266B, a mean 2.9-fold increase in the fraction 
of CD4 cells producing IL-17 was seen (p=0.043, paired student t-test).  In contrast, the 
fraction of CD4+ cells producing IFNγ after 4 days decreased under both culture 
conditions and was not significantly different between the two (28.5% and 45.4% 
respectively, p=NS).   
After 7 days of culture, a 2.75-fold increase in Th17 cells was seen in isolated culture, and 
an 11.7-fold increase under coculture conditions (p=0.004, paired student t-test).  After 7 
days of culture, IFNγ production by CD4+ cells was minimal under both isolated and 
coculture conditions, and not significantly different between the two (1.8% and 5.1% of 
baseline respectively, p=NS). 
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Attempts to continue co-culture beyond day 7 resulted in a high rate of cell death in CD4+ 
cells, presumably due to depletion of nutrients within the culture media.  Since renewal of 
culture media at this point would dilute any soluble mediators of coculture interactions, 
culture was not continued beyond this point for future experiments and the 7 days time 
point was selected for further characterisation.  As anticipated from the ex vivo 
assessment of samples from patients with MM, very few Th17-1 cells were identified under 
any culture conditions (data not shown). 
These results indicate that addition of the HMCL U266 to CD4+ T cell cultures results in 
an increased proportion of Th17 cells in a time-dependent manner.  The range of possible 
explanations for this effect includes induction of Th17 cells from naïve precursors, 
expansion of memory T cells and enhanced survival of existing Th17 cells compared to IL-
17- T cells.  
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F igure 4.1.  Representat ive dot plots of IL-17 and IFNγ  produced by CD4+ 
cel ls from a s ingle healthy donor cultured either a lone or with U266 for 0, 4 
and 7 days. 
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F igure 4.2.  Fract ion of CD4+ cel ls producing IL-17 (upper panel)  and IFNγ  
( lower panel)  after culture e ither a lone ( left )  or with the HMCL U266B (r ight)  
for 0, 4 or 7 days.  Percentages of cells are normalised to D0 levels for each donor 
and expressed as a fold change.  Mean values +/- SEM shown, n=5.  P values are for 
paired student t-tests. 
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In order to confirm this phenomenon was representative of a range of HMCLs, and not an 
idiosyncratic property of the cell line U266, these experiments were next repeated with a 
variety of HMCLs (Figure 4.3).  After 7 days of coculture, it was found that the majority of 
HMCLs tested were able to increase the percentage of CD4+ cells able to produce IL-17, 
compared to isolated culture of CD4+ cells.  The EBV-transformed B cell line IM9 was 
employed as a control and did not increase Th17 cells.  
On average, U266 was the most effective cell line at inducing Th17 cells, whereas JIM3’s 
effect was slightly smaller but more reproducible; these two cell lines were therefore 
selected for further characterisation. 
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F igure 4.3.  Th17 cel ls after culture of CD4+ T cel ls e ither a lone or in 
combinat ion with the HMCLs U266, JIM3, KMS11 or H929, or the B-cel l  
l ine IM9, at a 1:1 rat io for 7 days.  Th17 cells as a percentage of total CD4+ cells 
were enumerated as described previously.  Mean values were as follows: CD4+ alone: 
0.37%, U266 coculture: 1.1%, JIM3 coculture: 0.8%, KMS11 coculture: 0.3%, H929 
coculture: 0.9%, IM9 coculture: 0.1%.  Fold change vs. CD4+ alone: U266 coculture: 
2.97, JIM3 coculture: 2.20, KMS11 coculture: 0.81, H929 coculture: 2.52, IM9 coculture: 
0.36.  The histogram shows mean values +/- SEM, n=5.   
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Contribution of other immune subsets of peripheral blood 
Having established the ability of HMCL to drive differentiation of CD4+ T cells into Th17 
cells, the contribution of other peripheral blood immune subsets was next investigated by 
comparison of cocultures of HMCL with either unselected peripheral blood mononuclear 
cells (PBMC) or negatively-selected CD4+ cells.  There were no significant differences in 
Th17, Th17-1 or Th1 cells as a percentage of total CD4+ cells, or in fold change, between 
PBMC and CD4+ in any of the conditions examined (Figure 4.4).  Addition of the adherent 
fraction of the mononuclear cell population (which is enriched for monocytes) to coculture 
of CD4+ cells with HMCL also had no statistically significant effect on Th17 cells (p=NS, 
student’s t test, data not shown).   
These results indicate that the generation of Th17 cells in the bone marrow 
microenvironment in MM can result from direct interactions between MM PCs and T cells, 
although interactions with other BM-resident cells, such as bone marrow stromal cells, 
and non-T cell peripheral blood immune subsets remain possible.  
University of Leeds – School of Medicine Christopher Parrish 
- 109 - 
 
F igure 4.4.  Comparison of T cel l  subsets present after 7 days of culture of 
PBMC or CD4+ cel ls, e ither a lone or co-cultured 1:1 with U266B.  A: absolute 
number of Th17 (IL-17-producing), Th1 (IFNγ-producing) and Th17-1 (IL-17- and IFNγ-
producing) cells; p values are for paired two-tailed t tests.  B: fold change in subsets after 
coculture vs. cells cultured alone.  Histograms show means and standard deviations. 
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Contribution of Naïve and Memory T cells 
The Th17 cells seen in the previous experiments, and in the patients’ samples might derive 
either from expansion of existing memory T cells, or by de novo generation from naïve T 
cells.  In order to determine more specifically the origin of the Th17 cells identified, the 
CD4+ starting population was further selected, by MACS, for expression of CD45RA or 
CD45RO to enrich for naïve and memory T cells respectively.  Co-culture starting with 
these populations yielded similar numbers of Th17 cells from CD4+ and CD4+CD45RO+ 
populations, with a trend towards a reduced number when starting with CD4+CD45RA+ 
cells, although this did not reach statistical significance (Figure 4.5 shows a representative 
single donor and Figure 4.6 collated data).  As expected, addition of adherent 
mononuclear cells to these cultures did not alter the proportion of Th17 cells (data not 
shown).  These results, though not conclusive, suggest that the observed in vitro effect of 
Th17 generation after coculture of HMCL with CD4+ T cells is a consequence of expansion 
of an existing CD45RO+ memory population rather than generation from CD45RA+ naïve 
precursors. 
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F igure 4.5.  Representat ive dot plots of IL-17 and IFNγ  product ion by CD4+ 
T cel ls after 7 days coculture of JIM3 with CD4+, CD4+CD45RO+ or 
CD4+CD45RA+ cel ls from a s ingle healthy donor. 
 
F igure 4.6.  Cytokine product ion by CD4+ T cel ls after 7 days of coculture 
of JIM3 with CD4+, CD4+CD45RO+ or CD4+CD45RA+ cel ls.  N=2, p values are 
for paired two-tailed t tests. 
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Contribution of bone marrow stromal cells 
The potential contribution of bone marrow stromal cells to in vivo generation of Th17 cells 
in the bone marrow microenvironment was next assessed through incorporation of bone 
marrow stromal cells into the in vitro coculture model.  For these experiments, the human 
bone marrow stromal cells lines HS-5 and HS-27 were used.  Stromal cells were placed 
in culture plates and incubated for 24 hours; each well was then washed to remove non-
adherent cells before HMCL and CD4+ T-cells were added as before.  Figure 4.7 shows 
representative dot plots from a single donor; collated data are shown in Figure 4.8. 
Coculture of CD4+ T-cells with HS-5 or HS-27 without HMCLs was found to have no 
significant impact on the presence of IL-17 producing cells (0.19% and 0.2% respectively, 
compared to 0.16% of CD4+ cells cultured alone; fold changes 1.43 and 1.51 for addition 
of HS-5 and HS-27 respectively).  As previously, addition of JIM3 or U266 to CD4+ 
induced generation of Th17 cells (1.06% and 0.37% respectively; fold changes: 8.38 and 
2.56 respectively).  However, incorporation of HS-27 into the culture hugely augmented 
Th17 generation by both JIM3 and U266 (5.89% and 5.36% respectively); fold changes: 
39.34 and 37.86 respectively); HS-5 increased Th17 generation by JIM3, but not by U266 
(3.81% and 0.37% respectively; fold changes: 26.59 and 2.63 respectively).  Whilst a 
trend was seen, after 4 repetitions, statistical significance was not reached for either 
absolute numbers or fold-change in Th17 cells, reflecting wide variation in the propensity to 
Th17 generation between donors – indeed some donors generated almost no Th17 cells 
under any culture conditions tested. 
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F igure 4.7.   Representat ive dot plots of IL-17 and IFNγ  product ion by CD4+ 
T cel ls after 7 days coculture of CD4+ T cel ls from a s ingle donor with 
HMCLs (U266 or JIM3) and stromal cel ls (HS-5 or HS-27). 
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F igure 4.8.  Prevalence of Th17 cel ls as a fract ion of CD4+ T cel ls (A) and 
fo ld change over CD4+ cultured alone (B) after culture e ither a lone or in 
combinat ion with the HMCLs U266 and JIM3 and/or the human bone 
marrow stromal cel ls HS-5 and HS-27.  Histograms show mean values +/- SEM, 
n=4. 
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Characterisation of parental population 
A broad consensus of literature describes the phenotype of Th17 cells as being 
CD4+CD161+CCR4+CCR6+, however, as demonstrated in Chapter 3, the phenotype of 
Th17 cells in patients with myeloma is aberrant, with attenuated expression of CD161 and 
CCR6.  It was therefore important to determine whether Th17 cells in myeloma patients 
derive from CD4+ cells previously expressing those markers, in which expression of the 
surface antigens was subsequently down-regulated as a result of immune-tumour 
interactions, or from surface antigen-negative populations, which have not previously 
been reported to give rise to Th17 cells under any physiological or in vitro culture 
conditions.   
In order to address this question, CD4+ cells were labelled with fluorochrome-conjugated 
antibodies against CD161 and CCR6 and separated using flow cytometric cell sorting into 
4 populations: CD161-CCR6-, CD161-CCR6+, CD161+CCR6- and CD161+CCR6+ (Figure 
4.9).  The post-sort purity of sorted populations was >85% in all cases (gates for purity 
checks were identical to the pre-sort gating; fluorophore bleaching is likely to account for 
the slight loss of signal intensity seen after sorting).  Sorted cells were then cultured alone, 
with and without JIM3 and/or BMSCs (at 10 T-cell : 10 JIM3 : 1 BMSC ratio).  After 7 
days of culture, cells were harvested, stimulated with PMA/ION/GP, labelled with 
fluorochrome-conjugated antibodies and examined by flow cytometry to assess the 
proportion of CD4+ cells producing IL-17 (Figures 4.10 and 4.11).    
Surprisingly, no significant difference in the proportion of IL-17-secreting lymphocytes 
was found between the four different starting CD4+ populations.  Furthermore, the trend 
that was seen, was towards increased IL-17+ cells in those cultures starting with CD161-
CCR6- cells, although due to inter-donor variability, this difference did not reach 
significance.  As previously, coculture with HMCL and BMSC was found to result in the 
highest proportion of IL-17-secreting CD4+ lymphocytes irrespective of starting CD4+ 
population. Figures 4.10B and 4.11B show the generation of Th17 cells expressed as a 
fold increase over the same starting T cell subset cultured alone; error bars are not shown 
on some histograms since Th17 cells were often completely undetectable after isolated T 
cell culture meaning a fold increase could not be calculated. 
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F igure 4.9.  Expression of CD161 and CCR6 on al l  CD4+ T cel ls before (A) 
and sorted populat ions after (B-E) sort ing by FACS.   
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F igure 4.10.  Expression of IL-17 by CD4+ T cel ls sorted by expression of 
CCR6 and CD161 (start ing populat ion showed with square brackets on x-
axis),  and cultured either a lone or with JIM3 and/or HS-27.  After 7 days of 
culture, cells were harvested, stimulated with PMA/ION/GP, stained with fluorochrome-
conjugated antibodies against CD4, IL-17 and IFNγ, and assessed by flow cytometry.  
Percentage of CD4+ cells producing IL-17 (A) and fold change in IL-17-producing cells (B) 
are shown, histograms show means, error bars indicated SEM, n=3. 
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F igure 4.11.  Expression of IL-17 by CD4+ T cel ls sorted by expression of 
CCR6 and CD161 (start ing populat ion showed with square brackets on x-
axis),  and cultured either a lone or with JIM3 and/or HS-5.  After 7 days of 
culture, cells were harvested, stimulated with PMA/ION/GP, stained with fluorochrome-
conjugated antibodies against CD4, IL-17 and IFNγ, and assessed by flow cytometry.  
Percentage of CD4+ cells producing IL-17 (A) and fold change in IL-17-producing cells (B) 
are shown, histograms show means, error bars indicated SEM, n=3. 
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In view of the abnormal expression of CD161 seen on peripheral blood Th17 cells in 
myeloma, CD161 expression by CD4+ cells after each of the culture conditions was next 
examined (Figure 4.12).  Interestingly, although purity checks had confirmed successful 
sorting of populations according to CD161 and CCR6 expression (Figure 4.9), CD161 
expression was noted to be low after isolated culture of CD4+ T cells, irrespective of 
CD161 status at the beginning of co-culture (CD161-CCR6- starting population: 2.69%, 
CD161-CCR6+: 3.16% CD161+CCR6-: 8.5%, CD161+CCR6+: 18.6%, p=NS).  This might 
reflect internalisation of CD161 after ligation by an antibody for sorting. 
Addition of JIM3 to culture conditions had no effect on CD161 expression at the end of 
coculture.  However, addition of either HS-5 or HS-27 to culture conditions significantly 
increased CD161 on T cells at the end of coculture, irrespective of both starting 
population and presence of JIM3 (p=0.0262, 2-way ANOVA). 
These results suggest the stromal cell lines HS-5 and HS-27 are able to induce CD161 
expression on CD161- T cells; addition of JIM3 may augment this effect, although the 
latter effect did not reach significance.  It is conceivable that stromal cells might instead 
have lead to differential expansion of contaminating CD161+ cells, although this appears 
unlikely since the levels of CD161+ cells after coculture might then be expected to be 
higher in the cocultures starting with CD161+ cells. 
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F igure 4.12.  Expression of CD161 after culture by CD4+ T cel ls in it ia l ly 
sorted on expression of CCR6 and CD161, and cultured either a lone, or 
with JIM3 and/or HS-27 or HS-5.  After 7 days of culture, cells were harvested, 
stimulated with PMA/ION/GP, stained with fluorochrome-conjugated antibodies against 
CD4, IL-17 and CD161, and assessed by flow cytometry.  Histograms show median, 
error bars indicated SEM, n=3. 
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Development of protocol for Th17 generation/expansion from 
peripheral blood CD4+ T cells 
In order to begin to assess the mechanisms through which the differentiation or 
expansion of Th17 cells might be driven, and to allow comparison of the effects of these 
mechanisms in health and disease, it was next necessary to develop protocols to drive 
differentiation of Th17 cells in vitro.  As discussed previously, an extensive literature over 
the last ten years has attempted to delineate the optimal conditions for Th17 generation.  
However, a number of differences are evident between ‘optimal’ protocols, probably due 
to discrepancies in techniques, reagents, starting populations and definitions of Th17 cells.  
For these reasons, the optimal conditions for Th17 generation were reassessed 
experimentally.   
Initially, a range of culture conditions were selected from existing published work and 
tested for their ability to drive differentiation/expansion/preferential survival of Th17 cells 
from the peripheral blood of a healthy donor.   In keeping with the classical tenet of T cell 
immunology that the fate of T cells depends on the integration of T cell receptor 
stimulation (signal 1), co-receptor ligation (signal 2) and the prevailing cytokine milieu 
(signal 3), each of these signals was varied (Figure 4.13).   
For this initial screen, peripheral blood mononuclear cells were isolated from a healthy 
donor using Lymphoprep density centrifugation.  CD4+ T cells were then isolated using 
MACS (CD4+ T cell Isolation Kit II, Miltenyi Biotec, UK), and cultured at 106/ml in CM; 106 
CD4+ cells were seeded for each condition and time point.  T cell receptor stimulation and 
signal 2 stimulation were provided by anti-biotin MACSiBead particles (Miltenyi Biotec) 
loaded with combinations of biotinylated antibodies against CD3 and CD28, CD3 and 
CD5, or CD3 and ICOS.  A range of cytokines was also added: IL-2 (200IU/ml), IL-1β 
(10ng/ml), IL-6 (20ng/ml), TGFβ (5ng/ml), and anti-IL-12 neutralising antibody (1ng/ml).  
After 24, 48, 72 and 168 hours, cells were harvested, stimulated with PMA/ION/GP and 
assessed by flow cytometry for total number of live cells, and for expression of IL-17 by 
CD4+ cells (Figure 4.13).   
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F igure 4.13.  Total cel l  numbers and IL-17 product ion after st imulat ion of 
CD4+ T cel ls with combinat ions of TCR l igat ion, s ignal 2 and cytokines ( left  
panel)  and culture for 24, 48, 72 and 168 hours.  At the end of culture, cells 
were restimualted with PMA/ION/GP and assayed by flow cytometry for the percentage of 
cells producing IL-17 (middle panel) and the total number of CD4+ cells (right panel).  
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Considerable variation was noted between culture conditions in terms of both the total 
numbers of CD4+ T cells present at the end of culture, and the percentage of them 
producing IL-17 after re-stimulation.  As expected, those conditions giving rise to the 
largest number of CD4+ cells in total were not the same as those producing the maximal 
proportion of CD4+ cells making IL-17.  IL-2, well-described as a growth factor for CD4+ T 
cells was present in many of the combinations giving rise to the largest numbers of CD4+ 
cells, but was absent from the top four combinations for Th17 percentage yield.  CD3/28, 
the TCR and signal two combination conventionally used for stimulation of T cells did 
indeed appear to produce high numbers of CD4+ cells in most cases.  However, 
surprisingly, this combination was not effective in producing a high proportion of Th17 
cells, which was instead maximal after signal two stimulation targeting either CD5 or 
ICOS.  As predicted from the published literature, the cytokine combination of IL-1β, IL-6 
and TGFβ further enhanced the fraction of CD4+ cells producing IL-17 after CD3/5 or 
CD3/ICOS stimulation, although was ineffective without TCR stimulation.  Blockade of IL-
12 with neutralising antibodies appeared to have little effect on the cultures.  
Unsurprisingly, but importantly, considerable interactions were apparent between the 
different variables assessed. 
On the basis of these preliminary data, experiments were next designed to assess in turn 
each of the most significant variables on a larger panel of donors.  TCR/signal 2 
combinations were first assessed with and without the ‘Th17 cytokine cocktail’ (IL1β, IL-6 
and TGFβ).  As with the initial screen, CD3/ICOS with the ‘Th17 cocktail’ was found to be 
the most potent inducer of Th17 cells (Figure 4.14).  As previously, considerable variation 
was noted between donors in terms of their propensity to form Th17 cells after culture, and 
as a consequence results did not reach statistical significance. 
The fraction of CD4+ cells producing IFNγ (Th1 cells) under the same conditions was next 
examined, and the ratio of cells producing IL-17 to those producing IFNγ calculated 
(Th17:Th1 ratio; Figure 4.15).  This indicated that whilst all other combinations tested 
decreased the IL-17 to IFNγ ratio, the CD3/ICOS ‘Th17 cocktail’ combination actually 
increased the proportion of Th17 cells relative to Th1 cells. 
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F igure 4.14.  Percentage of CD4+ T cel ls producing IL-17 on rest imulat ion 
after pr ior culture with combinat ions of TCR and signal 2 st imulat ion, with 
and without Th17-polar is ing cytokines ( ‘Th17’;  IL-1β  10ng/ml, IL-6 20ng/ml 
and TGFβ  5ng/ml).   N=3 
 
 
 
F igure 4.15.  Rat io of CD4+ T cel ls producing IL-17 to CD4+ cel ls producing 
IFNγ  on rest imulat ion after pr ior culture with combinat ions of TCR and 
signal 2 st imulat ion, with and without Th17-polar is ing cytokines ( ‘Th17’;  IL-
1β  10ng/ml, IL-6 20ng/ml and TGFβ  5ng/ml).   N=3 
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The interactions between IL-2 and the other variables tested was next assessed.  Whilst 
IL-2 had previously been found to increase the total yield of CD4+ T cells at the end of 
culture, the addition of IL-2 decreased the ratio of IL-17-secreting to IFNγ-secreting CD4+ 
cells under all conditions tested (Figure 4.16). 
A number of recent publications have examined other variables that may affect Th17 
polarisation, and the effect of a number of these factors on IL-17-secretion by CD4+ T 
cells after culture with CD3/ICOS stimulation and the ‘Th17 cytokine cocktail’ was next 
examined (Figure 4.17).  CD25-depletion, culture in the dark or in IMDM instead of RPMI 
and addition of tryptophan all actually decreased the fraction of CD4+ cells producing IL-
17 at the end of culture, although this did not reach significance.  Culture under controlled 
hypoxic conditions was found to increase the generation of Th17 cells; again, this did not 
reach statistical significance. 
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F igure 4.16.  Rat io of CD4+ T cel ls producing IL-17 to CD4+ cel ls producing 
IFNγ  on rest imulat ion after pr ior culture with combinat ions of TCR and 
signal 2 st imulat ion, Th17 polar is ing cytokines ( ‘Th17’;  IL-1β  10ng/ml, IL-6 
20ng/ml and TGFβ  5ng/ml) and IL-2 (200IU/ml).  N=3 
 
 
F igure 4.17.  Percentage of CD4+ T cel ls that produced IL-17 on 
rest imulat ion, after culture with combinat ions of culture media (RPMI or 
IMDM), CD25 deplet ion, avoidance of l ight exposure and tryptophan 
supplementat ion.  N=3, p=NS for all comparisons. 
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On the basis of the preceding experiments, the conditions chosen for optimal Th17 
expansion from unselected CD4+ T cells were CD3/ICOS stimulation, IL-1β, IL-6, TGFβ in 
RPMI, at 21% O2 without tryptophan supplementation.  Peripheral blood CD4+ T cells 
from healthy donors and patients with multiple myeloma were next cultured under these 
conditions and the fraction of Th17 cells at the end of culture enumerated (Figure 4.18 
shows dot plots from two representative donors and figure 4.19 collated data).  With 
healthy donors, culture under polarising conditions increased the Th17 fraction from 0.63% 
to 1.75% (p=NS; fold change: 2.78), whereas when the myeloma samples were cultured 
under these conditions, Th17 cells were increased from 0.8% to 3.78% (p=0.01; fold 
change: 4.73). 
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F igure 4.18.  IL-17 and IFNγ  secret ion by CD4+ T cel ls from a healthy donor 
and a pat ient with MM, before and after culture under Th17 polar isat ion 
condit ions. 
 
 
 
F igure 4.19.  Percentage of CD4+ T cel ls from healthy donors ( left )  and 
pat ients with myeloma (r ight)  that produced IL-17 on rest imulat ion after 7 
days of culture in CM alone (orange) or with polar isat ion (CD3/ICOS 
st imulat ion, IL-1β ,  IL-6 & TGFβ ;  purple).  Healthy donors n=10, MM patients n=8.  
P values are for paired student T tests. 
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Discussion	
The co-culture experiments described here clearly demonstrate an ability of human 
myeloma plasma cells to modulate T cell lineage determination to increase the frequency 
of Th17 cells after co-culture.  This is in keeping with the data presented in the previous 
chapter, and those published by other authors74, showing an expansion of Th17 cells in 
the bone marrow of patients with multiple myeloma.  In contrast, Th1 cells, characterised 
by secretion of IFNγ on re-stimulation, were reduced by co-culture with tumour cells.  
Sub-selection of CD4+ cells by expression of CD45 isoforms indicated that Th17 cells were 
derived predominantly from CD45RO+ activated and memory T cells. 
Taken in conjunction, these results are suggestive of redirection of T cell lineage 
determination from Th1 to Th17, however it is also possible that co-culture might provide 
conditions optimal for survival and expansion of existing Th17 cells and/or leading to death  
or loss of secretory function of Th1 cells.  The lack of a definitive cell surface phenotype for 
Th17 cells, discussed in the previous chapter, means that they can be identified only 
through stimulation and assay of cytokine secretion, most easily by flow cytometry.  
Unfortunately, as discussed previously, the only robust method for Th17 stimulation was 
found to be using PMA, ionomycin and brefeldin A, and although the use of cytokine 
capture-based FACS sorting was tested (data not shown), Th17 cells so harvested were 
found to have extremely low viability and were thus unsuitable for subsequent cell culture.  
Co-culture of CD161/CCR6-sorted CD4+ cells, which would be expected to enrich or 
deplete starting populations of Th17 cells, revealed no difference in the final proportions of 
Th17 cells, providing further evidence that HMCLs can drive modulation of lineage 
determination. 
Interestingly, whilst a range of HMCLs were found to have this capability to induce Th17 
cells, the line KMS11 did not display this effect.  Analysis of the cell surface and cytokine 
secretion phenotype of this cell line may be one avenue of investigation into the 
mechanisms underlying the effect. 
Modification of the co-culture model to incorporate other cell types demonstrated that the 
other immune subsets of peripheral blood had no effect on polarisation of T cells.  
However, the addition of human bone marrow stromal cells to the cultures yielded 
marked augmentation of the generation of Th17 cells.  Since co-culture of CD4+ 
lymphocytes and BMSC without HMCLs did not result in generation of Th17 cells, these 
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experiments indicate three-way cellular interactions between the cell types are 
responsible.  Although the experiments reported here do not allow dissection of the 
underlying mechanisms it is of course well known that bone marrow stromal cells can 
create a permissive microenvironment for MM development284, and that MM cells in turn 
may modify the stromal niche to support their own prolfieration285; the BMME plays a key 
role in the pathophysiology of myeloma, tumour cell quiescence, support of cancer ‘stem 
cells’ and development of relapse286.  A number of the known reciprocal positive-
feedback interactions between BMSC and MM plasma cells, involving such mediators as 
Dkk1284, VEGF190, IL-6190 and TGFβ287 are likely candidates here – the latter two in 
particular have well-described roles in the polarisation of Th17 cells.  Future experiments 
using cytokine supplementation/blocking and transwells to abrogate cell surface 
interactions could be used to further examine this phenomenon.   
When CD4+ cells were sorted by FACS on their surface expression of CD161 and CCR6 
prior to culture with HMCLs, no significant difference was seen in the prevalence of Th17 
at the end of culture.  This is surprising, since a robust body of previous evidence 
indicates that under normal circumstances, human IL-17 producing cells arise exclusively 
from CD161+ precursors165,166,288-291.  In the context of rheumatoid arthritis, IL-26-
stimulated monocytes have been reported to switch CD161- memory T cells into RORγt+ 
Th17 cells, through secretion of IL-1β 292, suggesting that in other inflammatory disease 
states, some abnormal plasticity may exist.  Whilst IL-1β was not found to be increased in 
the patient cohort examined here by Luminex, other authors have reported increased 
levels of this cytokine in MM293-295, correlating this with disease stage294,296,297.  
Furthermore, polymorphisms in IL-1β have been associated with risk of myeloma298 and 
outcomes after treatment299,300.  The role of IL-1β and IL-26 are relatively unexplored in 
MM and warrant further exploration. 
Recently published work also indicates that IL-34- and M-CSF-induced macrophages 
(which have many similarities to tumour-associated macrophages) are able to induce 
reconfiguration of CD4+CCR6-CD161-IL23R- T cells into Th17 cells, through membrane IL-
1α301.  However, in contrast to those reports, CD161 expression was found to be low on 
the Th17 cells induced by the co-culture, irrespective of initial CD161 status.  This low level 
of CD161 expression after coculture is intriguing since sort purities were good meaning 
CD161 was known to be expressed in the appropriate cells at the beginning of the 
cultures.  Certainly, it is tempting to suggest MM cells or BMSC might reduce CD161 
expression, which would be in keeping with a previous publication reporting 
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downregulated CD161 on Th17 cells in patients with head and neck cancer, and suggests 
alternate mechanisms may exist for Th17 generation in cancer.  However, in fact, CD161 
expression was lowest of all in those CD4+ cells cultured alone after sorting, and alternate 
mechanisms are therefore probably responsible.  For example, ligation of CD161 by 
monoclonal antibodies prior to FACS may lead to internalisation of the antigen.  It is 
unclear whether this is a physiologically relevant phenomenon. 
In the context of the observational data presented in the previous results chapter, the 
coculture experiments yield some interesting observations.  Firstly, they corroborate the 
hypothesis that the expansion of Th17 cells seen in patients with MM results from 
interactions between the tumour clone, BMSC and CD4+ T cells in the marrow.  This also 
provides a putative explanation for the relatively greater expansion seen in BM compared 
to PB.  Secondly, with respect to the loss of cell surface expression of CD161 and CCR6 
on Th17 cells in MM, the coculture experiments are strongly suggestive that MM-BMSC-
CD4+ interactions are able to subvert the normal rules of Th17 lineage determination and 
induce IL-17 production from CD161- cells.   
These observations in turn lead to a number of further questions.  Firstly, modification of 
the coculture model will allow more detailed dissection of the actual mechanisms leading 
to Th17 generation.  For example, use of contact-free culture systems (e.g. Transwells), 
culture supernatants (e.g. tumour-conditioned media), cytokine supplementation and 
specific cytokine and cell surface blocking will allow determination of the relative 
contributions of contact- and soluble factor-mediated mechanisms.  This is an important 
question, particularly since this model is based on a modified one-way mixed lymphocyte 
reaction and is therefore allogeneic 
Secondly, the in vitro work conducted to date does not compare the functional 
characteristics of Th17 cells derived from tumour cell cocultures and those derived from 
healthy donor peripheral blood or induced by cytokine polarisation.  This line of 
investigation could firstly employ stimulation with the MP65 protein, and then build upon 
the functional assays postulated in the previous results chapter (e.g. neutrophil migration, 
epithelial immune responses and trafficking in response to chemokine gradients).  It 
should be noted that since Th17 cells have proven so difficult to isolate from either patients 
or healthy donors, characterisation of the effects of naturally occurring Th17 cells from the 
two states may not prove possible, but assessment of the cytokines individually or in 
combination through coculture is a natural extension of this work. 
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Thirdly, assessment of the effects of CD161 engagement, e.g. by monoclonal antibodies, 
might also be revealing, as may examination of MM BM by immunohistochemistry to 
assess localisation of Th17 cells in relation to tumour cells and BMSC.  Effects of IL-17 on 
osteoclast function have also been reported199 and immunohistochemistry may provide a 
useful avenue for examining this further. 
Finally, and perhaps most importantly of all, work should now be undertaken to examine 
in detail the effect of Th17 cells, and their cytokines, on the growth of tumour cells, and 
their survival after chemotherapeutic attack (in addition to IL-17, other Th17 cytokines such 
as IL-22, IL-21 and TNFα might also play a role196).  These experiments will likely prove 
difficult to conduct using HMCLs since the majority of these are highly proliferative, grow 
in the absence of cytokine supplementation and respond poorly to a number of 
chemotherapy strategies.  Prabhala et al. reported acceleration of cell division in HMCLs 
treated with IL-17 74, although the concentrations used were not specified and attempts 
to repeat these experiments have demonstrated no effect on growth of a range of HMCLs 
at a range of concentrations of rhIL-17 (data not shown).  Development of a protocol for 
harvesting and in vitro culture of primary tumour cells may therefore be necessary to 
conduct these experiments.   
In order to examine the propensity of CD4+ T cells to become Th17 cells and to begin to 
dissect the mechanisms that might underlie the generation of Th17 cells in myeloma, a 
second group of experiments were next undertaken to create an optimised protocol for 
driving Th17 generation in vitro.  In addition, since Th17 cells are such a rare population, it 
was envisaged that ex vivo expansion might facilitate future work such as more detailed 
phenotyping and assessment of the role and functional capacity of Th17 cells in health and 
disease.  A body of work by multiple authors has examined the issue of Th17 cell 
expansion, often with conflicting findings91-99,102,109-112, and the data presented here may 
shed some light on the potential reasons for this.   
It was apparent from the initial screening experiments that those culture conditions giving 
rise to the largest numbers of CD4+ cells were quite distinct from those producing the 
highest proportion of IL-17-secreting CD4+ cells.  This is not surprising, but underlines the 
importance of considering the starting population when determining the optimal 
polarisation cocktail.  For example, IL-2 has long been recognised as a major promoter of 
clonal expansion in T cells, but its role in Th17 polarisation protocols has been the subject 
of some debate in the literature with the majority of authors advocating its use302-305 and 
others not incorporating or even blocking it306, or using it only for the maintenance of 
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previously sorted populations129.  In the polarisation experiments, IL-2 was found to 
augment total T cell numbers, and therefore potentially the total number of Th17 cells, but 
potently reduced the proportion of CD4+ cells producing IL-17 – i.e. the purity of the 
population.  It is likely therefore, that the effects of IL-2 may depend heavily on the starting 
population with a potential favourable role in purified populations, and adverse effects 
seen in mixed populations where it may allow other subsets (e.g. Th1 cells) to out-
compete Th17 cells, or may even directly suppress IL-17 production.  The recognition that, 
in mice at least, STAT5 signalling, which is up-regulated by IL-2, can oppose Th17 
differentiation117, and of the inability of Th17 cells to produce and their reduced ability to 
respond to, IL-2307, provide additional support for this conjecture. 
When TCR and signal 2 stimulation was examined, Th17 cells were found to expand 
optimally not after stimulation with CD3 & CD28, but rather with either CD3 and CD5 or 
CD3 and ICOS stimulation.  CD5 co-stimulation has previously been reported as 
promoting Th17 development, through sustained STAT3 activation and up-regulation of IL-
23R expression129.  Similarly, ICOS has been shown to be superior to CD28 co-
stimulation in driving differentiation of both Th17 and Th17-1 cells 128.  These findings may 
partly reflect the inability of Th17 cells to produce IL-2 in response to CD3/28 
stimulation307, although the signalling involved in these alternate signal 2 pathways is also 
probably discrete – for example ICOS induces both c-MAF and IL-21 thereby augmenting 
Th17 function128, and also appears to have a role in polarisation of Th17-1 cells128,308 , 
although these were not seen at appreciable levels in the polarisation experiments.  The 
central role of ICOS in Th17 generation is of interest in light of previous work from our 
group which has shown ICOS/ICOS-L interactions to be central to the generation of 
regulatory T cells in myeloma309, and offers a further likely mechanism for the generation 
of Th17 cells by myeloma plasma cells – this will require exploration in further work. 
As predicted from the majority of the body of published work on Th17 polarisation91-
99,102,109-112, the combination of TGFβ with pro-inflammatory cytokines such as IL-1β & IL-6 
was found to enhance Th17 generation.  IL-23 has also been ascribed a role in 
stabilisation of the Th17 phenotype, however, currently available sources of rhIL-23 were 
found to be financially prohibitive and this was therefore not investigated further.  
Interestingly, blockade of IL-12, an often-employed component of Th17 polarisation 
protocols, was found to have no significant efficacy.  Whilst this may relate to the 
particular reagent or concentrations used, these were in keeping with published work and 
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the result might equally reflect minimal generation of IL-12 under the best Th17-polarising 
conditions due to minimisation of Th1 proliferation and cytokine secretion.   
Hypoxia-inducible factor 1 (HIF-1) is a key metabolic sensor that is known to be one of 
the mediators regulating the balance between regulatory T cell (Treg) and Th17 
differentiation via multiple mechanisms151.  It has previously been shown that HIF-1α 
mRNA is upregulated in murine T cells under Th17-skewing conditions, in a STAT3-
dependent manner151.  Since it is now well-known that the bone marrow 
microenvironment in myeloma may be hypoxic310, experiments were undertaken to 
examine the effect of culture in hypoxic conditions (5% O2, 37°C); this modification of the 
coculture tended to increase generation of Th17 cells, although this did not reach 
significance.  Unfortunately, further exploration of this avenue of investigation was not 
possible at the time of these experiments due to technical problems with the hypoxic 
incubator used, but this may warrant revisiting.  Immunohistochemical analysis of bone 
marrow trephine biopsies for colocalisation of IL-17 (or RORC) and HIF-1α, or for 
localisation of Th17 cells within the micro-anatomy of the marrow might also be a useful 
way of assessing the true contribution of hypoxia to Th17-generation in the marrow of 
patients with MM. 
Th17 cell differentiation is also known to be modulated by activation of the aryl 
hydrocarbon receptor (AHR); Veldhoen et al. found that the presence of endogenous AHR 
agonists present in cell culture medium was thereby able to modulate the proportion of T 
cells able to produce IL-17 after culture, with Iscove’s modified Dulbecco’s medium 
(IMDM), which is richer in aromatic amino acids that give rise to AHR agonists, resulting in 
consistently greater Th17 expansion in both human and murine cells306.  Supplementation 
of RPMI with ι-tryptophan was found to increase Th17 polarisation.  Interestingly at least 
one tryptophan metabolite, FICZ, a high-affinity AHR ligand, is known to be produced 
through exposure of tryptophan to normal laboratory light conditions.  However, in the 
experiments reported here, no impact of IMDM use, light exposure or tryptophan 
supplementation was seen.  Whilst these factors might have provided useful means of 
increasing the yield of Th17 cells to allow more detailed experimental characterisation, they 
seem less likely to play a role in myeloma and were not examined further. 
Finally, since there is considerable evidence of reciprocal interactions in the development 
of Treg and Th17 cells, as well as suppression of IL-17 secretion by Treg populations305, 
CD25 depletion was undertaken, as described previously, to examine the effect of 
removal of the natural Treg population on Th17 numbers.  This modification resulted in a 
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non-significant decrease in Th17 cells, possibly reflecting removal of Treg which through T 
cell plasticity might provide one portal for Th17 generation. 
When the optimised Th17 polarisation protocols were applied to a larger number of 
samples from healthy donors, a modest and non-significant increase in Th17 cells was 
noted.  The difficulty in generating significant numbers of Th17 cells reflects the published 
experience, and is a very significant hurdle to the characterisation of these cells in health 
and disease.  Nonetheless, when peripheral blood samples from patients with myeloma 
were treated with the sample protocol, a significant increase in Th17 cells was seen.  This 
suggests that not only do MM patients have increased levels of circulating Th17 cells, but 
that in addition their non-committed T cells have a higher propensity to become 
differentiated Th17 cells.  This may partly reflect the increased numbers of circulating Treg 
cells in MM patients309, which are known to exhibit the plasticity typical of T cell subsets.  
In addition, a number of the key cytokines in Th17 development are known to be increased 
in the peripheral blood of patients with myeloma189,190,311, which may render T cells 
‘primed’ for Th17 generation.  Addition to cocultures of the Th17 polarisation cocktail 
and/or neutralising antibodies against the cytokines, may yield further insights into the 
mechanisms of Th17 generation in the cocultures.  Use of the cocktail on CD161/CCR6-
sorted populations may also allow further clarification of whether HMCLs are able to 
induce Th17 cells from a population otherwise unable to develop in this way, as appears to 
be the case from the data presented. 
The data presented in this chapter provide explanations for many of the observations 
detailed in the previous chapter.  The increase in Th17 cells seen in patients with MM is 
explained by cellular interactions occurring within the BMME, which lead to relative 
expansion or preferential survival of Th17 cells relative to other T cell subsets.  Moreover, it 
appears that these interactions may lead to expansion of Th17 cells from precursor 
populations previously thought unable to give rise to this lineage of cells.  A number of 
potential avenues of further investigation are apparent and will form the basis of future 
work. 
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Chapter 5 – Oncolytic virotherapy in Multiple 
Myeloma 
Introduction	
Reovirus in myeloma 
Following from the work presented in the preceding results chapters, the abilities of a 
range of potential therapeutic agents to modulate the immune dysfunction seen in MM 
were investigated.  The oncolytic virus, Reovirus, was found to have a number of 
interesting properties with respect to both myeloma and immune cells and more detailed 
characterisation was therefore undertaken and will be reported in this results chapter. 
Reovirus (originally respiratory enteric orphan virus) is a naturally occurring double-
stranded RNA virus and a ubiquitous but benign human pathogen, to which the majority 
of the population have been exposed by the age of five312.  The virus has been 
infrequently associated with upper respiratory symptoms, resembling a mild influenza-like 
illness, and gastrointestinal symptoms such as diarrhoea; close to 100% of human adults 
are seropositive208,313, although interestingly this does not appear to abrogate the effect of 
the virus since cellular carriage can sequester virus from neutralizing antibodies allowing 
delivery to tumour targets 314 
Reovirus, along with a number of other naturally occurring and genetically engineered 
viruses, has become of considerable interest to the field of oncology, due to its ability to 
enter, replicate in, and selectively lyse cancer cells, possibly due to the dysregulation of 
Ras signalling which renders such cells unable to appropriately phosphorylate double-
stranded RNA-activated protein kinase (PKR) and so clear viral infection210,315,316.  An 
expanding body of preclinical data, reviewed in the main introduction to this thesis, 
demonstrates the efficacy of the virus in a number of settings, predominantly solid 
malignancies. 
Some work has been conducted on reovirus in MM to date, much of which has been 
published whilst the experiments here were being conducted.  The virus has been shown 
to be capable of in vitro lysis of myeloma cell lines216, to mitigate tumour growth in 
NOD/SCID models216 and to selectively purge peripherally harvested stem cells of tumour 
cells232.  It has been postulated as a clinically useful agent216 and shown to be safe when 
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employed as a single agent in a phase I trial in patients with relapsed refractory 
myeloma236.  However, almost all of the work published to date on reovirus in myeloma 
has focused on the direct tumour-mediated lytic effects of virotherapy, ignoring the 
secondary immune-mediated effects which are beginning to prove so important for 
oncolytic virotherapy204,317, and furthermore have not examined combination therapies 
which might potentiate such effects.  The experiments presented within this chapter 
therefore attempt to expand existing evidence for the direct oncolytic effects of the virus in 
myeloma, assess immune activatory potential, and yield preliminary data for subsequent 
work examining rational reovirus-based combination therapies for clinical use. 
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Materials	and	Methods	
General techniques used in this chapter have been described in chapter 2.  Specific 
techniques employed for this work are outlined below. 
Reagents and solutions 
Reovirus Type 3 Dearing 
strain 
Reolysin® donated by Oncolytics Biotech Inc., 
stored at -80°C for long term storage, or in 
PBS in the dark at 4°C (maximum 4 weeks) 
Paraformaldehyde 4% solution (Sigma) 
Lenalidomide Donated by Celgene Corporation, stored at -
20°C 
zVAD-FMK  Source: BD Pharmingen (550377) 
Dexamethasone  Source: Sigma (D1756, 50-02-2), stored at -
20°C 
ACK Buffer  500ml PBS, 4.01g ammonium chloride 
(0.15M), 0.5g KHCO3 (10mM), 0.02g EDTA 
(0.1mM). 
Table 5.1  Reagents and solut ions.      
 
Live/Dead flow cytometry assays 
Tumour cells were treated as described in individual experiments.  An intracellular amine 
stain was added (1μl per 106 cells in 100μl of FACS buffer) and cells incubated for 30 
minutes on ice.  Cells were then fixed in 4% paraformaldehyde for 10 minutes to 
inactivate any remaining reovirus before flow cytometric analysis as described previously. 
 
NK cell degranulation assays 
This assay operates on the principle that the lysosomal protein CD107a becomes 
expressed on the cell plasma membrane as a consequence of degranulation of NK cells.  
HMCL were labeled using a cell tracker dye (CellTracker™ Blue CMAC, Invitrogen) – 
briefly, tumour cells were incubated with the cell tracker at 1μM for 30 minutes in RPMI 
media without FCS, washed and incubated for a further 30 minutes in RPMI media 
without FCS, and then resuspended in CM.  Whole PBMC were treated as detailed in 
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individual experiments.  Both tumour cells and PBMC were then resuspended at 2x106/ml 
and combined at a range of PBMC to tumour cell ratios (9:1, 3:1 and 1:1) in round-
bottomed 96-well plates, always with 2x105 cells in total in 100μl of medium per well.  
Cells were then incubated for 1 hour at 37°C, before the addition of GolgiStop and 
GolgiPlug, each at 1:1000 (both Miltenyi Biotec) and a fluorophore-conjugated antibody 
against CD107a (see table 5.2).  After a further 2 hours, antibodies against CD3 and 
CD56 and a dead cell discriminator were added (table 5.2) and cells incubated for a 
further 30 minutes at room temperature.  Finally, cells were centrifuged at 300g, 
resuspended in FACS buffer and assayed by flow cytometry as described previously. 
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Live/Dead 
discriminator 
PI-like Blue 
(488) 
625 Miltenyi Biotec (130-091-163) 
μLIVE/DEAD 
Fixable Red 
 Blue 
(488) 
615 Life 
Technologies 
(L231012) 
CellTracker™ 
Blue CMAC 
CMAC UV (350) 466 Invitrogen C2110 
CD3 PE Blue 
(488) 
578 Miltenyi-Biotec BW264/56  
(130-091-374) 
CD56 APC Red 
(633) 
660 Miltenyi-Biotec REA196  
(130-100-698) 
CD107a FITC Blue 
(488) 
520 Miltenyi-Biotec H4A3  
(130-095-518) 
JAM1 PE Blue 
(488) 
578 BD Pharmingen M.Ab.F11 
(552556) 
Table 5.2.  F luorophore-conjugated ant ibodies and cel l  sta ins used for f low 
cytometry. 
 
Cytotoxicity assays on stromal cell layers 
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For these assays stromal cells were seeded into sterile 48-well tissue culture plates at a 
density of 105 cells per well in 1ml of CM and incubated at 37°C and 5% CO2 in a 
humidified incubator for 24 hours.  Media and non-adherent cells were then removed and 
2ml of fresh CM added containing 105 HMCLs, resulting in incubation at a 1:1 ratio and 
an initial cell density of 2x105 cells in 2ml in each well.  These cultures were then 
incubated for a further 48 hours prior to assessment of cell death in tumour cells as 
described previously.   
 
C57BL/KaLwRijHsd 5TGM1 murine model 
All animal work was conducted under an appropriate Project License (License holder: 
Prof Alan Melcher), by Home Office licensed and appropriately trained individuals.  All 
murine experiments were conducted in collaboration with Dr Fiona Errington-Mais.  
C57BL/KaLwRijHsd mice were purchased at age 6-10 weeks from a colony already 
established at the University of Leeds, which was in turn originally purchased from Harlan 
Laboratories (Indianopolis).  Mice were ear-notched for identification and housed in 
groups of 4-5 in OPTIcages, until injected with reovirus, when they were transferred into 
ISOcages and kept separately from uninfected animals.  All animals were monitored daily, 
and any mice exhibiting hind limb paralysis, hunched posture, reduced activity levels, skin 
ulceration, weight loss, difficulty breathing or other distress were removed from the colony 
and euthanized via cervical dislocation; at the end of experiments animals were similarly 
euthanized via cervical dislocation. 
The 5TGM1 and 5TGM1-eGFP cell lines were obtained from Dr Oyajobi, Department of 
Molecular Medicine, University of Texas Health Science Centre, San Antonio, under an 
appropriate material transfer agreement, and cultured in CM.  Cell lines were passaged in 
vivo in C57BL/KaLwRijHsd mice and bone-resident tumour cells isolated and cultured in 
vitro for 2-3 passages prior to use in in vivo experiments.  The method and vector 
employed for generation of the eGFP-transduced line are described318. 
After sacrifice of animals, post-mortem dissection was undertaken to isolated both femora 
and tibias, and the spleen.  Bone marrow cells were isolated by removal of the epiphyses 
and flushing of the shaft of the long bones with media.  These cells were then processed 
as described in individual experiments.  Spleens were crushed in a Falcon cell strainer 
(BD Biosciences) using the plunger from a 12ml syringe (BD Biosciences) into CM.  Cells 
were then centrifuged at 400g for 5 minutes and resuspended in ACK red cell lysis buffer 
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(5ml per spleen) for 2 minutes.  Excess cold medium was then added, before centrifuging 
at 400g for 5 minutes, resuspension in CM and assessment by flow cytometry as 
described previously.  Table 5.3 shows the antibodies used for flow cytometry for murine 
experiments. 
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) 
μLIVE/DEAD 
Fixable Red 
 Blue (488) 615 Life 
Technologies 
(L231012) 
CD4 APC Red (633) 660 Miltenyi GK1.5  
(130-102-594) 
CD8 PECy5 Blue (488) 655 BD Pharmingen 53-6.7  
(553034) 
DX5 PE Blue (488) 578 Miltenyi DX5  
(130-102-337) 
CD69 FITC Blue (488) 520 Miltenyi H1.2F3  
(130-103-950) 
CD138 PE Blue (488) 578 Miltenyi REA104  
(130-102-580) 
Table 5.3.  F luorophore-conjugated ant ibodies and cel l  sta ins used for f low 
cytometry for murine experiments. 
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Results	
Expression of JAM1 of human myeloma cell lines 
Junctional adhesion molecule 1 (JAM1) is known to be the cell surface receptor for 
reovirus209,213,216 and the expression of this protein on the surface of human myeloma cell 
lines was therefore evaluated first.  A panel of human myeloma cell lines (HMCLs), and the 
erythroleukaemia cell lines K562, were cultured in complete media.  Live cells were 
purified by density centrifugation on Lymphoprep, stained with a PE-conjugated antibody 
against JAM1 (or with an isotype-matched control antibody), and then assessed for 
expression of this protein by flow cytometry.  Representative examples are given in Figure 
5.1; Figure 5.2 shows compiled results for all HMCLs examined (n=3).  A proportion of all 
cell lines tested was found to express the marker, although a range of levels of expression 
was seen – KMS11, KMS18, RPMI 8226 and U266 as well as K562 expressed JAM1 on 
close to all cells, whereas OPM2 demonstrated only low level expression with 
intermediate results seen on other lines.   
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F igure 5.1.  Mean f luorescence intensity of JAM1 stain ing on the HMCLs 
KMS18, U266, JIM3 and OPM2. 
 
F igure 5.2.  Percentage of HMCLs with surface expression of JAM1. 
Histograms show medians and standard deviations, n=3. 
Isotype(control(stain(
KMS18(
U266(
JIM3(
OPM2(
JAM1(expression(
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Direct reovirus-induced oncolysis of HMCLs 
Direct cytotoxic effects of reovirus type 3 Dearing strain (reovirus hereafter) treatment on 
HMCLs were next assessed.  For these experiments HMCLs were incubated with reovirus 
at a range of multiplicities of infection (MOI) for a range of periods of time, then the dead 
cells labelled using an intracellular amine stain (LIVE/DEAD® Fixable Dead Cell Stain Kits, 
Invitrogen) and quantified by flow cytometry.  Figure 5.3 shows representative example 
flow cytometry scatter plots and histograms, in this case for treatment of U266B with 
reovirus for 72 hours.  Treatment with reovirus was associated with a dose- and time-
dependent alteration in forward and side scatter characteristics and uptake of LIVE/DEAD 
discriminator, indicating cell death. 
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F igure 5.3.  Representat ive scatter plots of forward scatter (FSC) and side 
scatter (SSC, left  panel)  and intracel lu lar amine sta in ing (r ight panel)  of 
U266 after treatment for 72 hours with a range of mult ip l ic i t ies of infect ion 
with reovirus. 
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Collated data for, JIM3, U266B and OPM2 are shown in Figures 5.4-5.6.  H929, JIM3, 
KMS11 and U266B all exhibited time- and MOI-dependent killing by reovirus, p<0.0001 
for both variables by 2-way ANOVA in all cases.  As expected, some variation was seen 
between these lines in terms of sensitivity to the virus, with H929 being the most 
susceptible line tested.  Further cell lines (H929, KMS11, JJN3, KMS18 and RPMI8226) 
were found to be similarly sensitive to reovirus treatment (data not shown).  One HMCL, 
OPM2 (previously demonstrated to have only low level surface expression of JAM1), 
showed no change in viability even after treatment with the highest tested MOI of reovirus 
for 96 hours (2-way ANOVA, p=NS). 
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F igure 5.4.  Fract ion of JIM3 cel ls dead after incubat ion with reovirus at a 
range of mult ip l ic i t ies of infect ion (MOIs) for the durat ions shown, as 
determined by intracel lu lar amine sta in ing and f low cytometry.  N=3.  Mean 
and standard deviations shown.  p values are for 2-way ANOVA. 
  
F igure 5.5.  Fract ion of U266B cel ls dead after incubat ion with reovirus at a 
range of mult ip l ic i t ies of infect ion (MOIs) for the durat ions shown, as 
determined by intracel lu lar amine sta in ing and f low cytometry.  N=3.  Mean 
and standard deviations shown.  p values are for 2-way ANOVA. 
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F igure 5.6.  Fract ion of OPM2 cel ls dead after incubat ion with reovirus at a 
range of mult ip l ic i t ies of infect ion (MOIs) for the durat ions shown, as 
determined by intracel lu lar amine sta in ing and f low cytometry.  N=3.  Mean 
and standard deviations shown.  p values are for 2-way ANOVA. 
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Reovirus has previously been reported to induce apoptosis in susceptible tumour lines; in 
order to assess whether this may be mechanism of action in HMCLs, a selection of cell 
lines were cultured with and without reovirus treatment (MOI=1) for 96 hours, cell lysates 
made and Western blots performed for the anti-apoptotic protein bcl2 (Figure 5.7).  Equal 
cell numbers were loaded in each lane. 
Reovirus treatment was seen to reduce bcl2 expression in a range of cell lines.  The 
tumour cell line JIM3 was then incubated for 96 hours with reovirus, as previously, with or 
without the addition of the cell-permeable general caspase inhibitor zVAD-FMK 50μM, 
and the proportion of dead cells assayed as previously (Figure 5.8).  Addition of the 
caspase inhibitor was seen to militate against reovirus-induced killing. 
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F igure 5.7.  Western blots for bcl2 on cel l  lysates from JIM1, JIM3, JJN3 
and KMS18 with and without Reovirus treatment.  Cells were treated for 96 
hours at Reovirus MOI=1. 
 
F igure 5.8.  Fract ion of JIM3 cel ls dead after incubat ion with and without 
reovirus at MOI=1 for 48 hours in CM or CM with zVAD.  N=3.  Mean and 
standard deviations shown.  P values are for two-tailed paired student t tests. 
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Oncolysis in combination with immunomodulatory agents 
Since it was the intention of this work to examine the potential for combination of reovirus 
with immunomodulatory agents (IMiDs), particularly in light of the immunological effects of 
reovirus discussed later, the effects of combination with the IMiD lenalidomide on direct 
cytotoxicity was next examined.  Firstly, a panel of HMCLs, and the erythroleukaemia cell 
lines K562, were cultured in complete media or complete media with lenalidomide 10μM 
for 96 hours.  Live cells were then purified by density centrifugation on Lymphoprep, 
stained with a PE-conjugated antibody against JAM1 (or with an isotype-matched control 
antibody), and then assessed for expression of this protein by flow cytometry.  The 
experiment was repeated in triplicate (Figure 5.9).  Treatment with lenalidomide did not 
significantly affect the fraction of cells expressing JAM1 for any of the cell lines tested.  
Mean fluorescence intensity for JAM1 expression was similarly unaffected by lenalidomide 
treatment, indicating no change in the level of expression of the protein on those cells 
already expressing it at baseline (Figure 5.10) 
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F igure 5.9.  Percentage of HMCLs with surface expression of JAM1 as 
determined by f low cytometry, after culture for 96 hours in RPMI with 10% 
FBS, with or without addit ion of 10μM lenal idomide.   
 
F igure 5.10.  Mean f luorescence intensity of JAM1 stain ing on a range of 
HMCLS, as determined by f low cytometry, after culture for 96 hours in 
RPMI with 10% FBS, with or without addit ion of 10μM lenal idomide.   
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The effect of combination treatment of cells lines with reovirus and lenalidomide was next 
investigated.  Since in clinical use lenalidomide is usually combined with corticosteroid 
therapy, at least for a number of cycles of chemotherapy before tapering, the effects of 
dexamethasone treatment were also examined.  The cell lines KMS11, JIM3 and OPM2 
were therefore treated with combinations of reovirus (at the previously examined range of 
MOIs), lenalidomide 10μM and dexamethasone 5μM; cultures were incubated for periods 
known from the previous experiments to result in suboptimal reovirus-induced killing for 
KMS11 and JIM3 (48 hours and 72 hours respectively) and for 96 hours for OPM2, which 
is resistant to reovirus.  Cell death at the end of cultures is shown in Figures 5.11-5.13. 
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F igure 5.11.  Fract ion of KMS11 cel ls dead after incubat ion for 48 hours 
with reovirus at a range of MOIs and/or lenal idomide and dexamethasone.  
N=3.  Mean and standard deviations shown.  2-way ANOVA: p=0.0094 for reovirus MOI, 
p=0.3016 for lenalidomide/dexamethasone, p=0.8377 for interaction. 
 
F igure 5.12.  Fract ion of JIM3 cel ls dead after incubat ion for 72 hours with 
reovirus at a range of MOIs and/or lenal idomide and dexamethasone.  N=3.  
Mean and standard deviations shown.  2-way ANOVA: p=0.0014 for reovirus MOI, 
p=0.9369 for lenalidomide/dexamethasone, p=0.229 for interaction. 
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F igure 5.13.  Fract ion of OPM2 cel ls dead after incubat ion for 96 hours with 
reovirus at a range of MOIs) and/or lenal idomide and dexamethasone.  N=3.  
Mean and standard deviations shown.  2-way ANOVA: p=0.3776 for reovirus MOI, 
p=0.0063 for lenalidomide/dexamethasone, p=0.3902 for interaction. 
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The effects of these combination therapies were next tested on a primary bone marrow 
sample from a patient with multiple myeloma; the fraction of all bone marrow cells 
expressing CD138+ after treatment for 48 hours and the cell death in CD138+ cells are 
presented (Figure 5.14). 
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F igure 5.14.   Number of CD138+ cel ls (A) and cel l  death in CD138+ cel ls 
(B) after treatment of a MM BM sample with reovirus, dexamethasone and 
lenal idomide.   
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Reovirus-induced activation of peripheral blood immune cells 
The effects of reovirus treatment on peripheral blood immune cells was next examined.  
For these experiments PBMC were isolated from a healthy donor and incubated with 
reovirus at MOI=0.1 or 1, and/or lenalidomide 10μM; dexamethasone was found to be 
markedly lympholytic in this context and was not evaluated further.  Activation of 
peripheral blood immune subsets at 24 hours and 7 days was estimated using surface 
CD69 expression (Figure 5.15).  It should be noted that since CD69 expression is induced 
on activation, but then down-regulated by 72 hours, expression of CD69 at day 7 is likely 
to represent ongoing activation. 
Since promising results were seen in this pilot experiment using PBMC from a healthy 
donor, the more relevant question of activation of immune subsets in myeloma patients, 
who have marked immuneparesis, was next explored.  Here PBMC were isolated from 
patients with MM and were incubated with reovirus alone for 1, 4 or 7 days, and 
activation of CD4+, CD8+ and CD3-CD56+ (NK cells) subsets estimated by CD69 
expression (Figure 5.16-5.18); since immune subset activation at baseline was found to 
vary markedly between donors, CD69 expression was normalised against expression in 
the untreated group at D1 and expressed as a fold increase. 
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F igure 5.15.  CD69 expression on per ipheral b lood immune subsets after 
incubat ion of healthy donor PBMC with reovirus and lenal idomide 
combinat ions at the concentrat ions shown for 24 hours (panel A) and 7 
days (panel B).    
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F igure 5.16.  CD69 expression on per ipheral b lood CD4+ cel ls after 
incubat ion of PBMC from pat ients with MM with reovirus at the MOIs 
shown.  CD69 expression is normalised to expression in the untreated sample at D1 for 
each donor.  n=3, histogram shows means and standard deviations.  2-way ANOVA: 
MOI: p<0.0001, time: p=0.0006, interaction: p<0.0001. 
 
F igure 5.17.  CD69 expression on per ipheral b lood CD8+ cel ls after 
incubat ion of PBMC from pat ients with MM with reovirus at the MOIs 
shown.  CD69 expression is normalised to expression in the untreated sample at D1 for 
each donor.  n=3, histograms show means and standard deviations.  2-way ANOVA: 
MOI: p=0.0023, time: p=0.0080, interaction: p=0.0007. 
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F igure 5.18.  CD69 expression on per ipheral b lood CD3- CD56+ cel ls after 
incubat ion of PBMC from pat ients with MM with reovirus at the MOIs 
shown.  CD69 expression is normalised to expression in the untreated sample at D1 for 
each donor.  n=3, histogram shows means and standard deviations.  2-way ANOVA: 
MOI: p=NS, time: p=NS, interaction: p=NS. 
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The effect of addition of lenalidomide to these cultures was next investigated.  In order to 
allow for potential for synergy between the agents, the doses of reovirus MOI 0.1 and 1, 
and lenalidomide 1μM ad 10μM were selected.  Incubations were again conducted for 1, 
4 and 7 days (Figure 5.19-5.21).  
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F igure 5.19.  CD69 expression on per ipheral b lood CD4+ cel ls after 
incubat ion of PBMC from pat ients with MM with reovirus and/or 
lenal idomide at the doses shown.  CD69 expression is normalised to expression in 
the untreated sample at D1 for each donor.  n=3, means and standard deviations shown. 
 
F igure 5.20.  CD69 expression on per ipheral b lood CD8+ cel ls after 
incubat ion of PBMC from pat ients with MM with reovirus and/or 
lenal idomide at the doses shown.  CD69 expression is normalised to expression in 
the untreated sample at D1 for each donor.  n=3, means and standard deviations shown. 
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F igure 5.21.  CD69 expression on per ipheral b lood CD3- CD56+ cel ls after 
incubat ion of PBMC from pat ients with MM with reovirus and/or 
lenal idomide at the doses shown.  CD69 expression is normalised to expression in 
the untreated sample at D1 for each donor.  n=3, means and standard deviations shown. 
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Reovirus-induced, NK cell-mediated tumour killing 
In view of the demonstrated ability of reovirus to activate peripheral blood immune cells, 
the implications of these findings for immune-mediated secondary tumour killing were 
next investigated, in particular the ability of NK cells so activated to induce lysis of tumour 
targets. 
PBMC were incubated for 48 hours with and without Reovirus (MOI=1) prior to NK cell 
degranulation assays conducted as described in the methods section of this chapter.  
The cell line K562, an erythroleukaemia line known to be sensitive to NK cell-mediated 
lysis, was first examined to validate the assay protocol (Figure 5.22); H929, JIM3 and 
OPM2 were then assessed for susceptibility to NK cell-mediated lysis and the ability of 
reovirus to augment this (Figures 5.23-5.25). 
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F igure 5.22.  NK cel l  degranulat ion assay against K562.  The fraction of NK 
cells (defined as CD3+CD56-) expressing surface CD107a at the end of the assay is 
shown .  N=3.  Means and SEM shown. 
 
F igure 5.23.  NK cel l  degranulat ion assay against H929.  The fraction of NK 
cells (defined as CD3+CD56-) expressing surface CD107a at the end of the assay is 
shown .  N=3.  Means and SEM shown. 
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F igure 5.24.  NK cel l  degranulat ion assay against JIM3.  The fraction of NK cells 
(defined as CD3+CD56-) expressing surface CD107a at the end of the assay is shown .  
N=3.  Means and SEM shown. 
 
F igure 5.25.  NK cel l  degranulat ion assay against OPM2.  The fraction of NK 
cells (defined as CD3+CD56-) expressing surface CD107a at the end of the assay is 
shown .  N=3.  Means and SEM shown. 
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NK degranulation assays were next conducted after treatment of PBMC with both 
reovirus and lenalidomide for 48 hours.  Lenalidomide was found not to increase NK cell 
degranulation above that already seen with reovirus treatment; Figure 5.26 shows the 
results for H929 – other HMCLs yielded similar results (data not shown). 
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F igure 5.26.  NK cel l  degranulat ion assay against H929 with and without 
pr ior lenal idomide treatment of PBMC.  Histograms show the fraction of NK cells 
(defined as CD3+CD56-) expressing surface CD107a at the end of the assay.  N=6.  
Histograms show medians and standard deviations. 
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Attempts were next made to assess the impact of NK cell degranulation in these assays 
on death of tumour cells.  Tumour cells were labeled with cell tracker prior to the 
degranulation assay, as described previously, and cell death in the labeled cells was then 
determined by intracellular amine staining after the assay.  Figures 5.27 and 5.28 show 
cell death in H929 and OPM2 respectively. 
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F igure 5.27.  Cel l  death in H929 after NK cel l  granulat ion assay.  Histograms 
show the fraction of tumour cells dead after 3 hours of incubation with NK cells, which 
were either pretreated with reovirus for 48 hours (red) or not (orange).  Histograms show 
medians and standard deviations; n=4. 
 
F igure 5.28.  Cel l  death in OPM2 after NK cel l  granulat ion assay.  Histograms 
show the fraction of tumour cells dead after 3 hours of incubation with NK cells, which 
were either pretreated with reovirus for 48 hours (red) or not (orange).  Histograms show 
medians and standard deviations; n=3. 
University of Leeds – School of Medicine Christopher Parrish 
- 174 - 
 
Oncolysis of HMCLs on stromal cell layers 
A body of evidence points to an ability of bone marrow stromal cells to confer protection 
to tumour cells against cytotoxic agents.  For this reason, it was important to determine 
whether the lytic effect of reovirus on HMCLs would be abrogated by the presence of 
bone marrow stromal cells.  Tumour cells were therefore cultured either alone, or on a 
basal layer of stromal cells; the human bone marrow stromal cell lines HS-5 and HS-27, 
the murine bone marrow stromal cell line M2-10B4 and a CD40L+ human fibroblast line 
L929 were used for these assays.  Cultures were then treated with reovirus, lenalidomide 
or dexamethasone for 48 hours as described previously.   
When U266 was treated in the absence of stromal cells (Figure 5.29), both 
dexamethasone and reovirus treatments induced a significant increase in cell death 
(p=0.04 and p=0.013 respectively), although lenalidomide did not.  However, when 
cultured with HS-27, HS-5 or M2-10B4, dexamethasone did not induce a significant 
increase in cell death above the untreated control; reovirus on the other hand induced 
significant cell death in HMCLs cultured on both HS-27 and HS-5 (p=0.009 and p=0.011 
respectively).  Both dexamethasone and reovirus induced significant killing of cells 
cultures on the L929 cell line (p=0.004 and p=0.002 respectively). 
Figure 5.30 shows the results of treatment of H929 with lenalidomide, dexamethasone 
and reovirus during culture on stromal cell layers.  In these experiments, neither 
dexamethasone nor lenalidomide resulted in a significant increase in cell killing even in the 
absence of stromal cells, so little can be inferred from their failure to induce killing of 
HMCLs on stromal cell layers.  Nonetheless, reovirus was able to induce significant killing 
of H929 under all conditions, irrespective of the presence of stromal cell layers. 
 
 
University of Leeds – School of Medicine Christopher Parrish 
- 175 - 
 
F igure 5.29.  Cel l  death in U266B after culture for 48 hours e ither a lone or 
on the stromal cel l  l ines HS-5, HS-27, M2-10B4 or L929, in the presence 
of reovirus, lenal idomide, or dexamethasone at the doses shown, or 
untreated.  Histograms indicate medians and standard deviations; n=3.  P values are for 
two-tailed paired student t tests. 
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F igure 5.30.  Cel l  death in H929 after culture for 48 hours e ither a lone or on 
the stromal cel l  l ines HS-5, HS-27, M2-10B4 or L929, in the presence of 
reovirus, lenal idomide, or dexamethasone at the doses shown, or 
untreated.  Histograms indicate medians and standard deviations; n=3.  P values are for 
two-tailed paired student t tests. 
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Development of an in vivo model 
The experiments described thus far provide compelling evidence that reovirus may 
represent a useful agent for therapy of myeloma, exhibiting multiple mechanisms of action 
and an ability to overcome stromal-mediated cytoprotection.  In order to allow further 
elucidation of the mechanism of action of reovirus in myeloma, and elaboration of clinical 
strategies – for example examination of dosing and combination chemotherapy strategies 
– an in vivo model was therefore required.  A number of models were considered 
(discussed in introduction) and the C57BL/KaLwRijHsd model with the 5TGM1 cell line 
selected. 
C57BL/KaLwRijHsd mice aged 6-10 weeks were injected with 2x105 5TGM1 tumour 
cells.  After 21 days, bone marrow was harvested and unselected bone marrow cells 
were stained using a Live/Dead intracellular amine stain and an antibody against CD138.  
The percentage of live CD138+ cells present was assessed by flow cytometry and 
compared to wild type mice; Figure 5.31 shows representative flow cytometry histograms 
and collated data.  Engraftment of myeloma plasma cells was seen with 46.6% vs. 1.0% 
CD138+ cells seen (p<0.0001).  Since splenic haematopoiesis is seen in mice, and some 
extramedullary myeloma is expected in this model, splenic cells were next assessed in the 
same way.  Splenic plasma cells were expanded in diseased mice compared to control 
mice: 33.9% vs. 2.1% (p=0.017, Figure 5.32). 
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F igure 5.31.  Fract ion of l ive BM cel ls expressing CD138 in wi ld-type and 
5TGM1-bearing C57BL/KaLwRijHsd mice. Representative histograms (panel A) 
and collated data (panel B) are shown.  Mean and standard deviation are shown in panel 
B, p value is for unpaired student t-test. 
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F igure 5.32.  Fract ion of l ive splenic cel ls expressing CD138 in wi ld-type 
and 5TGM1-bearing C57BL/KaLwRijHsd mice. Representative histograms (panel 
A) and collated data (panel B) are shown.  Mean and standard deviation are shown in 
panel B, p value is for unpaired student t-test. 
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The susceptibility of the 5TGM1 cell line to treatment with reovirus was next explored.  
C57BL/KaLwRijHsd mice aged 6-10 weeks were injected with 2x105 5TGM1 tumour 
cells.  After 21 days, bone marrow was harvested and unselected bone marrow treated 
ex vivo with reovirus, dexamethasone and/or lenalidomide and incubated for 48 hours at 
37°C and 5% CO2 in a humidified incubator.  Cells were then harvested, stained using a 
Live/Dead intracellular amine stain and an antibody against CD138, and the percentage of 
live cells expressing CD138+ was assessed by flow cytometry (Figure 5.33). 
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F igure 5.33.  CD138+ cel ls as a fract ion of l ive cel ls after ex-vivo  treatment 
of bone marrow samples from 5TGM1-bearing C57BL/KaLwRijHsd mice 
with lenal idomide, dexamethasone and reovirus in the combinat ions and at 
the doses indicated.  Flow cytometry histograms (panel A) and percentages of 
CD138+ cells as a fraction of live cells (panel B) are shown.  n=1. 
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Since this pilot experiment revealed marked purging of CD138+ cells from the BM by ex 
vivo reovirus therapy, protocols for in vivo therapy were next developed.  The remaining 
work presented here represents pilot data, which will form the basis of planned ongoing 
experimental work. 
C57BL/KaLwRijHsd mice aged 6-10 weeks were divided into 3 groups:  
• Group 1: naïve mice (n=5) 
• Group 2: 5TGM1 (n=6) 
• Group 3: 5TGM1 + reovirus (n=10) 
Mice in groups 2 and 3 were injected with 2x105 5TGM1 tumour cells in 100μl of PBS via 
tail vein injection (Day 0).  On days 12, 14 and 16, mice in group 3 were injected with 
2x107 plaque forming units (PFU) reovirus.  On day 28, one animal in each of groups 2 
and 3 developed hind limb paralysis, at which point all animals were sacrificed.   
Body and spleen weights were not significantly different between groups, although a 
trend towards higher splenic mass was seen in the tumour-bearing animals, which was 
reduced by reovirus treatment (Figure 5.34).  The mean fraction of bone marrow cells 
expressing the plasma cell marker CD138 was as follows: Group 1: 0.82% (SEM 0.10%), 
Group 2: 33.42% (SEM: 3.93%), Group 3: 21.89% (SEM: 2.33%), with a significant 
decrease seen in the reovirus treated cohort (group 3) compared to untreated (group 2): 
p=0.017; unpaired two-tailed student t test (Figure 5.35).  The mean fraction of 
splenocytes expressing the plasma cell marker CD138 was as follows: Group 1: 2.06% 
(SEM: 0.82%), Group 2: 31.98% (SEM: 8.82%), Group 3: 20.03% (SEM: 3.94%), the 
reduction associated with reovirus treatment did not reach significance here (p=0.173, 
unpaired two-tailed student t test, Figure 5.35). 
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F igure 5.34  Post-mortem body and splenic masses in naïve (n=5), 5TGM1-
bearing (n=6) and 5TGM1-bearing in-v ivo  reovirus-treated (n=10) 
C57BL/KaLwRijHsd mice.  Histograms represent means and standard deviations; p 
values are for un-paired two-tailed student t-tests. 
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F igure 5.35  Fract ion of bone marrow cel ls expressing CD138 in naïve 
(n=5), 5TGM1-bearing (n=6) and 5TGM1-bearing in-v ivo  reovirus-treated 
(n=10) C57BL/KaLwRijHsd mice.  A: representative flow cytometry histograms, B: 
collated data showing means and standard deviations; p values are for un-paired two-
tailed student t-tests. 
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The activation status of bone marrow- and splenic-resident CD4+, CD8+ and DX-5+ (NK 
cell) lymphocytes, as measured by surface CD69 expression, was next assessed (Figure 
5.34).  CD4+ cells were found to be activated in Group 2 vs Group 1 in both BM and 
spleen (p<0.0001 in both cases), CD8+ cells in BM (p<0.0001) but not spleen (p=NS) and 
NK cells in spleen (p=0.0021) but not BM (p=NS).  This suggests the induction of a host 
immune response by the presence of tumour cells.  The reovirus-treated group, group 3, 
exhibited significantly increased CD69 expression on BM NK cells compared to group: 
62.82% (SD 9.25%) vs. 46.19% (21.69%), indicating further activation of NK cells by 
reovirus treatment. 
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F igure 5.36.  Fract ion of bone marrow and splenic NK (DX5+, panel A) CD4+ 
(panel B), and CD8+ (panel C) cel ls expressing the act ivat ion marker CD69 
in naïve (n=5), 5TGM1-bearing (n=6) and 5TGM1-bearing in-v ivo  reovirus-
treated (n=10) C57BL/KaLwRijHsd mice.  Histograms represent means and 
standard deviations and p values are for un-paired two-tailed student t-tests. 
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As a refinement of this model, C57BL/KaLwRijHsd mice aged 6-10 weeks were injected 
with 2x105 eGFP-transduced 5TGM1 tumour cells in 100μl of PBS via tail vein injection.  
After 21 days, mice were sacrificed, shaved, depilated and imaged using an IVIS200 live 
imaging system with excitation at 465nm and emission collected at 520nm.  A 
representative image, overlayed on a standard monochrome visible light image is shown 
in figure 5.35.  Mouse A had a clinical evident plasmacytoma, which is clearly illuminated 
on the imaging.  Some illumination of the axial skeletons is visible, despite subsequent 
flow cytometric examination of BM from these mice revealing only MGUS-levels of BM 
infiltration (<5% CD138+ cells in all three cases).  Splenic uptake is seen in mouse C. 
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F igure 5.37.  Composite image of monochrome vis ib le l ight photograph and 
luminescent imaging (excitat ion: 465nm, emission f i l ter:  520nm) of three 
C57BL/KaLwRijHsd mice in jected with eGFP-transduced 5TGM1 tumour 
cel ls.  Images taken after 21 days. 
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Discussion	
The data presented here demonstrate multifaceted activity of reovirus type 3 Dearing 
strain against multiple myeloma.  Firstly the majority of HMCLs tested were found to 
express junctional adhesion molecule 1 (JAM1) a widely expressed cell surface protein 
that in addition to regulating endothelial and epithelial tight junctions and serving as an 
integrin ligand, also functions as a receptor for reovirus.  Interestingly, one cell line, OPM2, 
was found to express the receptor only at very low levels.  A panel of HMCLs was then 
shown to be susceptible to direct killing by the virus, with only the JAM1low cell line OPM2 
proving resistant.   
Preliminary experiments presented here are suggestive that death in the tumour cells is 
via apoptosis, since bcl2 is downregulated by reovirus, and the pan-caspase inhibitor 
zVAD-FMK abrogated reovirus-induced killing of JIM3.  This is in keeping with the bulk of 
published work 220,319,320, but it remains to be clarified whether this is the case for all 
HMCLs, and whether other mechanisms of cell death, such as autophagy, necroptosis or 
direct virally-programmed lysis, which have been reported to result from reovirus infection 
in certain cell types, might also be contributory.  Some data in the published literature are 
conflicting on this point221,320 , and further elaboration of the mechanisms is warranted, 
particularly since this may provide for rational combination therapies, for example with 
clinically available bcl family inhibitors321.  Furthermore, preliminary work examining bcl2 
levels after reovirus infection, by Western blotting (data not shown), have suggested that 
reovirus might actually reduce bcl2 levels even in the resistant HMCL OPM2, suggesting 
that the most obvious explanation for resistance – that the virus is unable to enter cells 
due to inadequate expression of JAM1 – may be overly simplistic and that examination for 
dysregulation of apoptotic or other pathways in this cell may be central to understanding 
the mechanism of resistance.  Further work will examine the modulation and role of other 
members of the bcl2 and other pathways (e.g. bcl-xl,LPARP) 
When HMCLs were incubated with lenalidomide, no effect was seen on expression of 
JAM1 across a wide range of lines.  Furthermore, when HMCLs were treated with 
combinations of reovirus, lenalidomide and dexamethasone, no significant interaction 
between their treatment effects was noted by 2-way ANOVA analysis, indicating no 
synergism or potentiation of the effects of one by the other.  For example, with KMS11, 
which is sensitive to lenalidomide, dexamethasone and reovirus, additive effects were 
seen, with maximal killing induced by the top dose of reovirus in combination with either 
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dexamethasone or both lenalidomide and dexamethasone.  JIM3, which is resistant to 
lenalidomide and dexamethasone, showed a dose-dependent sensitivity to reovirus which 
was unaffected by lenalidomide and dexamethasone dosing, whereas OPM2 exhibited 
sensitivity to both lenalidomide and to dexamethasone, maximum death when treated 
with the two in combination and no effect of reovirus on any combination.   
Of course, there are considerations in assessing the efficacy of lenalidomide and 
dexamethasone treatments using a simplistic in vitro assay such as this.  Firstly, this 
assay only assesses direct drug-induced effects on the tumour cells – other cellular 
interactions are deliberately excluded, and some of the later work presented in this 
chapter addresses this issue.  Scheduling effects are also ignored – for example it is 
currently unknown what effect either dexamethasone or lenalidomide may have on the 
replication cycle of reovirus, and it is conceivable that treatment at different points in the 
cycle may have different effects.  Dosing of lenalidomide and dexamethasone for in vitro 
assays is also difficult, since detailed data on the clinically relevant concentrations (i.e. in 
the bone marrow microenvironment of patients on tolerable treatment doses) are not 
available.  The cell lines used for these assays are also necessarily primarily derived from 
patients with end-stage disease, usually plasma cell leukaemia, often with atypical 
features such as ascites or pleural effusion – it is likely therefore that these HMCLs may 
misrepresent any potential for synergy in less heavily pre-treated tumour clones.  When 
whole bone marrow from a patient with MM was treated with reovirus, effective purging of 
CD138+ cells from the culture and induction of death in plasma cells was seen, 
particularly when reovirus was used in combination with lenalidomide and 
dexamethasone, and further study of such ‘whole marrow’ cultures may prove a useful 
avenue of further investigation. 
Reovirus was also shown to activate immune cells from both healthy donors and patients 
with myeloma, and it was further found that this effect was augmented by combination 
with lenalidomide.  On the basis of this activation, NK cell degranulation assays were 
undertaken which demonstrated increased degranulation of NK cells against tumour 
targets when stimulated by reovirus, and furthermore that this degranulation translated 
into increased NK-mediated killing of tumour targets; from previous work it is likely this NK 
activation is mediated through monocyte-derived IFNα207.  Interestingly, in the assays 
conducted here, addition of lenalidomide was not found to increase reovirus-induced NK 
degranulation against tumour targets, although again it will be worth assessing the effect 
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of combination therapy on NK cell degranulation in the context of less selected 
populations, for example, on whole marrow cultures. 
A considerable body of evidence now points to an ability of bone marrow stromal cells to 
confer protection to tumour cells against chemotherapeutic strategies through myriad 
mechanisms, for example upregulation of cell cycle regulating and anti-apoptotic 
proteins322, tumour cell entrapment within the marrow323,324, and secretion of MM-
supporting cytokines325-327.  It was therefore of considerable interest to assess the impact 
of stromal cells on the susceptibility of HMCLs to reovirus-induced lysis.  Reovirus was 
able to induce significant killing of two tumour lines under almost all culture conditions, 
irrespective of the presence of ‘protective’ stromal cell layers.  Further studies in this area 
might include cellular adhesion assays328,329, and assessment of viral replication in and 
modulation of stromal cells. 
In concert with these in-vitro and ex-vivo data, the C57BL/KaLwRijHsd murine model 
seeded with the 5TGM1 cell line offers platform for elaborating a number of aspects of 
this work.  As an immunocompetent model, it will allow dissection of the contribution of 
immune cells to both the anti-tumour action of reovirus and of course clearance of the 
organism by the host, and in particular will allow dissection of these interactions in the 
context of a fully-populated immune-competent myeloma-bearing bone marrow 
microenvironment.  The preliminary data presented here indicate upregulation of CD69 on 
immune cells induced by the presence of tumour cells and therefore suggest this model 
may also be useful to examine the interactions between tumour and host immunity during 
the evolution of myeloma from MGUS – perhaps allowing elucidation of mechanisms that 
determine whether elimination, equilibrium or escape occurs.  A number of preliminary 
experiments have been conducted, and are presented.  Firstly an ex-vivo purging 
experiment confirms that the virus is able to induce death in the murine myeloma cells 
and provides further evidence of the ability of the virus to purge BM of malignant plasma 
cells.  The in-vivo therapy experiment reveals the same ability in the intact bone marrow 
microenvironment and well as providing further evidence of the immune activatory 
properties of reovirus, which require further investigation.  Finally, a eGFP-transduced 
modification of this model was assessed, and this will provide a platform for in vivo live 
imaging to assess tumour responses to experimental therapies.  
A number of lines of evidence now indicate that for a number of oncolytic viruses (OV) 
being investigated as therapy of a range of solid and haematological malignancies, the 
primary ‘lytic’ phase of oncolytic action may in fact be far less important than a 
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subsequent secondary phase of immune-mediated oncolysis.  There may be multiple 
mechanisms by which this occurs, involving both innate and adaptive immunity.  For 
example, we have recently shown in CLL that reovirus is able to enhance antibody-
dependent cytotoxicity against tumour cells, when used in conjunction with anti-CD20 
antibodies207.  The experiments presented in this thesis show NK cell function against MM 
can also be augmented by the virus. 
However, true adaptive immune responses are probably still more important - in fact, in in 
vivo use, the primary viral infection and oncolysis may serve primarily to induce a highly 
immunogenic death in a proportion of cancer cells that serves to prime a far more potent 
adaptive immune response against cancer-associated antigens.  A number of preclinical 
models have demonstrated that the efficacy of OV is dependent on generation of 
systemic antitumour immunity203,204,330,331, and there is additionally evidence of secondary 
immune responses from human trials, for example a phase II trial demonstrated 
regression of metastases following intratumoural injection of a primary melanoma lesion 
with herpes simplex virus (HSV) expressing granulocyte-macrophage colony stimulating 
factor (GM-CSF)332.  A recent manuscript has reported durable remissions in two patients 
after therapy of relapsing refractory MM with the engineered measles virus MV-NIS333 – 
both of these responding patients developed a severe cytokine storm-like syndrome after 
infusion, in contrast to a large body of non-responding patients, who experienced no 
benefit from the virus, probably due to the presence of neutralizing antibodies; it seems 
likely that here too a secondary immune effect may have mediated the impressive 
responses in these patients.  Understanding in more detail these ‘priming’ effects and 
adaptive immune responses in the context of reovirus therapy of myeloma are likely to be 
extremely important in devising rational therapeutic strategies including the agent. 
Reovirus has recently been examined as a single agent in a phase I trial in patients with 
relapsed multiple myeloma 236, which demonstrated safety in this population.  Building on 
the data presented within this chapter, an early phase clinical trial to examine the agent in 
combination with lenalidomide is now in the setup stage.  In conjunction with this trial, 
promising avenues of investigation to inform future trials will now be undertaken using 
murine modeling, including examination of combination therapies with monoclonal 
antibodies and checkpoint blockade, as well as ‘sub-optimal’ initial therapy to examine 
the use of reovirus alone or in combination in the relapse setting after treatment with other 
agents.  
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Chapter 6 – Conclusions and Future Directions 
In Chapter 3, a robust protocol for identification and phenotypic assessment of Th17, Th17-
1 and Th1 cells in healthy donors and in patients with MM has been presented.  A weak 
but significant correlation between Th17 frequency and age in health was demonstrated.  
This clearly has importance in the context of MM, a disease of the elderly – it casts light 
on interpretation of the validity of previously published work, which often did not employ 
age-matched controls.  However, there are also wider implications in terms of immune 
senescence, particularly in a dawning age of immunotherapy, where selection of 
treatment modalities may increasingly depend upon characterisation of patients’ 
underlying immune function.  On the basis of published data on Th17 phenotypes, the 
expression of a range of cell surface markers was assessed.  Disappointingly, CD161 and 
CCR6 were found not to be robust methods for identification of the subset, even in 
health, although they did allow relative enrichment of IL-17-producing populations. 
Examination of patient peripheral blood samples revealed an increase in Th17 cells in MM 
compared to age-matched healthy donors, and this was found to occur in a disease 
stage-related manner.  This defect was associated with a decrease in the level of IL-17 
secretion by those Th17 cells still present under both supraphysiological and physiological 
stimulation, and a trend towards decreased serum levels of Th17 signature cytokines.  
When bone marrow samples were assessed, Th17 cells were seen to be relatively 
expanded in MM-bearing marrow compared to health, albeit with an unaffected Th17:Th1 
ratio.  The latter data were subsequently corroborated by coculture experiments and 
indicate MM plasma cells and the associated BM microenvironment are able to induce 
Th17 differentiation or survival.  Th17 cells in MM were also demonstrated to have an 
aberrant cell surface phenotype, with relative loss of CD161and CCR6 expression relative 
to health. 
In Chapter 4, in vitro coculture of CD4+ T cells with HMCLs revealed tumour-driven 
expansion of Th17 cells, predominantly from CD45RO+ activated and memory T cells, and 
suppression of the Th1 population.  Interestingly, and somewhat unexpectedly, selection 
of starting populations for CD161 and CCR6 expression had no significant effect on final 
numbers of Th17 cells derived from coculture whereas incorporation of bone marrow 
stromal cells in the culture system resulted in marked augmentation of Th17 polarisation.  
A T cell polarisation protocol was devised, and when CD4+ cells from healthy donors and 
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patients with MM were treated with this protocol an increased propensity to Th17 
differentiation was seen in the patient samples. 
These data add to the currently published knowledge by documenting an additional 
aspect to the profound immune dysfunction seen in MM, and in turn lead to a number of 
further questions which may warrant further study.  The quantitative and qualititative 
defects seen in Th17 immunity have a number of important implications.  Firstly, the normal 
role of Th17 cells lies predominantly in delivering anti-infective immune responses, in 
particular against fungal pathogens, and the phenotypic abberancy and functional 
compromise shown herein may contribute to the increased predisposition to infections 
seen in patients with MM.  Further assessment of this defect could follow a number of 
directions.  Initially, the secretion of peripheral blood Th17 signature cytokines in health and 
disease might first be corroborated by another method, for example qRT-PCR – this is 
likely to be important since my data are contradictory to published work, as discussed in 
detail earlier.  The functional consequences might also be examined, for example by 
assaying the capacity of cell culture supernatants to induce neutrophil activation, 
migration and recruitment or upregulation of endothelial defensins, or indeed their impact 
on the NK cell degranulation assays reported in Chapter 5. 
Secondly, the relative expansion of PB Th17 cells seen in MGUS and AMM, but lost by the 
time of progression to symptomatic MM or at time of relapse warrants further 
examination.  Clearly the interaction between CD4+ cells and the tumour clone is more 
complex than a simple positive feed-forward loop.  It is of interest, for example, that 
certain HMCLs are unable to drive Th17 generation.  It is tempting to speculate, in light of 
a wealth of published work suggesting MGUS may represent a state of immune 
equilibrium during which the tumour clone is controlled by immune responses, that Th17 
cells in this situation might even mediate anti-tumour responses; certainly there is 
evidence from the published literature that Th17-1 cells have efficacy in the context of 
adoptive cellular therapy.  Mapping of the TCR repertoire of Th17 cells in each of these 
states might therefore be illuminating, and indeed serial examination of the repertoire 
within patients could be considered.  An interesting aside here is that a very large 
proportion of Th17 cells were seen to respond to Candidal antigens, suggestive either of a 
highly restricted TCR repertoire within the subset, or perhaps more likely an ability to 
respond via a PAMP receptor of some sort.  In view of the relative expansion of Th17 cells 
seen in MM BM (in contrast to the peripheral blood findings), immunohistochemistry to 
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examine the localisation of Th17 cells in the BM may also be a useful method to begin to 
infer which additional cellular players may be contributing to lineage determination. 
Balanced against such postulated anti-tumour immunity are published data indicating IL-
17, and indeed other Th17 signature cytokines, may act as growth factors for MM cells 74.  
Importantly, I have been unable to corroborate these experiments and this should be 
further examined using additional methods to assess the effect of IL-17 on HMCLs e.g. 
thymidine incorporation, Ki67 staining, serum starvation of cell lines, and use of primary 
MM plasma cells.  
Thirdly, the loss of CD161 and CCR6 on Th17 cells in MM is intriguing, and this body of 
work might be developed in a number of directions.  The role of CD161 remains poorly 
characterised, so one group of experiments could aim to examine the contribution of 
CD161 to the immune synapse, for example testing the effect of CD161 ligation on IL-17 
production after physiological stimulation (e.g. with fungal antigens), or as a costimulatory 
molecule with TCR stimulation.  The issue of whether CD161 is downregulated by Th17 
activation also remains to be clarified.  Building upon the functional assays already 
proposed, the capacity of CD161+ and CD161- Th17 cells, in health and disease, to exert 
normal physiological effects on immunity could also be tested.  It would also be 
interesting to examine the responses of these two groups of cells to immune synapse 
formation with MM cells, in particular whether one group is more supportive than the 
other of the tumour clone.  CCR6 was also found to be lost on Th17 cells in MM, and the 
implications for this in terms of Th17 cell migration might also be assessed.   
Fourthly, the coculture and polarisation data suggest several avenues of work exploring 
both deranged Th17 immunity in MM and the role of costimualtory pathways in T helper 
cell lineage determination.  An increased propensity to Th17 differentiation in MM was seen 
and the underlying reasons for this are not known.  Plausibly this might result from 
circulating cytokines that prime CD4+ cells for Th17 differentiation, which could be 
examined for example through modification of the coculture system to include additional 
cytokine supplementation or neutralising antibodies.  In light of the clear contribution of 
bone marrow stromal cells to the T cell modulating immune interactions, the role of 
additional cell types should now be assessed in coculture – for example osteoclasts and 
osteoblasts, cell types known to play a key role in the development of bone disease so 
characteristic of MM.  It is known from work previously undertaken in our laboratory that 
Treg cells are expanded in patients with MM and are expanded by interactions between 
HMCLs and CD4+ T cells, and a large body of literature addresses the plasticity between 
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Th17 and Treg cells.  In light of this, investigation of the Th17:Treg balance in the coculture 
model, potentially including the effect of therapy within the model (e.g. immunomodulatory 
agents, proteasome inhibitors etc.), might help to illuminate whether Th17 cells are 
predominantly pro or anti-tumour immune effectors. 
The polarisation data also suggest some questions of more fundamental immunological 
interest.  The publications to date examining polarisation cocktails designed for driving 
Th17 differentiation have yielded a range of different recommendations, and often 
conflicting results.  My data highlight the importance of considering the starting population 
– conditions giving rise to the largest total number of Th17 cells were often distinct from 
those yielding the purest population and this may be partly due to expansion of 
contaminating populations, such as Th1 cells, which subsequently negatively regulate Th17 
development.  Such contaminating cells might for example explain the widely disparate 
effect of IL-2 reported in the literature.  In addition, when signal 2 combinations were 
assessed, CD5 and ICOS were found to induce Th17 differentation more potently than the 
more traditionally employed CD28.  Previous work has shown ICOS/ICOS-L interactions 
to be important in driving Treg generation309, and further work to examine the contribution 
of signal two in determining lineage determination may be warranted.  It is likely from the 
data presented here that there are complex interactions between TCR stimulation, signal 
two and the cytokine microenvironment so that, for example, a particular signal 2 may 
have different effects on T cell fate depending on the cytokine costimulation. 
Chapter 5 focused on the potential for the use of the oncolytic virus reovirus for treatment 
of multiple myeloma.  HMCLs were seen to express JAM1, and to be susceptible to 
reovirus-mediated lysis in vitro, probably via an apoptotic mechanism; additive effects 
were seen when lenalidomide was added.  Reovirus was also noted to induce marked 
immune activation of peripheral blood immune effectors from both healthy donors and 
patients with MM, an effect that was again augmented by the inclusion of lenalidomide.  
Reovirus was able to upregulate NK cell-mediated killing of tumour cells.  Finally, a murine 
model was developed to allow further examination of reovirus as an in vivo therapy, and 
preliminary data were presented confirming effective ex vivo purging of MM-bearing 
muring marrow, in vivo immune activation and effective clearance of MM cells from BM 
and spleen by in vivo reovirus therapy. 
These data on reovirus are extremely exciting and indicate a potential novel 
immunotherapy for MM.  On the basis of this work a phase I/IIa clinical trial has been 
devised to examine reovirus in combination with lenalidomide or pomalidomide in patients 
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developing serological relapse on IMiD therapy.  Further preclinical work, and planned 
companion translational studies for the trial, will now be undertaken to characterise the 
immune effect of reovirus-based combination therapy, and to develop rational treatment 
combinations to augment reovirus treatment.  The mechanisms of cell death induced by 
reovirus should be investigated in more detail, incorporating assays and blocking of 
apoptosis, necroptosis and autophagy pathways – this would then allow subsequent 
evaluation of combination therapy strategies with inhibitors of these pathways to optimise 
direct reovirus-induced cell lysis.  The mechanisms by which reovirus is able to augment 
NK cell-mediated tumour cell lysis also warrant further examination.  Previous work 
indicates this may be via monocyte-derived IFNα 207, and furthermore that monocytes are 
capable of reovirus carriage 334; combination of reovirus with cellular therapies or cytokine 
conditioning may therefore have the potential to augment tumour killing.  Preliminary 
experiments, not presented herein, also suggested soluble factors from reovirus-treated 
PBMC can kill HMCL, meaning a large body of work to characterise in more detail the 
effect of reovirus on PBMC may yield strategies for augmenting immune-mediated tumour 
killing.  The continued efficacy of reovirus even in the context of stromal-mediated 
protection is also of interest.  This work could be developed in a number of directions, for 
example the replication in, and modulation of, stromal cells by reovirus remains to be 
characterised.  Cellular adhesion assays may also be of interest as one possible 
explanation is that reovirus is able to disrupt the interactions between HMCL and their 
stromal support.  Of course, the murine model now offers a platform for in vivo testing of 
any promising potential combination strategies. 
The work presented in thesis documents a new aspect of immune dysfunction in MM, 
with implications for anti-infective and anti-tumour immunity.  Furthermore a novel 
immunotherapeutic strategy against multiple myeloma has been described and this is 
currently in translation to an early phase clinical trial.  Subsequent pre-clinical and 
translational work will now allow rational development of further combination 
immunotherapy strategies. 
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Glossary 
AC    Apheresis cone; used as a source of peripheral blood 
mononuclear cells from normal donors 
AHR    Aryl hydrocarbon receptor 
AlloSCT   Allogeneic stem cell transplant 
APC    Antigen presenting cell 
β2M    Beta-2-microglobulin 
BM    Bone marrow 
BMSC   Bone marrow stromal cell(s) 
BMME   Bone marrow microenvironment 
CM    Complete medium 
CTL    Cytotoxic T lymphocyte 
DC    Dendritic cell 
DMSO   Dimethyl sulphoxide 
EDTA    Ethylenediaminetetraacetic acid 
FACS   Fluorescence-assisted cell sorting; used within the text to indicate 
both cell analysis and physical cell sorting using the technique 
FBS    Fetal bovine serum 
FoxP3   Foxhead box P3; the signature transcription factor for regulatory T 
cells (Treg) 
HBSS   Hank’s buffered salt solution 
HMCL   Human myeloma cell line 
ICOS    Inducible T cell co-stimulator; CD278 
IFNγ    Interferon gamma 
IMiD    Immunomodulatory drug 
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ION    Ionomycin 
IRF4    Interferon-regulatory factor 4 
MACS   Magnetic-assisted cell sorting 
MACS buffer  Solution used for MACS (see reagents and solutions) 
MFI    Mean fluorescence intensity; a flow cytometric parameter 
considered a surrogate for level of antigen expression 
MGUS   Monoclonal gammopathy of uncertain significance (see Appendix 
1) 
MHC    Major histocompatibility complex 
MitC    Mitomycin C; used to impair HMCL proliferation in coculture 
MM    Multiple myeloma 
MNC    Mononuclear cells 
MP65   Candida albicans mannoprotein 65, used within the text to 
indicate the Peptivator® lyophilised pooled peptide product 
derived from MP65 (Miltenyi Biotec). 
NK    Natural killer cell 
NKT    Natural killer T cell 
PB    Peripheral blood 
PBMC   Peripheral blood mononuclear cells 
PBS    Phosphate-buffered saline 
PC    Plasma cell 
PMA    Phorbol 12-myristate 13-acetate 
PP    Paraprotein; M-protein; myeloma clonal immunogloublin 
RARα   Retinoic acid receptor alpha 
RORC   The human homologue of RORγt 
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RORγt   Thymic isoform of RAR (retinoic acid receptor)-related orphan 
receptor gamma – RORC is the human homologue; the signature 
transcription factor of Th17 cells 
STAT    Signal transducer and activator of transcription 
T-bet    T-box expressed in T cells; the signature transcription factor of 
Th1 cells. 
TCR    T cell receptor 
TGFβ    Transforming growth factor beta 
TLR    Toll-like receptor 
Treg    Regulatory T cell 
VEGF    Vascular endothelial growth factor 
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Appendices 
Appendix	1	–	Plasma	cell	disease	classification	
(adapted from 2) 
Diagnostic criteria for MGUS, Asymptomatic and symptomatic MM 
 MGUS Asymptomatic 
myeloma 
Symptomatic 
myeloma 
Monoclonal 
protein in serum 
<30g/l ≥30g/l 
 
 
AND/OR 
 
 
≥10% 
Present in serum 
and/or urine at any 
concentration† 
Bone marrow 
clonal plasma 
cells 
<10% and low 
level of plasma 
cell infiltration in 
a trephine biopsy 
if done 
Present, or biopsy-
proven 
plasmacytoma 
Related organ 
or tissue 
impairment* 
None (including 
bone lesions) 
None (including bone 
lesions); no 
symptoms 
Present 
Table A1.1 Diagnostic criter ia for MGUS, asymptomatic and 
symptomatic myeloma. 
† A small percentage of patients have no detectable M-protein in serum or urine 
but do have myeloma-related organ impairment and increased bone marrow 
plasma cells (non-secretory myeloma) 
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Myeloma-related organ or tissue impairment 
Clinical effect Definit ion 
Hypercalcaemia Corrected serum calcium >0.25 mmol/l above the upper limit 
of normal or >2.75 mmol/l 
Renal 
insufficiency 
Creatinine >173μmol/l 
Anaemia Haemoglobin ≥2g/sl below the lower limit of normal, or 
<10g/dl 
Bone lesions Lytic lesions or osteoporosis with compression fractures 
(magnetic resonance imaging (MRI) or computed tomography 
(CT) may clarify) 
Other Symptomatic hyperviscosity 
Amyloidosis 
Recurrent bacterial infection (>2 episodes in 12 months) 
 
Table A1.2 Myeloma-related organ or t issue impairment 
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Appendix	2	–	Donor	Information	and	Consent	Forms	
Patient Information Sheet (Patient) 
THE	HOST-IMMUNE	CONFLICT	IN	MULTIPLE	MYELOMA	
	
You	have	been	invited	to	take	part	in	a	research	study,	but	before	you	decide	to	take	part,	it	is	
important	 for	 you	 to	 understand	 why	 the	 research	 is	 being	 done	 and	 what	 it	 will	 involve.		
Please	take	time	to	read	the	following	information	carefully.		Ask	the	doctor	informing	you	of	
the	study,	 if	 there	 is	anything	that	 is	not	clear	 to	you	or	 if	you	would	 like	more	 information.		
Take	time	to	decide	whether	or	not	you	wish	to	take	part.	
	
Thank	you	for	reading	this.	
	
What	is	the	purpose	of	this	study?	
The	 immune	system	 is	 the	body’s	defence	not	only	against	 infection	but	also	abnormal	 cells	
and	 tissues.	 We	 are	 investigating	 the	 role	 of	 immune	 cells	 in	 a	 condition	 called	 multiple	
myeloma.	 Through	 these	 studies	 we	 wish	 to	 understand	 how	 to	 manipulate	 the	 diseased	
(tumour)	cells	to	increase	their	susceptibility	and	potential	killing	by	the	patient’s	own	immune	
system.	Immune	cells,	found	both	in	the	blood	and	bone	marrow,	are	important	in	helping	to	
control	myeloma.	 This	 study	 aims	 to	 determine	whether	 there	 are	 enough	 of	 these	 cells	 or	
whether	there	is	a	problem	with	how	these	cells	work	and	thus	do	not	fight	the	myeloma.	It	is	
by	studying	this,	that	we	aim	to	develop	a	way	in	which	we	can	help	the	patient’s	own	immune	
system	to	fight	the	myeloma	cells.	
	
This	study	aims	to	detail	the	different	type	of	immune	cells	found	in	both	the	blood	and	bone	
marrow,	 in	particular	whether	there	 is	any	evidence	of	cells	 that	could	potentially	attack	the	
myeloma	 cells.	 The	 ultimate	 aim	 of	 this	 research	 is	 to	 gain	 a	 better	 understanding	 of	what	
effect	myeloma	has	on	the	immune	system	so	that	we	can	design	treatment	plans	which	may	
help	to	boost	the	patient’s	immunity	whilst	setting	groundwork	for	a	new	therapeutic	system	
for	multiple	myeloma.	The	study	you	are	being	invited	to	participate	in	is	to	investigate	if	any	
defects	exist	 in	 the	 immune	system.	 It	does	not	 involve	any	 specific	experimental	 treatment	
and	will	not	affect	any	treatment	being	planned	by	you	doctor.	
	
Do	I	have	to	take	part?	
It	is	up	to	you	to	decide	whether	or	not	to	take	part.		If	you	do	decide	to	take	part,	you	will	be	
given	this	information	sheet	to	keep	and	will	be	asked	to	sign	a	consent	form,	to	indicate	that	
you	are	willing	to	take	part	 in	this	study.	 	You	will	also	be	given	a	copy	of	that	consent	form.		
You	can	always	withdraw	from	the	study	at	any	time	without	giving	a	reason.	A	decision	not	to	
take	part	or	to	withdraw	from	the	study	will	not	affect	the	standard	of	care	you	receive.	
	
What	will	happen	to	me	if	I	take	part?	
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If	 you	 agree	 to	 take	 part	 in	 this	 study,	 once	 you	 have	 read	 and	 understood	 this	 patient	
information	sheet,	you	will	be	asked	to	sign	your	written	consent	form.		This	is	a	paper	record	
that	will	show	the	authorities	that	you	voluntarily	agreed	to	take	part	in	this	study.		
	
If	you	agree	to	participate	 in	this	study,	a	small	amount	 (5	ml)	of	extra	bone	marrow	will	be	
taken	at	the	same	time	as	your	scheduled	bone	marrow.	We	would	also	take	one	extra	sample	
(30-40	mls)	of	blood	on	the	same	day	as	your	bone	marrow,	which	may	take	an	additional	30	
minutes	of	your	time	at	this	visit.	If	you	are	scheduled	for	a	procedure	called	vertebroplasty,	a	
small	amount	of	the	bone	marrow	tissue	extracted	will	be	taken	aside	for	this	study.		
	
All	samples	will	be	taken	to	the	Research	Laboratory	where	the	different	cell	types	of	interest	
to	 the	 study	will	be	analysed.	 Information	collected	will	be	 stored	on	a	database,	which	will	
only	record	your	age,	sex	and	disease	type.		The	data	will	be	anonymous	(i.e.	will	not	have	your	
name	connected	with	this	data)	and	will	only	be	available	to	the	principal	 investigator	of	this	
study	 (Prof	 G	 Cook)	 and	 his	 researchers.	 	 No	 external	 organisation,	 charity	 or	 commercial	
organisation	will	be	permitted	access	to	this	data.		Samples	taken	will	be	stored	in	a	freezer	so	
that	 follow-on	experiments	can	be	performed	to	verify	the	research	results,	 if	 required,	over	
the	period	of	the	study.	With	your	permission,	any	surplus	samples	may	be	used	in	any	other	
future	myeloma	research.		You	will	not	be	identified	in	any	future	research.		
	
	
Why	have	I	been	chosen?	
You	have	been	chosen	to	take	part	in	this	study	because	you	have	been	diagnosed	of	myeloma	
or	a	related	condition	called	MGUS.		
	
What	are	the	possible	benefits	of	taking	part?	
There	is	no	immediate	benefit	to	you	if	you	decide	to	take	part.		However,	the	information	we	
get	 from	 this	 research	 may	 lead	 to	 development	 of	 treatment	 strategies	 for	 patients	 with	
multiple	myeloma	in	the	future.	
	
What	are	the	possible	risks	of	taking	part?	
There	is	a	small	risk	of	bruising	and	discomfort,	and	a	very	small	risk	of	infection	at	the	site	of	
the	blood	sample.	If	you	are	listed	for	a	bone	marrow	or	vertebroplasty,	there	is	no	additional	
risk	to	what	has	already	been	explained	to	you	for	the	procedure.	Taking	an	additional	sample	
does	not	significantly	prolong	the	time	of	the	procedure.	
	
Will	my	taking	part	in	the	study	be	kept	confidential?	
If	you	consent	 to	 take	part	 in	 this	 study	 then	your	medical	 records	will	only	be	 inspected	by	
your	doctors.		Laboratory	generated	information	will	be	kept	on	a	data	base	in	an	anonymised	
fashion	(i.e.	your	name	will	not	be	associated	with	any	laboratory	information)	which	will	only	
be	 available	 for	 scrutiny	 by	 the	 principal	 investigator	 or	 his	 researchers.	 Sections	 of	 your	
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medical	 notes	 may	 be	 looked	 at	 by	 responsible	 individuals	 from	 regulatory	 authorities.	 No	
external	body,	charity	or	commercial	organisation	will	have	access	to	this	data.		Your	name	will	
not	be	disclosed	outside	of	the	hospital/clinic.	
	
What	will	happen	to	the	results	of	the	research	study?	
Once	the	study	has	finished,	the	 information	will	be	analysed	and	a	report	will	be	written	to	
record	your	results.		It	is	hoped	that	the	results	from	this	study	will	be	suitable	for	publication	
in	a	scientific	journal	or	presented	at	scientific	meetings.		Your	doctor	will	keep	you	informed	
of	the	results	from	the	study.	
	
Who	is	organising	and	funding	the	research?	
This	study	is	being	conducted	under	the	guidance	of	the	principal	investigator,	Professor	Cook,	
by	 the	Transplant	 Immunology	Group	based	at	 the	University	of	Leeds.	 	This	 study	has	been	
funded	by	the	Leeds	Teaching	Hospitals	Charitable	Trust	Foundation	and	the	Yorkshire	Cancer	
Network.			
	
Will	I	receive	any	expenses	for	taking	part	in	the	study?	
	No.	
	
Who	has	reviewed	this	study?	
This	study	has	been	reviewed	by	NRES	Committee	Yorkshire	&	the	Humber	-	Leeds	
East.	
	
Contact	for	further	information: 
If	 you	 have	 any	 questions	 regarding	 how	 this	 study	 will	 be	 conducted	 you	 may	 contact:	
Professor	Gordon	Cook	(telephone	0113	2068433).	
	
Thank	you	for	reading	this	information	sheet	and	for	considering	taking	part	in	this	study.	
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Donor Consent Form 
 
 
 	
Version 2 01 September 2012 
 
 
Volunteer Consent Form                               
 
THE HOST-IMMUNE-CONFLICT IN MULTIPLE MYELOMA. 
 
Principle Investigator:  Prof G Cook 
 
 
PLEASE INITIAL BOX 
1. I confirm that I have read and understand the information sheet 
dated………. (version……..) for the above study and have had the 
opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving reason, without my medical 
care or legal rights being affected. 
3. I understand that sections of any of my medical notes may be 
looked at by responsible individuals from regulatory authorities 
where it is relevant to my taking part in research. I give permission 
for these individuals to have access to my records. 
4. I understand that relevant sections of my medical notes (if 
applicable and data collected during the study may be looked at by 
individuals from regulatory authorities and/or Leeds Teaching 
Hospitals NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to 
my records”  
5. I give permission for my samples of blood and bone marrow to be 
stored and use in future scientific research linked to this study.  
6. I understand that my samples will be anonymised and that strict 
confidentiality will be maintained. 
7. I agree to take part in the above study 
 
 
 
                                                                                                                                           
Name of Volunteer   Date   Signature 
 
 
 
Name of Person taking consent Date   Signature 
 
 
 
Researcher    Date   Signature 
 
 
 
1 copy for the donor, 1 for the researcher and 1 to be kept in the hospital notes  
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Appendix	3	–	Human	myeloma	cell	line	characteristics	
Name Source Cell 
surface 
markers 
Cytogenetics Molecular abnormalities Notes 
H929 62 year old 
caucasian with 
IgAκ-producing 
plasmacytoma, 
CD38+  
HLA-DR- 
 
hypodiploid  
43-46, X  
t(4;14) 
 
c-myc rearranged 
myc RNA expressed,  
NRAS G13D het 
Secretes 
large 
amounts of 
IgA 
JIM1 Myeloma plasma 
cells derived from 
pleural fluid of 
patient with 
advanced MM 
CD38+ 
 
t(4;14) TP53 R273C hom Homoplastic 
with JIM3 
JIM3 Myeloma plasma 
cells derived from 
pleural fluid of 
patient with 
advanced MM 
CD38+ 
 
t(4;14) FGFR3 not expressed 
KRAS G12D het 
TP53 R273C homo 
Homoplastic 
with JIM1 
JJN3 Plasma cell 
leukaemia in 57-
year old women, 
IgAκ-producing. 
CD138+ 
HLA-DR+ 
hypotriploid  
58-67, XX 
t(14;16) 
TP53 homo del 2 copies of 
t(14;16) 
associated 
with c-maf 
activation 
KMS11 Pleural effusion in 
female with 
myeloma 
CD138+ t(4;14), t(14;16) FGFR3 het 
TP53 homo del 
TRAF3 homo del. 
κ light 
chain-
secretor 
KMS18 58 year-old male CD138+ t(4;14) BIRC2/3 homo del 
FGFR3 G382D het 
 
Patient had 
hyperammoni
aemia and 
produces 
ammonia in 
culture 
OPM2 Plasma cell 
leukaemia of 56-
year old woman, 
IgGλ 
CD138+ 
HLA-DR- 
hypertriploid  
77-82, XX 
t(4;14) 
 
CDKN2C homo del 
FGFR3 K650E het 
TP53 R175H homo 
Cryptic 
t(4;14) 
associated 
with IgH-
FGFR3 fusion 
RPMI82
26 
IgGλ plasma cell 
leukaemia in 61-
year old man 
CD38+ 
CD138+ 
HLA-DR+ 
hypotriploid  
62-67, XXY 
t(14;16) 
CDKN2C homo del 
KRAS G12A het 
TP53 E285K homo 
TRAF3 homo del 
Secretes λ 
light chains 
only 
U266B Plasma cell 
leukaemia in 
patient with IgEλ 
MM 
CD38+ 
CD138+ 
t(11;14) BRAF K601N het 
TP53 A161T homo 
TRAF3 K550lfsX3 homo 
RB1 E419X homo 
RB1 K228R homo 
Secretes IL-6 
and IgE 
 
Table A3.1 Human myeloma cel l  l ine characterist ics. 
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Appendix	4	–	Western	Blotting	Solutions	
Basic solut ions: 
Acrylamide: 30g acrylamide, 0.8g bis acrylamide, 100ml H20. 
1M Tris-HCl pH 8.8: 60.6g Tris, pH adjusted to 8.8 with HCl, 500ml H20 
0.25M Tris-HCl pH 6.8: 15.5g Tris, pH adjusted to 6.8 with HCl, 500ml H20 
5% SDS: 5g SDS (sodium dodecyl sulphate), 100ml H20 
10% APS: 0.5g APS (ammonium persulphate), 5ml H20 
PBS/TWEEN: 500ml phosphate-buffered NaCl, 0.1% TWEEN 20 
ECL (electrochemiluminescence) solution 1: 400μl luminol, 176μl P-coumaric acid, 4ml 
Tris pH 8.8, 40ml distilled H20 
ECL solution 2: 24μl H2O2, 4ml Tris pH 8.8, 40ml distilled H20. 
 
 
Loading buffer (2x),  for 50ml: 
0.25M Tris-HCl pH6.8 25ml 
SDS 2g 
Bromophenol Blue 1mg 
Glycerol 20ml 
Distilled H20 5ml 
 
Gel Running Buffer (10x), for 1 l i t re: 
0.025M Tris 30.3g 
0.192M Glycine 144g 
0.1% SDS 10g 
Distilled H20 1000ml 
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Blot Transfer Buffer (10x),  for 1 l i t re: 
25mM Tris 30.3g 
0.192M Glycine 142.6g 
20% Methanol 200ml 
Distilled H20 800ml 
 
10% Resolv ing gel,  for 50ml (2 gels):  
Acrylamide 16.7ml 
Tris-HCl pH8.8 18.75ml 
Distilled H20 13.3ml 
5% SDS 1ml 
10% APS 200μl 
TEMED (Tetramethylethylenediamine) 50μl 
 
Stacking gel,  for 20ml (2 gels):  
Acrylamide 3ml 
Tris pH6.8 10ml 
Distilled H20 6ml 
5% SDS 0.4ml 
10% APS 100μl 
TEMED 20μl 
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Appendix	5	–	Th17	frequency	and	disease-specific	
variables	
 
F igure A3.1.  Fract ion of CD4+ T cel ls producing IL-17 according to pat ient 
paraprotein subtype.  LC: light chain disease, NS: non-secretory disease. 
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F igure A3.2.  Fract ion of CD4+ T cel ls producing IL-17 according to pat ient 
paraprotein l ight chain subtype.  
 
F igure A3.3.  Fract ion of CD4+ T cel ls producing IL-17 according to pat ient 
paraprotein heavy chain subtype.  LC: light chain disease only (no intact 
paraprotein).  
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Figure A3.4.  Fract ion of CD4+ T cel ls producing IL-17 according to: A: pr ior 
l ines of therapy, B: pr ior autologous stem cel l  t ransplantat ion, C: pr ior 
treatment with lenal idomide, D: pr ior treatment with thal idomide, E: pr ior 
treatment with bortezomib, F: pat ient paraprotein level,  G: fract ion of bone 
marrow plasma cel ls with a mal ignant phenotype, H: serum creat in ine.  Lines 
on scatter plots show linear regression best fits, with 95% confidence intervals.  P=NS for 
histograms. 
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F igure A3.5.  Fract ion of CD4+ T cel ls producing IL-17 according to: A: 
expression of CD56, B: expression of CD27, C: expression of CD45, D: 
presence of del13, E: presence of IgH rearrangement or IgH abnormal i ty in 
mal ignant bone marrow plasma cel ls.   P=NS for all comparisons. 
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